Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33170484,time to maximum pimasertib concentration,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,1.5,271,DB00640,Adenosine
,33170484,apparent terminal half-life,"The median time to maximum pimasertib concentration was 1.5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules.",Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33170484/),h,5,272,DB00640,Adenosine
,33990984,t1/2,"After intravenous infusion, RDV is rapidly metabolized (t1/2 = 1 h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and then it can be found in plasma in its nucleoside analogue form (GS-441524).",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,1,1908,DB00640,Adenosine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],<,1909,DB00640,Adenosine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1910,DB00640,Adenosine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1911,DB00640,Adenosine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1912,DB00640,Adenosine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],122.3,1913,DB00640,Adenosine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2637.3,1914,DB00640,Adenosine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1915,DB00640,Adenosine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1916,DB00640,Adenosine
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1917,DB00640,Adenosine
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],3676.5,1918,DB00640,Adenosine
>,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2610,1919,DB00640,Adenosine
,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],140,1920,DB00640,Adenosine
>,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],1560,1921,DB00640,Adenosine
,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],2230,1922,DB00640,Adenosine
,33990984,t1/2,The mean t1/2 value for GS-441524 was 26.3 h.,Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,26.3,1923,DB00640,Adenosine
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,523.4,2195,DB00640,Adenosine
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,127.0,2196,DB00640,Adenosine
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,530.4,2197,DB00640,Adenosine
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,127.0,2198,DB00640,Adenosine
,30715279,flow rate,"Chromatographic separation was performed on a Phenomenex Luna® C18 column using a mobile phase consisting of 0.1% formic acid in water-acetonitrile (20:80, v/v) at a flow rate of 0.2 mL/min.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),[ml] / [min],0.2,2199,DB00640,Adenosine
,30715279,retention times,"The retention times of ticagrelor and IS were 1.03 min and 1.02 min, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),min,1.03,2200,DB00640,Adenosine
,30715279,retention times,"The retention times of ticagrelor and IS were 1.03 min and 1.02 min, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),min,1.02,2201,DB00640,Adenosine
,22282355,IC(100),"The median IC(100) and IC(50) to prolong collagen/adenosine diphosphate-induced closure timewere 27 nmol/L and 12 nmol/L, respectively.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),[nM] / [l],27,2423,DB00640,Adenosine
,22282355,IC(50),"The median IC(100) and IC(50) to prolong collagen/adenosine diphosphate-induced closure timewere 27 nmol/L and 12 nmol/L, respectively.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),[nM] / [l],27,2424,DB00640,Adenosine
,22282355,IC(50),"The median IC(100) and IC(50) to prolong collagen/adenosine diphosphate-induced closure timewere 27 nmol/L and 12 nmol/L, respectively.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),[nM] / [l],12,2425,DB00640,Adenosine
,22282355,terminal half-lives,"The IV and SC terminal half-lives in cynomolgus monkeys were 67 and 65 hours, respectively, and the SC bioavailability was ≈98%.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),h,67,2426,DB00640,Adenosine
,22282355,terminal half-lives,"The IV and SC terminal half-lives in cynomolgus monkeys were 67 and 65 hours, respectively, and the SC bioavailability was ≈98%.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),h,65,2427,DB00640,Adenosine
≈,22282355,bioavailability,"The IV and SC terminal half-lives in cynomolgus monkeys were 67 and 65 hours, respectively, and the SC bioavailability was ≈98%.",ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),%,98,2428,DB00640,Adenosine
,22282355,T(1/2),Allometric scaling estimates the human T(1/2) would be ≈217 hours.,ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282355/),h,217,2429,DB00640,Adenosine
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.861,4380,DB00640,Adenosine
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4381,DB00640,Adenosine
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.618,4382,DB00640,Adenosine
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4383,DB00640,Adenosine
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,5.0,5290,DB00640,Adenosine
,1681957,fractions of drug removed,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.6,5291,DB00640,Adenosine
,1681957,systemic clearance,"For paracetamol (1 g, single oral dose) and diclofenac (100 mg, single oral dose), the fractions of drug removed during PE effected within 2 h of drug intake, were respectively 5.0 +/- 3.1 per cent and 13.6 +/- 9.5 per cent, while plasmapheretic clearance reached, respectively, 13.0 +/- 10.7 per cent of the systemic clearance for paracetamol and 23.0 +/- 1.0 per cent for diclofenac.","Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681957/),%,13.0,5292,DB00640,Adenosine
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,42,5513,DB00640,Adenosine
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5514,DB00640,Adenosine
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,83,5515,DB00640,Adenosine
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,116,5516,DB00640,Adenosine
,8104793,time to reach maximum concentration (tmax),The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),h,0.8,5517,DB00640,Adenosine
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,51,5518,DB00640,Adenosine
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5519,DB00640,Adenosine
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1472,5817,DB00640,Adenosine
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],723,5818,DB00640,Adenosine
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],2391,5819,DB00640,Adenosine
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.31,5820,DB00640,Adenosine
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],14.6,5821,DB00640,Adenosine
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1616,5822,DB00640,Adenosine
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.21,5823,DB00640,Adenosine
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],31.3,5824,DB00640,Adenosine
,30689800,reactivity index,"On Day 45 after AMI the antiplatelet effect of ticagrelor was evaluated with the VASP assay and Multiplate, and there were no significant differences in platelet inhibition between patients on reduced vs. standard MD [VASP: 10.4 (5.6-22.2) vs. 14.1 (9.4-22.1) platelet reactivity index; P = 0.30; Multiplate: 30.0 (24.0-39.0) vs. 26.5 (22.0-35.0) U; P = 0.26].","Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689800/),u,26.5,7067,DB00640,Adenosine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [d·l],"18,125-20,000",8623,DB00640,Adenosine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [d·l],4415-4872,8624,DB00640,Adenosine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [d·l],"18,000-19,000",8625,DB00640,Adenosine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [d·l],4384-4628,8626,DB00640,Adenosine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"12,079 to 31,660",8627,DB00640,Adenosine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [l],2942 to 7712,8628,DB00640,Adenosine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"16,824",8629,DB00640,Adenosine
,22155501,clearance,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[ml] / [kg·min],1.74-6.94,8630,DB00640,Adenosine
,22155501,clearance,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[ml] / [kg·min],4.03,8631,DB00640,Adenosine
less,22155501,total AUC,"Graft failure occurred in 3 patients with total AUC less than 74,000 μg*h/L (18,026 μmol*min/L), and 2 patients with relatively high total AUC experienced veno-occlusive disease.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"74,000",8632,DB00640,Adenosine
,22155501,total AUC,"Graft failure occurred in 3 patients with total AUC less than 74,000 μg*h/L (18,026 μmol*min/L), and 2 patients with relatively high total AUC experienced veno-occlusive disease.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [l],"18,026",8633,DB00640,Adenosine
,21599605,intracellular initial half-life,The intracellular initial half-life is 13 h and the terminal half-life is 30 h.,"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599605/),h,13,8672,DB00640,Adenosine
,21599605,terminal half-life,The intracellular initial half-life is 13 h and the terminal half-life is 30 h.,"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599605/),h,30,8673,DB00640,Adenosine
,32919393,half-life,The median half-life was 39.5 h (range 27.2-50.4).,Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32919393/),h,39.5,9086,DB00640,Adenosine
>,24755129,peak inhibition,"In both groups, mean peak inhibition of platelet aggregation was > 86% after single doses (>= 100 mg ticagrelor) and > 84% after multiple doses.","Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),%,86,9339,DB00640,Adenosine
>,24755129,peak inhibition,"In both groups, mean peak inhibition of platelet aggregation was > 86% after single doses (>= 100 mg ticagrelor) and > 84% after multiple doses.","Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),%,84,9340,DB00640,Adenosine
>=,24755129,Bleeding times,Bleeding times were >= 60 minutes in more Japanese than Caucasians with multiple dosing of 100 mg and 300 mg ticagrelor Adverse events were similar between groups (mild-to-moderate intensity).,"Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),min,60,9341,DB00640,Adenosine
,9353401,terminal half-lives,The larger volume of distribution at steady state of the 8-substituted analogs resulted in terminal half-lives (ranging from 17 to 24 min) which were significantly longer than for CPA (7 min).,8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),min,17 to 24,9455,DB00640,Adenosine
,9353401,terminal half-lives,The larger volume of distribution at steady state of the 8-substituted analogs resulted in terminal half-lives (ranging from 17 to 24 min) which were significantly longer than for CPA (7 min).,8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),min,7,9456,DB00640,Adenosine
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,366,9457,DB00640,Adenosine
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,210,9458,DB00640,Adenosine
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,170,9459,DB00640,Adenosine
,9353401,"EC50,u","The in vivo EC50,u values for the reduction in HR (366 nM, 210 nM, 170 nM and 175 nM for 8MCPA, 8ECPA, 8PCPA and 8BCPA, respectively) were in the same order of magnitude as the affinities in receptor binding studies.",8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9353401/),nM,175,9460,DB00640,Adenosine
,1496913,initial half-life,"(ii) Release of cysteinyl leukotrienes into the blood circulation is followed by a rapid elimination with an initial half-life of 38 sec in rats and 4.0 min in man, as measured with the labeled, representative LTC4 catabolite, N-acetyl-LTE4.",Transport and in vivo elimination of cysteinyl leukotrienes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496913/),s,38,10404,DB00640,Adenosine
,1496913,initial half-life,"(ii) Release of cysteinyl leukotrienes into the blood circulation is followed by a rapid elimination with an initial half-life of 38 sec in rats and 4.0 min in man, as measured with the labeled, representative LTC4 catabolite, N-acetyl-LTE4.",Transport and in vivo elimination of cysteinyl leukotrienes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496913/),min,4.0,10405,DB00640,Adenosine
,171373,Plasma half-lives,Plasma half-lives in dogs were about 3 hr after oral or intravenous doses of 0.25 or 2.5 mg/kg and ranged from 5 to 12 hr after oral or intravenous doseas of 50 mg/kg.,"Metabolism of 8-(methylthio)cyclic 3',5'-adenosine monophosphate by rats and dogs after oral or intravenous dosing and in vitro by subcellular preparations of dog liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/171373/),h,3,10613,DB00640,Adenosine
,171373,Plasma half-lives,Plasma half-lives in dogs were about 3 hr after oral or intravenous doses of 0.25 or 2.5 mg/kg and ranged from 5 to 12 hr after oral or intravenous doseas of 50 mg/kg.,"Metabolism of 8-(methylthio)cyclic 3',5'-adenosine monophosphate by rats and dogs after oral or intravenous dosing and in vitro by subcellular preparations of dog liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/171373/),h,5 to 12,10614,DB00640,Adenosine
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,91,11928,DB00640,Adenosine
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,99,11929,DB00640,Adenosine
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],616,11930,DB00640,Adenosine
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],1273,11931,DB00640,Adenosine
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],3882,11932,DB00640,Adenosine
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],8206,11933,DB00640,Adenosine
,1943489,peak extracellular levels,The peak extracellular levels were in the range of 20 - 80 microM.,Drug distribution studies with microdialysis. III: Extracellular concentration of caffeine in adipose tissue in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1943489/),μM,20 - 80,12596,DB00640,Adenosine
,17211431,AUC,"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μMh,21.9,12761,DB00640,Adenosine
,17211431,t(1/2),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μM,3.5,12762,DB00640,Adenosine
,17211431,t(1/2),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[h·l] / [m(2],4.7,12763,DB00640,Adenosine
,17211431,Cl(total),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μM,3.5,12764,DB00640,Adenosine
,17211431,Cl(total),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[h·l] / [m(2],4.7,12765,DB00640,Adenosine
,17211431,V(SS),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [m(2],69.0,12766,DB00640,Adenosine
,17211431,Cl(renal),"Cl(renal) and the urine-recovery were 4.8 l/h, 43.7% of the fludarabine dose on day -6 and 3.9 l/h, 44.2% of the fludarabine dose on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [h],4.8,12767,DB00640,Adenosine
,17211431,Cl(renal),"Cl(renal) and the urine-recovery were 4.8 l/h, 43.7% of the fludarabine dose on day -6 and 3.9 l/h, 44.2% of the fludarabine dose on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [h],3.9,12768,DB00640,Adenosine
,30414387,half maximal inhibition,"On average, half maximal inhibition was reached at ticagrelor concentrations of 116 (RSE: 5.3%) nmol l-1 .",Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30414387/),%,116,13270,DB00640,Adenosine
,21465812,t1/2beta,"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,22.5-23.3,13888,DB00640,Adenosine
,21465812,V(d),"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),[l] / [kg],0.956 4-0.978 6,13889,DB00640,Adenosine
,21465812,CL,"Following i.v. administration of PCr 500 mg x kg(-1) and 1 000 mg x kg(-1) the C-T curve could be described by the two-compartment model with t1/2beta 22.5-23.3 min, V(d) 0.956 4-0.978 6 L x kg(-1), CL 0.029 L. kg(-1) x min(-1).",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),[l] / [kg·min],0.029,13890,DB00640,Adenosine
,21465812,t(max),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,20,13891,DB00640,Adenosine
,21465812,t1/2kappa (m),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,40.6-42.7,13892,DB00640,Adenosine
,21465812,f(m),"The Cr as PCr degraded product appeared as early as 2 min post i.v. dosing with t(max) 20 min, t1/2kappa (m) 40.6-42.7 min and f(m) 60%-76%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,60,13893,DB00640,Adenosine
,21465812,t(max),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,65-95,13894,DB00640,Adenosine
,21465812,t1/2kappa (m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,56.0-57.7,13895,DB00640,Adenosine
,21465812,bioavailability F(m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,55,13896,DB00640,Adenosine
,21465812,bioavailability F(m),"After po administration of PCr, the parent drug in plasma was undetectable, but the metabolite Cr was detected with t(max) 65-95 min, t1/2kappa (m) 56.0-57.7 min, metabolite-based bioavailability F(m) 55.02%-62.31%.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),%,62,13897,DB00640,Adenosine
,21465812,t(max),"PCr i.v. administration resulted in significant elevation of ATP level in RBC but not in plasma, the related-ATP in RBC was characterized by t(max) 68-83 min, t1/2kappa 49-52 min.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,68-83,13898,DB00640,Adenosine
,21465812,t1/2kappa,"PCr i.v. administration resulted in significant elevation of ATP level in RBC but not in plasma, the related-ATP in RBC was characterized by t(max) 68-83 min, t1/2kappa 49-52 min.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,49-52,13899,DB00640,Adenosine
,21465812,t(max),"In RBC no exogenous PCr was found but Cr was detected following i.v. administration of PCr, with the t(max) 120 min and t1/2k (m) 70 min for Cr.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,120,13900,DB00640,Adenosine
,21465812,t1/2k (m),"In RBC no exogenous PCr was found but Cr was detected following i.v. administration of PCr, with the t(max) 120 min and t1/2k (m) 70 min for Cr.",[Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21465812/),min,70,13901,DB00640,Adenosine
,10231888,molecular,"The molecular weights of mono-PEG-sCT and di-PEG-sCT were determined to be 16,094 and 29,077 Da, respectively.",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),da,"16,094",14000,DB00640,Adenosine
,10231888,molecular,"The molecular weights of mono-PEG-sCT and di-PEG-sCT were determined to be 16,094 and 29,077 Da, respectively.",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),da,"29,077",14001,DB00640,Adenosine
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,11.2,14002,DB00640,Adenosine
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,54.0,14003,DB00640,Adenosine
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,4.7,14004,DB00640,Adenosine
,22727067,relative bioavailability,The relative bioavailability of the test formulation was estimated to be 102.1% (13.5%).,"Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727067/),%,102.1,14459,DB00640,Adenosine
,1348236,elimination half-life,The mean elimination half-life (+/- SD) was 3.0 +/- 1.7 h.,Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348236/),h,3.0,15185,DB00640,Adenosine
,1348236,plasma clearance,The plasma clearance (mean +/- SD) was 195 +/- 270 ml/min when the dose was 7.5 mg/kg per day and 66.3 +/- 47 ml/min for a 15 mg/kg per day/dose (NS).,Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348236/),[ml] / [min],195,15186,DB00640,Adenosine
,1348236,plasma clearance,The plasma clearance (mean +/- SD) was 195 +/- 270 ml/min when the dose was 7.5 mg/kg per day and 66.3 +/- 47 ml/min for a 15 mg/kg per day/dose (NS).,Pharmacokinetics of vidarabine in the treatment of polyarteritis nodosa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348236/),[ml] / [min],66.3,15187,DB00640,Adenosine
<,27094990,clearance (Clpred),"In the independent cohort, the hazard ratio of NRM at day 100 was significantly higher in patients with predicted F-ara-A clearance (Clpred) <8.50 L/h (P < 0.01) and area under the curve (AUCpred) >6.00 μg × h/mL (P = 0.01).",Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094990/),[l] / [h],8.50,15216,DB00640,Adenosine
>,27094990,area under the curve (AUCpred),"In the independent cohort, the hazard ratio of NRM at day 100 was significantly higher in patients with predicted F-ara-A clearance (Clpred) <8.50 L/h (P < 0.01) and area under the curve (AUCpred) >6.00 μg × h/mL (P = 0.01).",Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094990/),[h·μg] / [ml],6.00,15217,DB00640,Adenosine
,28578536,apparent clearance (CL/F),"The final popPK model for children with SCA provided a reasonable fit to Pras-AM plasma concentrations over time, with estimates of apparent clearance (CL/F) (172 L/h) and apparent volume of distribution (Vd/F) (51.7 L) that were comparable to previous studies in adults.",Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578536/),[l] / [h],172,16689,DB00640,Adenosine
,28578536,apparent volume of distribution (Vd/F),"The final popPK model for children with SCA provided a reasonable fit to Pras-AM plasma concentrations over time, with estimates of apparent clearance (CL/F) (172 L/h) and apparent volume of distribution (Vd/F) (51.7 L) that were comparable to previous studies in adults.",Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578536/),l,51.7,16690,DB00640,Adenosine
,18568423,K(i),"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,22,18540,DB00640,Adenosine
,18568423,K(i),"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,"1,940",18541,DB00640,Adenosine
,18568423,K(i),"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),,"3,280",18542,DB00640,Adenosine
,18568423,K(i),"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,"1,070",18543,DB00640,Adenosine
,18568423,t (1/2),"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),h,4,18544,DB00640,Adenosine
>,18568423,F,"CV Therapeutics scientists discovered the selective, high affinity A(2B) AdoR antagonist 10, a 8-(4-pyrazolyl)-xanthine derivative [CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM] that has favorable pharmacokinetic (PK) properties (t (1/2) = 4 h and F > 35% rat).","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),%,35,18545,DB00640,Adenosine
,18568423,K(B),Compound 10 demonstrated functional antagonism at the A(2B) AdoR (K(B) = 6 nM) and efficacy in a mouse model of asthma.,"Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,6,18546,DB00640,Adenosine
,18568423,K(i),"A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,5.5,18547,DB00640,Adenosine
>,18568423,K(i),"A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,"1,000",18548,DB00640,Adenosine
>,18568423,K(i),"A second compound 20, 8-(5-pyrazolyl)-xanthine, has been nominated for development from Baraldi's group in conjunction with King Pharmaceuticals that has favorable A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 1,000; and K(i)(hA(3)) > 1,000 nM], and it has been demonstrated to be a functional antagonist.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),,"1,000",18549,DB00640,Adenosine
,18568423,K(i),"A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,17,18550,DB00640,Adenosine
>,18568423,K(i),"A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),nM,"1,000",18551,DB00640,Adenosine
>,18568423,K(i),"A third compound 32, a 2-aminopyrimidine, from the Almirall group has high A(2B) AdoR affinity and selectivity [K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM], and 32 has been moved into preclinical safety testing.","Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18568423/),,"2,500",18552,DB00640,Adenosine
,1299143,recovery,The recovery is 87.5%.,[Studies on pharmacokinetics of 9-beta-D-arabinofuranosyl adenine nanocapsules]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1299143/),%,87.5,20216,DB00640,Adenosine
,1299143,elimination half-time,"In mice given Ara-A injection a shorter elimination half-time (20.32 min), MRT (9.647 min) and a smaller AUC (233.4 micrograms.min.ml-1) were obtained compared with the group given Ara-A-NC injection.",[Studies on pharmacokinetics of 9-beta-D-arabinofuranosyl adenine nanocapsules]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1299143/),min,20.32,20217,DB00640,Adenosine
,1299143,MRT,"In mice given Ara-A injection a shorter elimination half-time (20.32 min), MRT (9.647 min) and a smaller AUC (233.4 micrograms.min.ml-1) were obtained compared with the group given Ara-A-NC injection.",[Studies on pharmacokinetics of 9-beta-D-arabinofuranosyl adenine nanocapsules]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1299143/),min,9.647,20218,DB00640,Adenosine
,1299143,AUC,"In mice given Ara-A injection a shorter elimination half-time (20.32 min), MRT (9.647 min) and a smaller AUC (233.4 micrograms.min.ml-1) were obtained compared with the group given Ara-A-NC injection.",[Studies on pharmacokinetics of 9-beta-D-arabinofuranosyl adenine nanocapsules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1299143/),[min·μg] / [ml],233.4,20219,DB00640,Adenosine
,30512187,AUC1,"The mean AUC1 was 7.20 ± 1.48 mg • h/L, which ranged from 4.70 to 9.46 mg • h/L.",Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.20,20380,DB00640,Adenosine
below,30512187,AUC1,The AUC1 was below the therapeutic concentration of 7.38 mg • h/L in 45% (9 of 20) of the patients.,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.38,20381,DB00640,Adenosine
,30512187,CLT,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.05,20382,DB00640,Adenosine
,30512187,CL1,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.03,20383,DB00640,Adenosine
,15292459,blood clearance,The blood clearance was 7.4 +/- 0.5 for MCPA and 7.2 +/- 1.4 ml min(-1) for 2'-dCPA.,Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),[ml] / [min],7.4,20450,DB00640,Adenosine
,15292459,blood clearance,The blood clearance was 7.4 +/- 0.5 for MCPA and 7.2 +/- 1.4 ml min(-1) for 2'-dCPA.,Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),[ml] / [min],7.2,20451,DB00640,Adenosine
,15292459,recoveries,"The in vivo microdialysis recoveries determined by the dynamic-no-net-flux method were independent of time with values of 0.21 +/- 0.02 and 0.22 +/- 0.01 for MCPA and 2'-dCPA, respectively.",Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),,0.21,20452,DB00640,Adenosine
,15292459,recoveries,"The in vivo microdialysis recoveries determined by the dynamic-no-net-flux method were independent of time with values of 0.21 +/- 0.02 and 0.22 +/- 0.01 for MCPA and 2'-dCPA, respectively.",Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),,0.22,20453,DB00640,Adenosine
,15292459,intercompartmental clearance,"The values of the intercompartmental clearance for the distribution from blood to brain were 1.9 +/- 0.4 versus 1.6 +/- 0.3 mul min(-1) for MCPA and 2'-dCPA, respectively.",Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),[mul] / [min],1.9,20454,DB00640,Adenosine
,15292459,intercompartmental clearance,"The values of the intercompartmental clearance for the distribution from blood to brain were 1.9 +/- 0.4 versus 1.6 +/- 0.3 mul min(-1) for MCPA and 2'-dCPA, respectively.",Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15292459/),[mul] / [min],1.6,20455,DB00640,Adenosine
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],1320,20838,DB00640,Adenosine
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],2346,20839,DB00640,Adenosine
,25659459,time from diagnosis to HCT,"The median number of previous therapies was 3 (range, 1-8) and median time from diagnosis to HCT was 32 months (range, 4.5-177.5 months).",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),month,32,21467,DB00640,Adenosine
,25659459,overall survival,"Three-year progression-free and overall survival for all patients was 47.8% and 55%, respectively.",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),,55,21468,DB00640,Adenosine
,25064036,IC50,SAR216471 blocks the binding of 2MeSADP to P2Y12 receptors in vitro (IC50=17 nM).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,17,22006,DB00640,Adenosine
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,108,22007,DB00640,Adenosine
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,62,22008,DB00640,Adenosine
,25064036,ED50,Pre-clinical study of SAR216471 in a rat shunt thrombosis model demonstrated a dose-dependent antithrombotic activity after oral administration (ED50=6.7 mg/kg).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.7,22009,DB00640,Adenosine
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.3,22010,DB00640,Adenosine
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],0.35,22011,DB00640,Adenosine
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],2.6,22012,DB00640,Adenosine
,9651106,constant flow rate,The liver was perfused with a recirculating system at a constant flow rate of 20 ml/min.,The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9651106/),[ml] / [min],20,22690,DB00640,Adenosine
,29577579,half-life,The estimated half-life of Fc-apelin-13 in blood was approximately 33 hours.,Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29577579/),h,33,22691,DB00640,Adenosine
,9516951,maximum tolerated plasma concentrations,"The maximum tolerated plasma concentrations for this combination regimen was 10 microM fludarabine for 48 h followed by 72 h of 15 microM ara-C, which were achieved at dose level 3.",Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516951/),μM,10,23245,DB00640,Adenosine
,7416747,elimination half-life,Therapeutic guidelines for adenine arabinoside in renal failure are provided based on an elimination half-life of 4.7 h and a plasma clearance of 87.9 ml/min for the hypoxanthine metabolite.,Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416747/),h,4.7,23312,DB00640,Adenosine
,7416747,plasma clearance,Therapeutic guidelines for adenine arabinoside in renal failure are provided based on an elimination half-life of 4.7 h and a plasma clearance of 87.9 ml/min for the hypoxanthine metabolite.,Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416747/),[ml] / [min],87.9,23313,DB00640,Adenosine
,9175243,systemic clearance,"The systemic clearance values for 14C-XU063 were 1 and 10 mL/min/kg for EDTA and citrated PPP, respectively.","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[ml] / [kg·min],1,25498,DB00640,Adenosine
,9175243,systemic clearance,"The systemic clearance values for 14C-XU063 were 1 and 10 mL/min/kg for EDTA and citrated PPP, respectively.","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[ml] / [kg·min],10,25499,DB00640,Adenosine
,9175243,volume of distribution at steady-state,"The values for the volume of distribution at steady-state were 0.2 and 1.3 L/kg, for EDTA and citrated PPP, respectively.","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[l] / [kg],0.2,25500,DB00640,Adenosine
,9175243,volume of distribution at steady-state,"The values for the volume of distribution at steady-state were 0.2 and 1.3 L/kg, for EDTA and citrated PPP, respectively.","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[l] / [kg],1.3,25501,DB00640,Adenosine
,9175243,terminal elimination half-life,The terminal elimination half-life appeared independent of the matrix with a median value of 2 h.,"Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),h,2,25502,DB00640,Adenosine
,9175243,IC50,"The estimated ex vivo IC50 values of XU063 ranged from 0.4 ng/mL (citrated PPP, platelet free drug) to 7 ng/mL (EDTA PPP, total drug).","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[ng] / [ml],0.4,25503,DB00640,Adenosine
,9175243,IC50,"The estimated ex vivo IC50 values of XU063 ranged from 0.4 ng/mL (citrated PPP, platelet free drug) to 7 ng/mL (EDTA PPP, total drug).","Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9175243/),[ng] / [ml],7,25504,DB00640,Adenosine
,20642549,t(max),"Ticagrelor was absorbed with median t(max) 1.5-3 h, exhibiting predictable pharmacokinetics over the 50-600 mg dose range.","Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642549/),h,1.5-3,25985,DB00640,Adenosine
,3960017,renal clearance,"However, the WKY had a significantly greater renal clearance of 45Ca than the SHR (0.48 +/- 0.04 vs. 0.24 +/- 0.02 ml/n, p less than 0.001).",Pathogenesis of hypercalciuria in spontaneously hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3960017/),[ml] / [n],0.48,26417,DB00640,Adenosine
,3960017,renal clearance,"However, the WKY had a significantly greater renal clearance of 45Ca than the SHR (0.48 +/- 0.04 vs. 0.24 +/- 0.02 ml/n, p less than 0.001).",Pathogenesis of hypercalciuria in spontaneously hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3960017/),[ml] / [n],0.24,26418,DB00640,Adenosine
,3486861,enhancement ratios (ER's),"The mean enhancement ratios (ER's) determined from the L-PAM dose response curves were 1.4 for 3'-dG, 1.3 for 3'-dA, and 1.4 for N6-BC.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),,1.4,28854,DB00640,Adenosine
,3486861,enhancement ratios (ER's),"The mean enhancement ratios (ER's) determined from the L-PAM dose response curves were 1.4 for 3'-dG, 1.3 for 3'-dA, and 1.4 for N6-BC.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),,1.3,28855,DB00640,Adenosine
,3486861,half-life,"In addition 3'-dG also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 28 minutes to 35 minutes.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),min,28,28856,DB00640,Adenosine
,3486861,half-life,"In addition 3'-dG also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 28 minutes to 35 minutes.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),min,35,28857,DB00640,Adenosine
,8496805,CL,Unbound R-PIA was rapidly cleared from blood (CL = 40 +/- 7 ml/kg/min) and had a large volume of distribution (VSS = 1.45 +/- 0.21 L/kg).,Correlation of (-)N6-phenylisopropyladenosine blood levels with cardiac responses in the anesthetized guinea pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8496805/),[ml] / [kg·min],40,28934,DB00640,Adenosine
,8496805,volume of distribution (VSS,Unbound R-PIA was rapidly cleared from blood (CL = 40 +/- 7 ml/kg/min) and had a large volume of distribution (VSS = 1.45 +/- 0.21 L/kg).,Correlation of (-)N6-phenylisopropyladenosine blood levels with cardiac responses in the anesthetized guinea pig. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8496805/),[l] / [kg],1.45,28935,DB00640,Adenosine
,32886279,area under the blood concentration-time curve,"In BuFlu, the median area under the blood concentration-time curve of Bu on the fourth day was 1183 μmol min/L (range 808-1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822-1453), P < 0.01].",Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886279/),[min·μM] / [l],1183,29910,DB00640,Adenosine
,32886279,area under the blood concentration-time curve,"In BuFlu, the median area under the blood concentration-time curve of Bu on the fourth day was 1183 μmol min/L (range 808-1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822-1453), P < 0.01].",Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886279/),[min·μM] / [l],1095,29911,DB00640,Adenosine
,8227467,apparent t1/2,"The postinfusion total 14C concentrations in plasma declined in a multiexponential manner, and the terminal phase had an apparent t1/2 of about 1 week.",Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227467/),week,1,30051,DB00640,Adenosine
,8227467,Total plasma clearance,"Total plasma clearance was 2.2 +/- 0.2 L/hour/kg, the acadesine blood/plasma ratio was unity, and plasma protein binding was negligible (approximately 1%).",Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227467/),[l] / [h·kg],2.2,30052,DB00640,Adenosine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB00640,Adenosine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB00640,Adenosine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB00640,Adenosine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB00640,Adenosine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB00640,Adenosine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB00640,Adenosine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB00640,Adenosine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB00640,Adenosine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB00640,Adenosine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB00640,Adenosine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB00640,Adenosine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB00640,Adenosine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB00640,Adenosine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB00640,Adenosine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB00640,Adenosine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB00640,Adenosine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB00640,Adenosine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB00640,Adenosine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB00640,Adenosine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB00640,Adenosine
,25069798,Cmax,"Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121.83 ng/mL [90% CI, 111.80-132.75]).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],121.83,30557,DB00640,Adenosine
,25069798,AUC0-τ,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],98.71,30558,DB00640,Adenosine
,25069798,Cmax,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],101.44,30559,DB00640,Adenosine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],96.54,30560,DB00640,Adenosine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],106.39,30561,DB00640,Adenosine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],89.67,30562,DB00640,Adenosine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],106.32,30563,DB00640,Adenosine
,27130252,Css,"In 81% of the patients who received BU doses adjusted based on the test dose (n = 21), the Css was within the target range of 600-900 ng/mL.",Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27130252/),[ng] / [ml],600-900,30574,DB00640,Adenosine
,12092745,elimination half-life (t1/2beta),"In the single-dose (10, 20, and 40 mg) study, the maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) increased in proportion to the dose when administered afterfasting, while the mean elimination half-life (t1/2beta) was essentially unchanged (7.79-7.93 h).",Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092745/),h,7.79-7.93,32290,DB00640,Adenosine
,12092745,Recovery,"Recovery of the unchanged and taurine-conjugated drugs in the urine within 24 hours was 6.5% to 8.4% and 11.9% to 14.2%, respectively.",Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092745/),%,6.5,32291,DB00640,Adenosine
,12092745,Recovery,"Recovery of the unchanged and taurine-conjugated drugs in the urine within 24 hours was 6.5% to 8.4% and 11.9% to 14.2%, respectively.",Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092745/),%,8.4,32292,DB00640,Adenosine
,12092745,Recovery,"Recovery of the unchanged and taurine-conjugated drugs in the urine within 24 hours was 6.5% to 8.4% and 11.9% to 14.2%, respectively.",Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092745/),%,11.9,32293,DB00640,Adenosine
,12092745,Recovery,"Recovery of the unchanged and taurine-conjugated drugs in the urine within 24 hours was 6.5% to 8.4% and 11.9% to 14.2%, respectively.",Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092745/),%,14.2,32294,DB00640,Adenosine
,20200269,CL/F,"The typical population PK parameters were CL/F (5.76 L/h), V2/F (198 L), Q (21.6 L/h), V3/F (307 L), and Ka (0.464 h(-1)) for a 70-kg, nonsmoking Caucasian who had 55.6 kg of lean body mass, no presence of CYP3A4 inhibitors, and unknown food status.",Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200269/),[l] / [h],5.76,32418,DB00640,Adenosine
,20200269,V2/F,"The typical population PK parameters were CL/F (5.76 L/h), V2/F (198 L), Q (21.6 L/h), V3/F (307 L), and Ka (0.464 h(-1)) for a 70-kg, nonsmoking Caucasian who had 55.6 kg of lean body mass, no presence of CYP3A4 inhibitors, and unknown food status.",Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200269/),l,198,32419,DB00640,Adenosine
,20200269,Q,"The typical population PK parameters were CL/F (5.76 L/h), V2/F (198 L), Q (21.6 L/h), V3/F (307 L), and Ka (0.464 h(-1)) for a 70-kg, nonsmoking Caucasian who had 55.6 kg of lean body mass, no presence of CYP3A4 inhibitors, and unknown food status.",Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200269/),[l] / [h],21.6,32420,DB00640,Adenosine
,20200269,V3/F,"The typical population PK parameters were CL/F (5.76 L/h), V2/F (198 L), Q (21.6 L/h), V3/F (307 L), and Ka (0.464 h(-1)) for a 70-kg, nonsmoking Caucasian who had 55.6 kg of lean body mass, no presence of CYP3A4 inhibitors, and unknown food status.",Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200269/),l,307,32421,DB00640,Adenosine
,20200269,Ka,"The typical population PK parameters were CL/F (5.76 L/h), V2/F (198 L), Q (21.6 L/h), V3/F (307 L), and Ka (0.464 h(-1)) for a 70-kg, nonsmoking Caucasian who had 55.6 kg of lean body mass, no presence of CYP3A4 inhibitors, and unknown food status.",Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200269/),1/[h],0.464,32422,DB00640,Adenosine
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],598.4,32936,DB00640,Adenosine
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],560.3,32937,DB00640,Adenosine
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],370.8,32938,DB00640,Adenosine
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],3256.1,32939,DB00640,Adenosine
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],3015.1,32940,DB00640,Adenosine
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],370.8,32941,DB00640,Adenosine
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],2188.8,32942,DB00640,Adenosine
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],152.3,32943,DB00640,Adenosine
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],130.8,32944,DB00640,Adenosine
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],111.7,32945,DB00640,Adenosine
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],1144.2,32946,DB00640,Adenosine
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],111.7,32947,DB00640,Adenosine
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],1000.4,32948,DB00640,Adenosine
,33317621,time to maximum absorption Tmax,"There was a significant food effect for MSI-195 with a delayed time to maximum absorption Tmax, going from 4.5 h under fasted conditions to 13 h under fed conditions, and area under the curve with food reduced to 55% of that seen under fasting conditions.","Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33317621/),h,4.5,33976,DB00640,Adenosine
,33317621,time to maximum absorption Tmax,"There was a significant food effect for MSI-195 with a delayed time to maximum absorption Tmax, going from 4.5 h under fasted conditions to 13 h under fed conditions, and area under the curve with food reduced to 55% of that seen under fasting conditions.","Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33317621/),h,13,33977,DB00640,Adenosine
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,63,34627,DB00640,Adenosine
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,61,34628,DB00640,Adenosine
,34262326,area under the curve (AUC; 0-T,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],300.342,35155,DB00640,Adenosine
,34262326,AUC 0-∞,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [h·l],320.462,35156,DB00640,Adenosine
,34262326,plasma peak concentration,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),[mg] / [l],30.622,35157,DB00640,Adenosine
,34262326,peak time,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35158,DB00640,Adenosine
,34262326,half-life,"The area under the curve (AUC; 0-T, 300.342 ± 35.832 mg/L* h; AUC 0-∞, 320.462 ± 40.213 mg/L* h), the plasma peak concentration (30.622 ± 9.917 mg/L*), and the peak time and half-life (7.954 ± 1.121 h) in the clopidogrel and the TCM groups were higher than those in the clopidogrel and pantoprazole groups.",Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34262326/),h,7.954,35159,DB00640,Adenosine
,1966907,FEV1,"Their mean baseline FEV1 was 83.8% of the predicted value, geometric mean (GM) PC20 FEV1 histamine 0.33 mg/ml (range 0.03-4.0), and GM PC50 baseline sGaw AMP 4.37 mg/ml (range 0.158-26.38).","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],0.33,35537,DB00640,Adenosine
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],28.84,35538,DB00640,Adenosine
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],7.24,35539,DB00640,Adenosine
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],7.94,35540,DB00640,Adenosine
,172107,Half-lives,Half-lives for radioactivity in plasma averaged 3-6 h.,Absorption and biotransformation of topically applied 8-(methylthio) cyclic AMP. Studies in dogs and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/172107/),h,3-6,35810,DB00640,Adenosine
,172107,half-life of,"The half-life of radioactivity in the plasma of the subject with the greatest absorption was 0-5 h during the first 2 h, and 11 h for the next 10 h.",Absorption and biotransformation of topically applied 8-(methylthio) cyclic AMP. Studies in dogs and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/172107/),h,0-5,35811,DB00640,Adenosine
,172107,half-life of,"The half-life of radioactivity in the plasma of the subject with the greatest absorption was 0-5 h during the first 2 h, and 11 h for the next 10 h.",Absorption and biotransformation of topically applied 8-(methylthio) cyclic AMP. Studies in dogs and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/172107/),h,11,35812,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.12,35902,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.28,35903,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.22,35904,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.85,35905,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.65,35906,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.75,35907,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.40,35908,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.43,35909,DB00640,Adenosine
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.24,35910,DB00640,Adenosine
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),h,2.0,37960,DB00640,Adenosine
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),h,2.0,37961,DB00640,Adenosine
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),,3.0,37962,DB00640,Adenosine
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),,3.0,37963,DB00640,Adenosine
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,6.02,38032,DB00640,Adenosine
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,2.21,38033,DB00640,Adenosine
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.86,38034,DB00640,Adenosine
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.29,38035,DB00640,Adenosine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"6,000",38404,DB00640,Adenosine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"7,500",38405,DB00640,Adenosine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"9,000",38406,DB00640,Adenosine
,22198540,AUC,"For level 1 patients, i.v. busulfan doses 1 and 2 were 170 mg/m(2)/day, then doses 3 and 4 were adjusted based on first-dose pharmacokinetic modeling to achieve an average daily AUC of 6,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"6,000",38407,DB00640,Adenosine
,22198540,AUC,"Doses 1 and 2 for the subsequent cohorts were based on the level 1 data: 180 mg/m(2)/day for AUC 7,500 μM-min (level 2) and 220 mg/m(2)/day for AUC 9,000 μM-min (level 3), with pharmacokinetic targeting for doses 3 and 4.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"7,500",38408,DB00640,Adenosine
,22198540,AUC,"Doses 1 and 2 for the subsequent cohorts were based on the level 1 data: 180 mg/m(2)/day for AUC 7,500 μM-min (level 2) and 220 mg/m(2)/day for AUC 9,000 μM-min (level 3), with pharmacokinetic targeting for doses 3 and 4.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"9,000",38409,DB00640,Adenosine
,22198540,AUC,"Within the confines of the trial's small sample size, there was no suggestion that escalating busulfan AUC from 6,000 to 7,500 μM-min × 4 days increased nonrelapse mortality.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),4·d·μM-min,6,38410,DB00640,Adenosine
,28629145,Ki,"The PX-D and PX-E analogues acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogues displayed relatively mild MAO-B inhibition potencies, with inhibitor dissociation constants (Ki values) ranging from 0.25 to 10 μM.",Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629145/),μM,0.27 to 10,40246,DB00640,Adenosine
,28629145,inhibitor dissociation constants (Ki values),"The PX-D and PX-E analogues acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogues displayed relatively mild MAO-B inhibition potencies, with inhibitor dissociation constants (Ki values) ranging from 0.25 to 10 μM.",Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28629145/),μM,0.25 to 10,40247,DB00640,Adenosine
,8540705,half-life,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),h,9.4,40839,DB00640,Adenosine
,8540705,Ki,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),nM,16,40840,DB00640,Adenosine
greater,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,100,40841,DB00640,Adenosine
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,12,40842,DB00640,Adenosine
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,11,40843,DB00640,Adenosine
,26626489,concentrations,"Brain temozolomide concentrations were significantly higher at 120 min when it was given with regadenoson versus alone (8.1 ± 2.7 and 5.1 ± 3.5 µg/g, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),µ,8.1,40865,DB00640,Adenosine
,26626489,concentrations,"Brain temozolomide concentrations were significantly higher at 120 min when it was given with regadenoson versus alone (8.1 ± 2.7 and 5.1 ± 3.5 µg/g, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),µ,5.1,40866,DB00640,Adenosine
,26626489,brain:plasma ratios,"A similar trend was noted in brain:plasma ratios (0.45 ± 0.08 and 0.29 ± 0.09, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),,0.45,40867,DB00640,Adenosine
,26626489,brain:plasma ratios,"A similar trend was noted in brain:plasma ratios (0.45 ± 0.08 and 0.29 ± 0.09, P < 0.05).",The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26626489/),,0.29,40868,DB00640,Adenosine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,113,41430,DB00640,Adenosine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,2536,41431,DB00640,Adenosine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,75,41432,DB00640,Adenosine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,317,41433,DB00640,Adenosine
,8405016,total plasma clearance,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [h·kg],0.13,41440,DB00640,Adenosine
,8405016,apparent terminal elimination half-life,The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l.h-1 x kg-1 and apparent terminal elimination half-life 1.9 h.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),h,1.9,41441,DB00640,Adenosine
,8405016,apparent volume of distribution,The apparent volume of distribution estimated at steady state (0.17 l.kg-1) was compatible with the localization of a major fraction of the compound in extracellular water.,Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),[l] / [kg],0.17,41442,DB00640,Adenosine
,8405016,absolute systemic bioavailability,"Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).",Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8405016/),%,77,41443,DB00640,Adenosine
,28216475,concentrations,Ticagrelor and its main metabolite AR-C124910XX concentrations were 85.2 (37.2-178.5) and 18.3 (6.4-52.4) ng/mL.,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),[ng] / [ml],85.2,42056,DB00640,Adenosine
,28216475,concentrations,Ticagrelor and its main metabolite AR-C124910XX concentrations were 85.2 (37.2-178.5) and 18.3 (6.4-52.4) ng/mL.,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),[ng] / [ml],18.3,42057,DB00640,Adenosine
,28216475,times to sufficient platelet inhibition,Median times to sufficient platelet inhibition below the HPR limit were 3 (2-6) hours (VFN) and 4 (2-8) hours (Multiplate).,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),h,3,42058,DB00640,Adenosine
,28216475,times to sufficient platelet inhibition,Median times to sufficient platelet inhibition below the HPR limit were 3 (2-6) hours (VFN) and 4 (2-8) hours (Multiplate).,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),h,4,42059,DB00640,Adenosine
,25839415,IC50,"The IC50 was 0.41 μg/ml for native DTX, 0.30 μg/ml for unconjugated SLN formulation, and 0.09 μg/ml for ADN conjugated SLN formulation in MCF-7 cell lines.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.41,42118,DB00640,Adenosine
,25839415,IC50,"The IC50 was 0.41 μg/ml for native DTX, 0.30 μg/ml for unconjugated SLN formulation, and 0.09 μg/ml for ADN conjugated SLN formulation in MCF-7 cell lines.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.30,42119,DB00640,Adenosine
,25839415,IC50,"The IC50 was 0.41 μg/ml for native DTX, 0.30 μg/ml for unconjugated SLN formulation, and 0.09 μg/ml for ADN conjugated SLN formulation in MCF-7 cell lines.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.09,42120,DB00640,Adenosine
,25839415,IC50,"IC50 was found to be 0.44 μg/ml for free DTX, 0.39 μg/ml for unconjugated SLN and 0.22 μg/ml for ADN-SLN.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.44,42121,DB00640,Adenosine
,25839415,IC50,"IC50 was found to be 0.44 μg/ml for free DTX, 0.39 μg/ml for unconjugated SLN and 0.22 μg/ml for ADN-SLN.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.39,42122,DB00640,Adenosine
,25839415,IC50,"IC50 was found to be 0.44 μg/ml for free DTX, 0.39 μg/ml for unconjugated SLN and 0.22 μg/ml for ADN-SLN.",Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25839415/),[μg] / [ml],0.22,42123,DB00640,Adenosine
,6103788,apparent half-lives,"Following injection of 2-F-AraA (30 mg/m2) into mice, serum levels fell with apparent half-lives of 17 min for the alpha-phase and 72 min for the beta-phase.","Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103788/),min,17,43231,DB00640,Adenosine
,6103788,apparent half-lives,"Following injection of 2-F-AraA (30 mg/m2) into mice, serum levels fell with apparent half-lives of 17 min for the alpha-phase and 72 min for the beta-phase.","Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103788/),min,72,43232,DB00640,Adenosine
,6103788,t1/2,"For dogs given a dose of 400 mg/m2, a single phase of disappearance of the drug (t1/2 = 130 min) was observed.","Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103788/),min,130,43233,DB00640,Adenosine
,6103788,half-lives,"For a single monkey, there were two phases, with half-lives of 15 min and 6.7 hr.","Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103788/),min,15,43234,DB00640,Adenosine
,6103788,half-lives,"For a single monkey, there were two phases, with half-lives of 15 min and 6.7 hr.","Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103788/),h,6.7,43235,DB00640,Adenosine
,9533533,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],47,43981,DB00640,Adenosine
,9533533,AUC,"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],22,43982,DB00640,Adenosine
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,15,43983,DB00640,Adenosine
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,10,43984,DB00640,Adenosine
,9533533,terminal t(1/2),The median terminal t(1/2) of CdA in plasma was 21 h.,Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,21,43985,DB00640,Adenosine
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,108.1,44112,DB00640,Adenosine
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,632.7,44113,DB00640,Adenosine
,9255268,area under the concentration versus time curves,A pharmacokinetic analysis of the seven patients without leukemic cells showed that their area under the concentration versus time curves of plasma cladribine increased dose-dependently from 2661.3 +/- 300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n = 4) (P = 0.034).,Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255268/),h·nM,2661.3,44738,DB00640,Adenosine
,9255268,area under the concentration versus time curves,A pharmacokinetic analysis of the seven patients without leukemic cells showed that their area under the concentration versus time curves of plasma cladribine increased dose-dependently from 2661.3 +/- 300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n = 4) (P = 0.034).,Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255268/),h·nM,3411.3,44739,DB00640,Adenosine
,19326772,AUC,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],0.66,44907,DB00640,Adenosine
,19326772,AUC,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],1.2,44908,DB00640,Adenosine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],1.2,44909,DB00640,Adenosine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),h,3.5,44910,DB00640,Adenosine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),h,4.5,44911,DB00640,Adenosine
,19326772,absolute bioavailability,The mean absolute bioavailability following the s.c. injection was close to 90%.,Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),%,90,44912,DB00640,Adenosine
,8978848,half-lives,"The half-lives of 6-AAP in serum and liver and brain homogenates were 3.73, 4.90, and 7.29 h, respectively.","Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8978848/),h,3.73,45947,DB00640,Adenosine
,8978848,half-lives,"The half-lives of 6-AAP in serum and liver and brain homogenates were 3.73, 4.90, and 7.29 h, respectively.","Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8978848/),h,4.90,45948,DB00640,Adenosine
,8978848,half-lives,"The half-lives of 6-AAP in serum and liver and brain homogenates were 3.73, 4.90, and 7.29 h, respectively.","Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8978848/),h,7.29,45949,DB00640,Adenosine
,9765317,clearance,"Values for clearance and volume of distribution were 1.2 +/- 0.2 ml/min and 88 +/- 10 ml in lean, and 1.6 +/- 0.1 ml/min and 110 +/- 7 ml in obese animals, respectively.",Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ml] / [min],1.2,46161,DB00640,Adenosine
,9765317,clearance,"Values for clearance and volume of distribution were 1.2 +/- 0.2 ml/min and 88 +/- 10 ml in lean, and 1.6 +/- 0.1 ml/min and 110 +/- 7 ml in obese animals, respectively.",Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ml] / [min],1.6,46162,DB00640,Adenosine
,9765317,volume of distribution,"Values for clearance and volume of distribution were 1.2 +/- 0.2 ml/min and 88 +/- 10 ml in lean, and 1.6 +/- 0.1 ml/min and 110 +/- 7 ml in obese animals, respectively.",Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),ml,88,46163,DB00640,Adenosine
,9765317,volume of distribution,"Values for clearance and volume of distribution were 1.2 +/- 0.2 ml/min and 88 +/- 10 ml in lean, and 1.6 +/- 0.1 ml/min and 110 +/- 7 ml in obese animals, respectively.",Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),ml,110,46164,DB00640,Adenosine
,9765317,EC50,Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ng] / [ml],99,46165,DB00640,Adenosine
,9765317,EC50,Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ng] / [ml],118,46166,DB00640,Adenosine
,9765317,Emax,Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),bpm,-,46167,DB00640,Adenosine
,9765317,Emax,Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),bpm,191,46168,DB00640,Adenosine
,9765317,Emax,Modelling of the concentration-heart rate relationship on the basis of the sigmoidal Emax model revealed no difference in EC50 (99 +/- 12 and 118 +/- 17 ng/ml) or Emax (-191 +/- 16 and -185 +/- 22 bpm) between the lean and obese rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),bpm,185,46169,DB00640,Adenosine
,9765317,EC50,Potent (EC50 = 18 +/- 3 ng/ml) inhibition of lipolysis was observed in the lean rats.,Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ng] / [ml],18,46170,DB00640,Adenosine
,9765317,EC50,"In obese rats, SPA was less potent (EC50 = 109 +/- 36 ng/ml) resulting in short lasting antilipolytic effect.",Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765317/),[ng] / [ml],109,46171,DB00640,Adenosine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,85,46188,DB00640,Adenosine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,95,46189,DB00640,Adenosine
,9848579,elimination half-life,"The five day schedule was selected because published pharmacokinetic studies had indicated that although pentostatin had an elimination half-life of approximately six hours and could inhibit plasma adenosine deaminase activity for 24 hours, recovery of enzyme activity rapidly took place and accumulation of dATP which has a toxic effect on non-replicating lymphoid cells could be increased by repeated dosing.",Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848579/),h,six,46597,DB00640,Adenosine
,9848579,overall response rate,"Of the 24 patients evaluable for response, complete responses were achieved in two and partial responses in five for an overall response rate of 29.2%.",Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848579/),%,29.2,46598,DB00640,Adenosine
,8951192,binding (dissociation) constant Kd,"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng·plasma] / [ml],0.87,47926,DB00640,Adenosine
,8951192,maximal specific binding capacity (Bmax),"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng·rbc] / [ml],164,47927,DB00640,Adenosine
,8951192,maximal specific binding capacity (Bmax),"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,14,47928,DB00640,Adenosine
,8951192,clearance,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ml] / [mm],22.0,47929,DB00640,Adenosine
,8951192,volume of distribution at steady-state,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),l,39.8,47930,DB00640,Adenosine
,8951192,terminal half-life,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),h,24.0,47931,DB00640,Adenosine
,8951192,clearance,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ml] / [min],551,47932,DB00640,Adenosine
,8951192,volume of distribution at steady-state,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),l,349,47933,DB00640,Adenosine
,8951192,terminal half-life,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),h,10.7,47934,DB00640,Adenosine
,8951192,Emax,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),%,100,47935,DB00640,Adenosine
,8951192,IC50,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng] / [ml],10.5,47936,DB00640,Adenosine
,8951192,Hill factor,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,0.9,47937,DB00640,Adenosine
,8951192,Emax,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),%,92.4,47938,DB00640,Adenosine
,8951192,IC50,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng] / [ml],76.0,47939,DB00640,Adenosine
,8951192,Hill factor,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,3.5,47940,DB00640,Adenosine
,10336576,Ivy bleeding time,"Ivy bleeding time increased very steeply with dose with a significant prolongation observed at doses of 5 to 7 mg of sibrafiban (5-7 min, >30 min in one case).","Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336576/),min,5-7,48532,DB00640,Adenosine
,10336576,Ivy bleeding time,"Ivy bleeding time increased very steeply with dose with a significant prolongation observed at doses of 5 to 7 mg of sibrafiban (5-7 min, >30 min in one case).","Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336576/),min,30,48533,DB00640,Adenosine
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],14.2,48756,DB00640,Adenosine
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],6.9,48757,DB00640,Adenosine
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.26,49026,DB00640,Adenosine
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.23,49027,DB00640,Adenosine
,9145874,Ki,"The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),nM,21,49028,DB00640,Adenosine
,9145874,IC50s,"1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines.","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,110,49029,DB00640,Adenosine
,9145874,oral bioavailability,1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT.,"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),%,105,49030,DB00640,Adenosine
,19398602,terminal disposition half-life,The mean terminal disposition half-life was between 41 and 43 hours independently of dose.,"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),h,41 and 43,50276,DB00640,Adenosine
,19398602,EC(50),"The effect of LXR-623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic-pharmacodynamic analysis, yielding EC(50) estimates of 526 ng/mL and 729 ng/mL, respectively.","Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),[ng] / [ml],526,50277,DB00640,Adenosine
,19398602,EC(50),"The effect of LXR-623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic-pharmacodynamic analysis, yielding EC(50) estimates of 526 ng/mL and 729 ng/mL, respectively.","Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398602/),[ng] / [ml],729,50278,DB00640,Adenosine
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],877.76,50402,DB00640,Adenosine
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],913.49,50403,DB00640,Adenosine
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],1911.53,50404,DB00640,Adenosine
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2053.09,50405,DB00640,Adenosine
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2021.33,50406,DB00640,Adenosine
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2188.25,50407,DB00640,Adenosine
,9733364,half-life of,"The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),min,4,51264,DB00640,Adenosine
,9733364,half-life of,"The half-life of the initial phase was 4 min, and that of the terminal phase was 162-209 min.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),min,162-209,51265,DB00640,Adenosine
,9733364,Plasma clearance,Plasma clearance for SM-20302 ranged from 6.58 to 9.73 ml/min/kg.,"Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ml] / [kg·min],6.58 to 9.73,51266,DB00640,Adenosine
,9733364,median,"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],14-19,51267,DB00640,Adenosine
,9733364,inhibitory concentration (IC50),"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],14-19,51268,DB00640,Adenosine
,9733364,inhibitory concentration (IC50),"By using a sigmoid Emax model, the in vivo median inhibitory concentration (IC50) for SM-20302 was estimated to be 14-19 ng/ml in cPRP and 79-89 ng/ml in hPRP.","Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9733364/),[ng] / [ml],79-89,51269,DB00640,Adenosine
,12408725,half-life,"This report describes the precursor synthesis and the no-carrier-added (nca) radiosynthesis of the new A(1) adenosine receptor (A(1)AR) antagonist [(18)F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX), 3, with fluorine-18 (half-life = 109.6 min).",Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408725/),min,109.6,51270,DB00640,Adenosine
>,12408725,specific radioactivity,"Nucleophilic radiofluorination of the precursor tosylate 8-cyclopentyl-3-(3-tosyloxypropyl)-7-pivaloyloxymethyl-1-propylxanthine, 2, with nca [(18)F]KF under aminopolyether-mediated conditions (Kryptofix 2.2.2/K(2)CO(3)) followed by deprotection was straightforward and, after formulation, gave the radioligand ready for injection with a radiochemical yield of 45 +/- 7%, a radiochemical purity of >98% and a specific radioactivity of >270 GBq/micromol (>7.2 Ci/micromol).",Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408725/),[gbq] / [μM],270,51271,DB00640,Adenosine
>,12408725,specific radioactivity,"Nucleophilic radiofluorination of the precursor tosylate 8-cyclopentyl-3-(3-tosyloxypropyl)-7-pivaloyloxymethyl-1-propylxanthine, 2, with nca [(18)F]KF under aminopolyether-mediated conditions (Kryptofix 2.2.2/K(2)CO(3)) followed by deprotection was straightforward and, after formulation, gave the radioligand ready for injection with a radiochemical yield of 45 +/- 7%, a radiochemical purity of >98% and a specific radioactivity of >270 GBq/micromol (>7.2 Ci/micromol).",Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408725/),[ci] / [μM],7.2,51272,DB00640,Adenosine
,12408725,Preparation time,Preparation time averaged 55 min.,Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408725/),min,55,51273,DB00640,Adenosine
,20919852,AUC,Busulfan levels after a test dose and conditioning dose 1 allowed targeting of subsequent AUCs and dose-escalation above the starting AUC of 4800 µmol-min/L.,Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],4800,51678,DB00640,Adenosine
,20919852,AUC,"Severe, late-occurring sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) was the dose-limiting toxicity seen in 5/8 patients at an AUC level of 6800 µmol-min/L.",Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],6800,51679,DB00640,Adenosine
,20919852,maximum-tolerated AUC,Busulfan dose-escalation to a maximum-tolerated AUC of 5800 µmol-min/L-higher than that achieved by current standard busulfan regimens-was accurate and achievable using real-time pharmacokinetics monitoring of the first conditioning dose.,Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],5800,51680,DB00640,Adenosine
,8823495,AUC,"The most important data points for estimation of the AUC were 2.5, 24, and 0.5 h after oral administration (AUC = 0.8630 x C0.5h + 4.2337 x C2.5h + 45.4364 x C24h) and 9, 1, and 16 h after s.c. injection (AUC = 1.8821 x C1h + 16.4256 x C9h + 25.4518 x C16h).","A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823495/),,1,52172,DB00640,Adenosine
,25384088,IC50,Our optimization efforts using structure-based drug design (SBDD) techniques on the basis of the X-ray crystal structure of PDE10A in complex with hit compound 1 (IC50 = 23 nM; 110-fold selectivity over other PDEs) led to the identification of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (27h).,"Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),nM,23,53376,DB00640,Adenosine
,25384088,IC50,"Compound 27h has potent inhibitory activity (IC50 = 0.30 nM), excellent selectivity (>15000-fold selectivity over other PDEs), and favorable pharmacokinetics, including high brain penetration, in mice.","Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),nM,0.30,53377,DB00640,Adenosine
,25384088,minimum effective dose (MED),"Oral administration of compound 27h to mice elevated striatal 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) levels at 0.3 mg/kg and showed potent suppression of phencyclidine (PCP)-induced hyperlocomotion at a minimum effective dose (MED) of 0.3 mg/kg.","Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),[mg] / [kg],0.3,53378,DB00640,Adenosine
,17433672,IC(50),This was confirmed by structural analysis and the resulting analog 2a was synthesized and found to be a potent DPP-4 inhibitor (IC(50)=21 nM) with excellent in vivo activity and pharmacokinetic profile.,"Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433672/),nM,21,53737,DB00640,Adenosine
,32052462,maximum concentration,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),[ng] / [ml],8749,53738,DB00640,Adenosine
,32052462,half-life,Noncompartmental pharmacokinetic analysis resulted in (mean ± standard deviation) a maximum concentration of 8749 ± 2840 ng/mL and half-life of 2.1 ± 0.71 hr.,"Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32052462/),h,2.1,53739,DB00640,Adenosine
,16953392,plasma AUC,"The nelarabine plasma AUC (median+/-s.d.) was 2,820+/-1,140 microM min and the ara-G plasma AUC was 20,000+/-8,100 microM min.",Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min·μM,"2,820",53883,DB00640,Adenosine
,16953392,plasma AUC,"The nelarabine plasma AUC (median+/-s.d.) was 2,820+/-1,140 microM min and the ara-G plasma AUC was 20,000+/-8,100 microM min.",Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min·μM,"20,000",53884,DB00640,Adenosine
,16953392,terminal half-life,The terminal half-life of nelarabine in plasma was 25+/-5.2 min and clearance was 42+/-61 ml/min/kg.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min,25,53885,DB00640,Adenosine
,16953392,clearance,The terminal half-life of nelarabine in plasma was 25+/-5.2 min and clearance was 42+/-61 ml/min/kg.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),[ml] / [kg·min],42,53886,DB00640,Adenosine
,16953392,terminal half-life,The terminal half-life of ara-G in plasma was 182+/-45 min.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min,182,53887,DB00640,Adenosine
,16953392,terminal half-life,In CSF the terminal half-life of nelarabine was 77+/-28 min and of ara-G was 232+/-79 min.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min,77,53888,DB00640,Adenosine
,16953392,terminal half-life,In CSF the terminal half-life of nelarabine was 77+/-28 min and of ara-G was 232+/-79 min.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),min,232,53889,DB00640,Adenosine
,16953392,AUCcsf:AUCplasma,The AUCcsf:AUCplasma was 29+/-11% for nelarabine and 23+/-12% for ara-G.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),%,29,53890,DB00640,Adenosine
,16953392,AUCcsf:AUCplasma,The AUCcsf:AUCplasma was 29+/-11% for nelarabine and 23+/-12% for ara-G.,Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16953392/),%,23,53891,DB00640,Adenosine
,28089878,maximum alemtuzumab concentration,"The median maximum alemtuzumab concentration was 2.39 µg/mL (interquartile range, 1.98 to 2.92).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),[μg] / [ml],2.39,54118,DB00640,Adenosine
,28089878,terminal half-life,"The median terminal half-life was 5.2 days (interquartile range, 2.7 to 7.8).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),d,5.2,54119,DB00640,Adenosine
,3186628,Half-times,Half-times of the two phases of accumulation were for theophylline 0.28 and 0.98 min.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.28,54322,DB00640,Adenosine
,3186628,Half-times,Half-times of the two phases of accumulation were for theophylline 0.28 and 0.98 min.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.98,54323,DB00640,Adenosine
,3186628,terminal disposition half-time,"The terminal disposition half-time for enprofylline was, however, 2.7 times higher than that of 0.91 min.",Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),min,0.91,54324,DB00640,Adenosine
,3186628,tissue-perfusion liquid ratios,Both xanthines accumulated against a concentration gradient showing myocardial tissue-perfusion liquid ratios of about 2.9 for theophylline and 3.7 for enprofylline.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),,2.9,54325,DB00640,Adenosine
,3186628,tissue-perfusion liquid ratios,Both xanthines accumulated against a concentration gradient showing myocardial tissue-perfusion liquid ratios of about 2.9 for theophylline and 3.7 for enprofylline.,Pharmacodynamics and pharmacokinetics of enprofylline and theophylline in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186628/),,3.7,54326,DB00640,Adenosine
,21967645,time to maximum concentration (t(max),Ticagrelor median time to maximum concentration (t(max); 2·5 h vs. 1·5 h) was slightly delayed in the fed vs. fasting state.,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,2·5,55330,DB00640,Adenosine
,21967645,time to maximum concentration (t(max),Ticagrelor median time to maximum concentration (t(max); 2·5 h vs. 1·5 h) was slightly delayed in the fed vs. fasting state.,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,1·5,55331,DB00640,Adenosine
,21967645,t(max),Median t(max) of the metabolite was slightly longer in the fed than fasting state (3·5 h vs. 1·5 h).,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,3·5,55332,DB00640,Adenosine
,21967645,t(max),Median t(max) of the metabolite was slightly longer in the fed than fasting state (3·5 h vs. 1·5 h).,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,1·5,55333,DB00640,Adenosine
,17469811,Ki,"In particular, compound 5 showed high affinity for the A(2B) receptor (Ki = 17 nM), good selectivity (IC(50): A(1) > 1000 nM, A(2A) > 2500 nM, A3 > 1000 nM), displayed a favorable pharmacokinetic profile in preclinical species, and showed efficacy in functional in vitro models.","Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469811/),nM,17,56029,DB00640,Adenosine
>,17469811,IC(50),"In particular, compound 5 showed high affinity for the A(2B) receptor (Ki = 17 nM), good selectivity (IC(50): A(1) > 1000 nM, A(2A) > 2500 nM, A3 > 1000 nM), displayed a favorable pharmacokinetic profile in preclinical species, and showed efficacy in functional in vitro models.","Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469811/),nM,1000,56030,DB00640,Adenosine
>,17469811,IC(50),"In particular, compound 5 showed high affinity for the A(2B) receptor (Ki = 17 nM), good selectivity (IC(50): A(1) > 1000 nM, A(2A) > 2500 nM, A3 > 1000 nM), displayed a favorable pharmacokinetic profile in preclinical species, and showed efficacy in functional in vitro models.","Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17469811/),nM,2500,56031,DB00640,Adenosine
,11300442,percent,"Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 +/- 16.8% with abciximab, 51.3 +/- 17.6% with tirofiban and 52.9 +/- 14.8% with eptifibatide (p = 0.37).","Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11300442/),%,45,56199,DB00640,Adenosine
,11300442,percent,"Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 +/- 16.8% with abciximab, 51.3 +/- 17.6% with tirofiban and 52.9 +/- 14.8% with eptifibatide (p = 0.37).","Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11300442/),%,51,56200,DB00640,Adenosine
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.65,56417,DB00640,Adenosine
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,2.12,56418,DB00640,Adenosine
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.09,56419,DB00640,Adenosine
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.17,56420,DB00640,Adenosine
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.07,56421,DB00640,Adenosine
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.02,56422,DB00640,Adenosine
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.86,56423,DB00640,Adenosine
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.93,56424,DB00640,Adenosine
,9453470,terminal half-lives,"The three adenosine agonists showed large differences in pharmacokinetic properties, resulting in terminal half-lives of 66 +/- 10, 8.2 +/- 0.4 and 24 +/- 1 min (mean +/- SEM) for SPA, CPA, and DCCA respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),min,66,56433,DB00640,Adenosine
,9453470,terminal half-lives,"The three adenosine agonists showed large differences in pharmacokinetic properties, resulting in terminal half-lives of 66 +/- 10, 8.2 +/- 0.4 and 24 +/- 1 min (mean +/- SEM) for SPA, CPA, and DCCA respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),min,8.2,56434,DB00640,Adenosine
,9453470,terminal half-lives,"The three adenosine agonists showed large differences in pharmacokinetic properties, resulting in terminal half-lives of 66 +/- 10, 8.2 +/- 0.4 and 24 +/- 1 min (mean +/- SEM) for SPA, CPA, and DCCA respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),min,24,56435,DB00640,Adenosine
,9453470,EC50,"For SPA, CPA, and DCCA the EC50 values based on free drug concentrations were 423 +/- 92, 1.8 +/- 0.4 and 9.5 +/- 1.1 nM respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,423,56436,DB00640,Adenosine
,9453470,EC50,"For SPA, CPA, and DCCA the EC50 values based on free drug concentrations were 423 +/- 92, 1.8 +/- 0.4 and 9.5 +/- 1.1 nM respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,1.8,56437,DB00640,Adenosine
,9453470,EC50,"For SPA, CPA, and DCCA the EC50 values based on free drug concentrations were 423 +/- 92, 1.8 +/- 0.4 and 9.5 +/- 1.1 nM respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,9.5,56438,DB00640,Adenosine
,9453470,Ki,"These in vivo values correlated closely with the affinity of the compounds for the adenosine A1 receptor as determined in radioligand binding studies, with corresponding Ki values of 1410 +/- 220, 4.7 +/- 0.6 and 102 +/- 74 nM (mean +/- SEM) respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,1410,56439,DB00640,Adenosine
,9453470,Ki,"These in vivo values correlated closely with the affinity of the compounds for the adenosine A1 receptor as determined in radioligand binding studies, with corresponding Ki values of 1410 +/- 220, 4.7 +/- 0.6 and 102 +/- 74 nM (mean +/- SEM) respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,4.7,56440,DB00640,Adenosine
,9453470,Ki,"These in vivo values correlated closely with the affinity of the compounds for the adenosine A1 receptor as determined in radioligand binding studies, with corresponding Ki values of 1410 +/- 220, 4.7 +/- 0.6 and 102 +/- 74 nM (mean +/- SEM) respectively.","Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453470/),nM,102,56441,DB00640,Adenosine
,24802860,t½,"After administration of rhPTH(1-84) 50 µg (n = 6) and 100 µg (n = 7), the approximate t½ was 2.5 to 3 hours.","Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802860/),h,2.5 to 3,56560,DB00640,Adenosine
,12643924,K(i),We searched for non-nucleoside inhibitors of adenosine deaminase by rational structure-based de novo design and succeeded in the discovery of 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide (FR221647: K(i)=5.9 microM to human ADA) as a novel inhibitor with moderate activity and good pharmacokinetics compared with the known inhibitors pentostatin and EHNA.,Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12643924/),μM,5.9,57863,DB00640,Adenosine
,12172971,peak,"In rats, [(3)H]8-Cl-AMP concentrations in PBMC were similar to those of the triphosphate metabolite which achieved a peak of 90 micro M 2 h after a bolus injection of 8-Cl-Ado (40 mg/kg).",Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172971/),μM,90,58665,DB00640,Adenosine
,30799546,AUC(0-12),"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[h·ng] / [ml],3403,58868,DB00640,Adenosine
,30799546,AUC(0-12),"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[h·ng] / [ml],8746,58869,DB00640,Adenosine
,30799546,Cmax,"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[ng] / [ml],475,58870,DB00640,Adenosine
,30799546,Cmax,"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[ng] / [ml],1568,58871,DB00640,Adenosine
,30799546,tmax,"Time to achieve maximal ticagrelor plasma concentration was also delayed in the MTH group (tmax for ticagrelor: 12 [6-24] vs. 4 [2-12] h, p = 0.01).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),h,12,58872,DB00640,Adenosine
,30799546,tmax,"Time to achieve maximal ticagrelor plasma concentration was also delayed in the MTH group (tmax for ticagrelor: 12 [6-24] vs. 4 [2-12] h, p = 0.01).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),h,4,58873,DB00640,Adenosine
,1998984,Binding,"Binding of ClddAd to human and mouse plasma proteins was determined by filtration to be 26.9% and 34.4%, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),%,26.9,59340,DB00640,Adenosine
,1998984,Binding,"Binding of ClddAd to human and mouse plasma proteins was determined by filtration to be 26.9% and 34.4%, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),%,34.4,59341,DB00640,Adenosine
,1998984,lethal dose,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],27,59342,DB00640,Adenosine
,1998984,lethal dose,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],24,59343,DB00640,Adenosine
,1998984,LD50,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],27,59344,DB00640,Adenosine
,1998984,LD50,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],24,59345,DB00640,Adenosine
,1998984,LD10,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],27,59346,DB00640,Adenosine
,1998984,LD10,"Estimates of the lethal dose for 50% (LD50) and 10% (LD10) of male CD2F1 mice that received a single i.v. dose of ClddAd were 27 and 24 mg/kg, respectively.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[mg] / [kg],24,59347,DB00640,Adenosine
,1998984,half-lives,"Elimination of a 24-mg/kg i.v. bolus dose of ClddAd from mouse plasma was biphasic, with half-lives of 0.73 and 14.7 min.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),min,0.73,59348,DB00640,Adenosine
,1998984,half-lives,"Elimination of a 24-mg/kg i.v. bolus dose of ClddAd from mouse plasma was biphasic, with half-lives of 0.73 and 14.7 min.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),min,14.7,59349,DB00640,Adenosine
,1998984,apparent volume of distribution,The apparent volume of distribution of ClddAd was 215 ml/kg and the total body clearance was 20 ml min-1 kg-1.,"Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[ml] / [kg],215,59350,DB00640,Adenosine
,1998984,total body clearance,The apparent volume of distribution of ClddAd was 215 ml/kg and the total body clearance was 20 ml min-1 kg-1.,"Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),[ml] / [kg·min],20,59351,DB00640,Adenosine
,1998984,total urinary excretion,"ClddAd was detected in the urine of mice within 2 min after exposure, and the total urinary excretion of unchanged ClddAd for 24 h after exposure to 24 mg/kg was 3.4% of the delivered dose.","Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998984/),%,3.4,59352,DB00640,Adenosine
,29332604,plasma AUC,The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],16.4,60224,DB00640,Adenosine
,29332604,plasma AUC,The mean plasma AUC was 16.4 ± 1.4 h µg/ml for temozolomide alone and 16.6 ± 2.87 h µg/ml with addition of regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],16.6,60225,DB00640,Adenosine
,29332604,AUC,The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],2.9,60226,DB00640,Adenosine
,29332604,AUC,The mean dialysate AUC was 2.9 ± 1.2 h µg/ml with temozolomide alone and 3.0 ± 1.7 h µg/ml with regadenoson.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),[h·μg] / [ml],3.0,60227,DB00640,Adenosine
,29332604,brain:plasma AUC ratio,The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),%,18.0,60228,DB00640,Adenosine
,29332604,brain:plasma AUC ratio,The mean brain:plasma AUC ratio was 18.0 ± 7.8 and 19.1 ± 10.7% for temozolomide alone and with regadenoson respectively.,The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332604/),%,19.1,60229,DB00640,Adenosine
,6882466,half-life,"The mononitrates were eliminated with a half-life of 30-70 min, giving rise to the completely denitrated product, adenosine-5'-(N-ethyl-carboxamide) (NECA).","Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),min,30-70,60525,DB00640,Adenosine
,6882466,half-life,The latter product was not further metabolized and was eliminated with a half-life of about 4 hr.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),h,4,60526,DB00640,Adenosine
,6882466,Urinary excretion,Urinary excretion averaged 50% of the administered dose within 4 days and was represented essentially by the completely denitrated drug.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,50,60527,DB00640,Adenosine
,6882466,Oral bioavailability,Oral bioavailability of the drug was about 90%.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,90,60528,DB00640,Adenosine
,23735758,half-life,"In addition, the half-life of the H12-(ADP)-liposomes in humans was predicted to be approximately 96 hours from pharmacokinetic data obtained for mice, rats, and rabbits using an allometric equation.",Pharmacokinetic study of the structural components of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735758/),h,96,62628,DB00640,Adenosine
,32157685,IC50,"TPE effectively inhibited the metabolism of ticagrelor in vitro, with epigallocatechin-3-gallate as the major constituent responsible for the observed inhibitory effects in human liver microsomes and intestinal microsomes (IC50 = 4.23 ± 0.18 µM).",Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32157685/),μM,4.23,63907,DB00640,Adenosine
,17310264,K(i),"SCH58261 was the most potent antagonist of the human A2A with a K(i) value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K(i) value of 1.2 nM.","Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310264/),nM,4,64151,DB00640,Adenosine
,17310264,K(i),"SCH58261 was the most potent antagonist of the human A2A with a K(i) value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K(i) value of 1.2 nM.","Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310264/),nM,1.2,64152,DB00640,Adenosine
,24291606,flow rate,"The separation was performed on a ZorbaxSB-C18 column (3.5μm, 2.1mm×100mm) at a flow rate of 0.2mL/min, using acetonitrile/water containing 0.1% formic acid (v/v) as mobile phase.",Determination of YZG-331 in mouse plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291606/),[ml] / [min],0.2,67038,DB00640,Adenosine
greater,24291606,recoveries,The average recoveries of analytes were greater than 94.3%.,Determination of YZG-331 in mouse plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291606/),%,94.3,67039,DB00640,Adenosine
,22167566,T(max),"Whereas T(max) was increased from 0.9 hours to 2.6 hours and maximum concentration (C(max)) was decreased (from 212 ng/mL to 128 ng/mL), the extent of absorption (area under the plasma concentration-time curve from time 0 to time of final quantifiable sample, or AUC([tf])) was unaffected by the meal.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),h,0.9,69616,DB00640,Adenosine
,22167566,T(max),"Whereas T(max) was increased from 0.9 hours to 2.6 hours and maximum concentration (C(max)) was decreased (from 212 ng/mL to 128 ng/mL), the extent of absorption (area under the plasma concentration-time curve from time 0 to time of final quantifiable sample, or AUC([tf])) was unaffected by the meal.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),h,2.6,69617,DB00640,Adenosine
,22167566,maximum concentration (C(max)),"Whereas T(max) was increased from 0.9 hours to 2.6 hours and maximum concentration (C(max)) was decreased (from 212 ng/mL to 128 ng/mL), the extent of absorption (area under the plasma concentration-time curve from time 0 to time of final quantifiable sample, or AUC([tf])) was unaffected by the meal.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),[ng] / [ml],212,69618,DB00640,Adenosine
,22167566,maximum concentration (C(max)),"Whereas T(max) was increased from 0.9 hours to 2.6 hours and maximum concentration (C(max)) was decreased (from 212 ng/mL to 128 ng/mL), the extent of absorption (area under the plasma concentration-time curve from time 0 to time of final quantifiable sample, or AUC([tf])) was unaffected by the meal.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),[ng] / [ml],128,69619,DB00640,Adenosine
,22167566,C(max),"Similarly, SCH434748 T(max) was prolonged in the fed state, and C(max) decreased from 43.7 ng/mL to 28.6 ng/mL.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),[ng] / [ml],43.7,69620,DB00640,Adenosine
,22167566,C(max),"Similarly, SCH434748 T(max) was prolonged in the fed state, and C(max) decreased from 43.7 ng/mL to 28.6 ng/mL.",Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22167566/),[ng] / [ml],28.6,69621,DB00640,Adenosine
,23955479,apparent clearance,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[ml] / [h·kg],110.5,69628,DB00640,Adenosine
,23955479,apparent clearance,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[ml] / [h·kg],157.4,69629,DB00640,Adenosine
,23955479,AUC0-6 (area under the plasma concentrations vs. time curve,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[h·μg] / [ml],7.9,69630,DB00640,Adenosine
,23955479,AUC0-6 (area under the plasma concentrations vs. time curve,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[h·μg] / [ml],5.7,69631,DB00640,Adenosine
,17706181,flow rate,"The system was operated at ambient temperature with a flow rate of 0.3 mL/min, and UV wavelength at 265 nm, and an operating pressure of ca. 1.56 kpsi.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),[ml] / [min],0.3,69932,DB00640,Adenosine
,17706181,retention times,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),min,13.5,69933,DB00640,Adenosine
,17706181,retention times,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),min,21,69934,DB00640,Adenosine
,17706181,recoveries,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),%,80 - 95,69935,DB00640,Adenosine
,14534354,maximum effect (Emax,"The maximum effect (Emax = 83.6%) was achieved rapidly and gradually returned to baseline values, although inhibition could be measured long after abciximab concentrations dropped below the detection limit.",Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534354/),%,83.6,70375,DB00640,Adenosine
,6150081,half-life of disappearance from serum,Its half-life of disappearance from serum was about 2 h during the initial 8 h after administration and then about 6.4 h for the next 16 h.,Physiological disposition of oral piracetam in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150081/),h,2,70940,DB00640,Adenosine
,6150081,half-life of disappearance from serum,Its half-life of disappearance from serum was about 2 h during the initial 8 h after administration and then about 6.4 h for the next 16 h.,Physiological disposition of oral piracetam in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6150081/),h,6.4,70941,DB00640,Adenosine
,18489992,Relapse rate,Relapse rate was 25% at 2 years.,Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18489992/),%,25,71153,DB00640,Adenosine
,21132026,area under the concentration-time curve (AUC),BU was given once daily at 130 mg/m(2) per day on days 1 and 2; doses for days 3 and 4 were adjusted in 92 patients (63%) to an average daily area under the concentration-time curve (AUC) of 5300 μM/min.,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[μM] / [min],5300,71274,DB00640,Adenosine
,21132026,clearance,Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P=0.001).,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[ml] / [kg·min],2.9,71275,DB00640,Adenosine
,21132026,clearance,Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P=0.001).,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[ml] / [kg·min],2.5,71276,DB00640,Adenosine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,20,71850,DB00640,Adenosine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,21,71851,DB00640,Adenosine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,12,71852,DB00640,Adenosine
,6489422,apparent volumes of distribution,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),[ml] / [kg],407,71984,DB00640,Adenosine
,6489422,apparent volumes of distribution,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),[ml] / [kg],443,71985,DB00640,Adenosine
,6489422,terminal half-lives,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),min,81,71986,DB00640,Adenosine
,6489422,terminal half-lives,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),min,101,71987,DB00640,Adenosine
,6489422,body clearances,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),[ml] / [kg·min],3.7,71988,DB00640,Adenosine
,6489422,body clearances,"The apparent volumes of distribution after the 100 and 500 mg doses were 407 +/- 27 and 443 +/- 36 ml/kg (mean +/- SEM), terminal half-lives 81 +/- 8 and 101 +/- 7 min and body clearances 3.7 +/- 0.5 and 3.1 +/- 0.2 ml/min per kg.",Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),[ml] / [kg·min],3.1,71989,DB00640,Adenosine
,6489422,Urinary excretion,Urinary excretion was 34 +/- 3 and 40 +/- 2% of the administered dose.,Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),%,34,71990,DB00640,Adenosine
,6489422,Urinary excretion,Urinary excretion was 34 +/- 3 and 40 +/- 2% of the administered dose.,Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489422/),%,40,71991,DB00640,Adenosine
,22061261,elimination half-life,"In comparison with free drug, encapsulation of the DZNep in pegylated liposomes resulted in 99.3% reduction of the plasma clearance, whereas it increased the elimination half-life from 1.1 h to 8.0 h and the area under the plasma concentration curve by 138-fold.",Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22061261/),h,1.1,72264,DB00640,Adenosine
,22061261,elimination half-life,"In comparison with free drug, encapsulation of the DZNep in pegylated liposomes resulted in 99.3% reduction of the plasma clearance, whereas it increased the elimination half-life from 1.1 h to 8.0 h and the area under the plasma concentration curve by 138-fold.",Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22061261/),h,8.0,72265,DB00640,Adenosine
,34329753,area under the curve,"The dosing of busulfan was determined from pharmacokinetic analyses to achieve for the course a target area under the curve of 20,000 ± 12% μmol/min, which is close to the average exposure of myeloablative dose of busulfan.",Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329753/),[%·μM] / [min],"20,000",73468,DB00640,Adenosine
more,28619366,half-life,"In in vivo pharmacokinetic study, the half-life of BPI-3016 was more than 95h after single dosing in diabetic cynomolgus monkeys.","BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28619366/),h,95,73759,DB00640,Adenosine
,12439044,clearance rate,"The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.",Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439044/),[l] / [h·m],12.4,74076,DB00640,Adenosine
,7850921,plasma concentrations at steady-state (Cpss),Average plasma concentrations at steady-state (Cpss) ranged from 3 ng/ml at the initial dose level to 13 ng/ml at the dose level of 8.1 mg/m2 per day.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),[ng] / [ml],3,74206,DB00640,Adenosine
,7850921,plasma concentrations at steady-state (Cpss),Average plasma concentrations at steady-state (Cpss) ranged from 3 ng/ml at the initial dose level to 13 ng/ml at the dose level of 8.1 mg/m2 per day.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),[ng] / [ml],13,74207,DB00640,Adenosine
,7850921,maximum tolerated dose,The maximum tolerated dose for 2-CdA given by 5-day continuous infusion was 8.1 mg/m2 per day in this study.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),mg,8,74208,DB00640,Adenosine
,9598154,terminal half life (t1/2),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,21.1,74598,DB00640,Adenosine
,9598154,area under the curve (AUC),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),μMh,1.2,74599,DB00640,Adenosine
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,14.6,74600,DB00640,Adenosine
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,9.7,74601,DB00640,Adenosine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],46.9,76468,DB00640,Adenosine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],16.6,76469,DB00640,Adenosine
,31511257,renal clearance,"The renal clearance (46.9 ± 4.9 ml/min per kilogram) of exogenously given m1A was decreased to near the glomerular filtration rates by Oct1/2 double knockout or Mate1 inhibition by pyrimethamine (16.6 ± 2.6 and 24.3 ± 0.6 ml/min per kilogram, respectively), accompanied by significantly higher plasma concentrations.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],24.3,76470,DB00640,Adenosine
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],244,76471,DB00640,Adenosine
,31511257,renal clearance,"The renal clearance of m1A in younger (21-45 year old) and older (65-79 year old) volunteers (244 ± 58 and 169 ± 22 ml/min per kilogram, respectively) was about 2-fold higher than the creatinine clearance.",Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511257/),[ml] / [kg·min],169,76472,DB00640,Adenosine
,9016325,oral bioavailability,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),%,47,77045,DB00640,Adenosine
,9016325,plasma elimination half-life,"With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.",Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9016325/),h,3,77046,DB00640,Adenosine
,6169773,half-lives,"The mean half-lives of ara-AMP, ara-A, and ara-Hx were 0.14 hr, 0.17 hr, and 3.5 hr, respectively.",Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6169773/),h,0.14,77175,DB00640,Adenosine
,6169773,half-lives,"The mean half-lives of ara-AMP, ara-A, and ara-Hx were 0.14 hr, 0.17 hr, and 3.5 hr, respectively.",Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6169773/),h,0.17,77176,DB00640,Adenosine
,6169773,half-lives,"The mean half-lives of ara-AMP, ara-A, and ara-Hx were 0.14 hr, 0.17 hr, and 3.5 hr, respectively.",Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6169773/),h,3.5,77177,DB00640,Adenosine
,1699279,t1/2 alpha,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),min,4.97,77345,DB00640,Adenosine
,1699279,t1/2 beta,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,1.38,77346,DB00640,Adenosine
,1699279,t1/2 gamma,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.41,77347,DB00640,Adenosine
,1699279,mean residence time,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.51,77348,DB00640,Adenosine
,1699279,total-body plasma clearance,The mean total-body plasma clearance was 67.98 +/- 19.58 mL/min/m2 (mean +/- SD).,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[ml] / [m2·min],67.98,77349,DB00640,Adenosine
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],7.49,77350,DB00640,Adenosine
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],0.20,77351,DB00640,Adenosine
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],44.17,77352,DB00640,Adenosine
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],1.19,77353,DB00640,Adenosine
,15757511,Clearance,"Clearance was found to be 39.3 L/hour, with a large interindividual variability.",Application of population pharmacokinetics to cladribine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),[l] / [h],39.3,77590,DB00640,Adenosine
,15757511,half-life,The half-life for the terminal phase was 16 hours.,Application of population pharmacokinetics to cladribine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),h,16,77591,DB00640,Adenosine
,15757511,Bioavailability,"Bioavailability was 100% and 35% for subcutaneous and oral administration, respectively, with low interindividual variability.",Application of population pharmacokinetics to cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),%,100,77592,DB00640,Adenosine
,15757511,Bioavailability,"Bioavailability was 100% and 35% for subcutaneous and oral administration, respectively, with low interindividual variability.",Application of population pharmacokinetics to cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),%,35,77593,DB00640,Adenosine
,15225677,retention times,"Based on the present study, the retention times for CPA and CHA were 3.029 +/- 0.017 min and 5.07 +/- 0.031 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,3.029,77917,DB00640,Adenosine
,15225677,retention times,"Based on the present study, the retention times for CPA and CHA were 3.029 +/- 0.017 min and 5.07 +/- 0.031 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,5.07,77918,DB00640,Adenosine
,15225677,half-lives,"In addition, the maximum concentrations of CPA and CHA were measured 60 and 80 min after the administration, and the half-lives of these compounds in the circulation were approximately 48.5 +/- 4.4 min and 106.6 +/- 7.4 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,48.5,77919,DB00640,Adenosine
,15225677,half-lives,"In addition, the maximum concentrations of CPA and CHA were measured 60 and 80 min after the administration, and the half-lives of these compounds in the circulation were approximately 48.5 +/- 4.4 min and 106.6 +/- 7.4 min, respectively.",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,106.6,77920,DB00640,Adenosine
,15225677,elimination half-life,"Moreover, in the present study, the elimination half-life was approximately sevenfold longer than that previously reported for CPA (48.5 +/- 4.4 min versus 6.9 +/- 0.5] min).",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,48.5,77921,DB00640,Adenosine
,15225677,elimination half-life,"Moreover, in the present study, the elimination half-life was approximately sevenfold longer than that previously reported for CPA (48.5 +/- 4.4 min versus 6.9 +/- 0.5] min).",Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15225677/),min,6.9,77922,DB00640,Adenosine
,27842891,Ki,"SAR optimization resulted in identification of two novel A2BAdoR antagonists, 8-{1-[5-Oxo-1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-1H-pyrazol-4-yl}-1,3-dipropyl-xanthine (31) and 8-(1-{2-Oxo-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl}-1H-pyrazol-4-yl)-1,3-dipropyl-xanthine (65), with high binding affinity (Ki = 1 and 1.5 nM, respectively) and selectivity for A2BAdoR with very good functional potency of 0.9 nM and 4 nM, respectively.","A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),nM,1,78418,DB00640,Adenosine
,27842891,Ki,"SAR optimization resulted in identification of two novel A2BAdoR antagonists, 8-{1-[5-Oxo-1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-1H-pyrazol-4-yl}-1,3-dipropyl-xanthine (31) and 8-(1-{2-Oxo-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl}-1H-pyrazol-4-yl)-1,3-dipropyl-xanthine (65), with high binding affinity (Ki = 1 and 1.5 nM, respectively) and selectivity for A2BAdoR with very good functional potency of 0.9 nM and 4 nM, respectively.","A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),nM,1.5,78419,DB00640,Adenosine
,27842891,oral bioavailability,Compound 31 and 65 also displayed good pharmacokinetic properties in mice with 27% and 65% oral bioavailability respectively.,"A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),%,27,78420,DB00640,Adenosine
,27842891,oral bioavailability,Compound 31 and 65 also displayed good pharmacokinetic properties in mice with 27% and 65% oral bioavailability respectively.,"A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),%,65,78421,DB00640,Adenosine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),min,30,79419,DB00640,Adenosine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),h,1.5,79420,DB00640,Adenosine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,84.1,79421,DB00640,Adenosine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,48.9,79422,DB00640,Adenosine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,78.8,79423,DB00640,Adenosine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,35.0,79424,DB00640,Adenosine
,22489610,time to maximum concentration,"Ticagrelor is rapidly absorbed, with a median time to maximum concentration of 1.3-2.0 hours.","Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22489610/),h,1.3-2.0,79556,DB00640,Adenosine
,23594968,exposure,Mean (coefficient of variation) exposure to R-138727 was 600 ng·h/mL (16%) after 60 mg prasugrel and 283 ng·h/mL (17%) after 30 mg.,Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],600,79636,DB00640,Adenosine
,23594968,exposure,Mean (coefficient of variation) exposure to R-138727 was 600 ng·h/mL (16%) after 60 mg prasugrel and 283 ng·h/mL (17%) after 30 mg.,Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],283,79637,DB00640,Adenosine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),,78.1,79638,DB00640,Adenosine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),,58.4,79639,DB00640,Adenosine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],38.3,79640,DB00640,Adenosine
,2612517,elimination t1/2,"S 9795 disappeared from plasma and brain almost in parallel, with comparable elimination t1/2 of about 0.8 h, regardless of the dose administered.","Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),h,0.8,80273,DB00640,Adenosine
,2612517,volume of distribution,The volume of distribution was high (about 3 1/kg) but total clearance was also high (about 40 ml/min/kg) and this explains the relatively short plasma and brain t1/2 of the drug in the rat.,"Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),[1] / [kg],3,80274,DB00640,Adenosine
,2612517,total clearance,The volume of distribution was high (about 3 1/kg) but total clearance was also high (about 40 ml/min/kg) and this explains the relatively short plasma and brain t1/2 of the drug in the rat.,"Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),[ml] / [kg·min],40,80275,DB00640,Adenosine
,2612517,t1/2,"Thereafter, S 10238 was likewise eliminated in parallel from both compartments, although at a slower rate (t1/2 of about 1.4 h) than its parent compound.","Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),h,1.4,80276,DB00640,Adenosine
less,2612517,AUC to plasma AUC ratio,"The brain AUC to plasma AUC ratio was slightly less than 1 for S 9795, about 0.1 for S 10238 and possibly more than 2 for norcyclizine, this latter being present in rat plasma at concentrations below the limits of sensitivity of the method (0.08 nmol/ml).","Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),,1,80277,DB00640,Adenosine
,2612517,AUC to plasma AUC ratio,"The brain AUC to plasma AUC ratio was slightly less than 1 for S 9795, about 0.1 for S 10238 and possibly more than 2 for norcyclizine, this latter being present in rat plasma at concentrations below the limits of sensitivity of the method (0.08 nmol/ml).","Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),,0.1,80278,DB00640,Adenosine
more,2612517,AUC to plasma AUC ratio,"The brain AUC to plasma AUC ratio was slightly less than 1 for S 9795, about 0.1 for S 10238 and possibly more than 2 for norcyclizine, this latter being present in rat plasma at concentrations below the limits of sensitivity of the method (0.08 nmol/ml).","Kinetics and brain uptake of S 9795, a new xanthine derivate, in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612517/),,2,80279,DB00640,Adenosine
,22658903,AUC,"Under the proposed approach, the topotecan dosing was selected so as to achieve the final AUC value of 140±20 ng/ml h.",Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22658903/),[ng] / [h·ml],140,81265,DB00640,Adenosine
,20590629,pIC(50),"The pIC(50) estimates for these receptors ranged from 7.3 to 8.5, while concentrations 300-fold higher had little or no effect on other P2X channels or on an assortment of receptors, enzymes and transporter proteins.","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,7.3 to 8.5,81834,DB00640,Adenosine
,20590629,oral bioavailability (%F,"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),,32.9,81835,DB00640,Adenosine
,20590629,half-life (t(1/2),"Favourable pharmacokinetic parameters were observed in rat, with good oral bioavailability (%F = 32.9), reasonable half-life (t(1/2) = 1.63 h) and plasma-free fraction (98.2% protein bound).","AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590629/),h,1.63,81836,DB00640,Adenosine
,12426519,peak concentration (C(max)),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],319.6,82575,DB00640,Adenosine
,12426519,area under the curve (AUC),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,239,82576,DB00640,Adenosine
,12426519,terminal half-life,"h/mL; and terminal half-life, 3.12 +/- 0.97 hours.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),h,3.12,82577,DB00640,Adenosine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],46.1,82578,DB00640,Adenosine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],81.7,82579,DB00640,Adenosine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],131.6,82580,DB00640,Adenosine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],119,82581,DB00640,Adenosine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],256,82582,DB00640,Adenosine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,389,82583,DB00640,Adenosine
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,2,82584,DB00640,Adenosine
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,5.9,82585,DB00640,Adenosine
,23473363,IC50,"G007-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice.","Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473363/),nM,46,83184,DB00640,Adenosine
,23473363,IC50,"G007-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice.","Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473363/),nM,25,83185,DB00640,Adenosine
,23473363,IC50,"G007-LK (66) displayed high selectivity toward tankyrases 1 and 2 with biochemical IC50 values of 46 nM and 25 nM, respectively, and a cellular IC50 value of 50 nM combined with an excellent pharmacokinetic profile in mice.","Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473363/),nM,50,83186,DB00640,Adenosine
,31871305,select,The selectivity for BTK over TEC found in these biochemical analyses was 1-1.5 for ibrutinib and 3.0-4.2 for acalabrutinib.,Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1-1.5,85108,DB00640,Adenosine
,31871305,select,The selectivity for BTK over TEC found in these biochemical analyses was 1-1.5 for ibrutinib and 3.0-4.2 for acalabrutinib.,Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,3.0-4.2,85109,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,2.53,85110,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.05,85111,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.51,85112,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,0.97,85113,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.13,85114,DB00640,Adenosine
,31871305,selectivities,"In MWCL-1 cells, BTK/TEC selectivities measured at 0.5, 1, and 3 hours were 2.53, 1.05, and 1.51 for ibrutinib and 0.97, 1.13, and 2.56 for acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,2.56,85115,DB00640,Adenosine
,31871305,selectivity,"The equivalent selectivity measured in samples from patients with CLL were 1.31 ± 0.27 and 1.09 ± 0.11 for ibrutinib and acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.31,85116,DB00640,Adenosine
,31871305,selectivity,"The equivalent selectivity measured in samples from patients with CLL were 1.31 ± 0.27 and 1.09 ± 0.11 for ibrutinib and acalabrutinib, respectively.",Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871305/),,1.09,85117,DB00640,Adenosine
,17125265,Ki,"Compound 14, the (R)-isomer of 7,8-dihydro-8-ethyl-2-(4-bicyclo[2.2.2]octan-1-ol)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the other three adenosine receptor subtypes: A1 (human) Ki=22 nM; A2A (human) Ki=4400 nM; A2B (human) Ki=580 nM; A3 (human) Ki>or=10,000 nM.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),nM,22,86823,DB00640,Adenosine
,17125265,Ki,"Compound 14, the (R)-isomer of 7,8-dihydro-8-ethyl-2-(4-bicyclo[2.2.2]octan-1-ol)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the other three adenosine receptor subtypes: A1 (human) Ki=22 nM; A2A (human) Ki=4400 nM; A2B (human) Ki=580 nM; A3 (human) Ki>or=10,000 nM.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),nM,4400,86824,DB00640,Adenosine
,17125265,Ki,"Compound 14, the (R)-isomer of 7,8-dihydro-8-ethyl-2-(4-bicyclo[2.2.2]octan-1-ol)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the other three adenosine receptor subtypes: A1 (human) Ki=22 nM; A2A (human) Ki=4400 nM; A2B (human) Ki=580 nM; A3 (human) Ki>or=10,000 nM.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),nM,580,86825,DB00640,Adenosine
>or=,17125265,Ki,"Compound 14, the (R)-isomer of 7,8-dihydro-8-ethyl-2-(4-bicyclo[2.2.2]octan-1-ol)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the other three adenosine receptor subtypes: A1 (human) Ki=22 nM; A2A (human) Ki=4400 nM; A2B (human) Ki=580 nM; A3 (human) Ki>or=10,000 nM.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),nM,"10,000",86826,DB00640,Adenosine
,17125265,pA2,Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.88 and is highly soluble in water (>100 mg/mL).,Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),,8.88,86827,DB00640,Adenosine
,17125265,oral bioavailability,"In addition, it has an oral bioavailability of 84% and an oral half-life of 3.8 h in rats.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),%,84,86828,DB00640,Adenosine
,17125265,oral half-life,"In addition, it has an oral bioavailability of 84% and an oral half-life of 3.8 h in rats.",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),h,3.8,86829,DB00640,Adenosine
,17125265,ED50,"When orally administered in a rat diuresis model, compound 14 promoted sodium excretion (ED50=0.01 mg/kg).",Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125265/),[mg] / [kg],0.01,86830,DB00640,Adenosine
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],21.4,87213,DB00640,Adenosine
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],88.1,87214,DB00640,Adenosine
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],34.4,87215,DB00640,Adenosine
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],41.4,87216,DB00640,Adenosine
,7582553,Emax,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),b·m·p,198,89720,DB00640,Adenosine
,7582553,EC50,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),[ng] / [ml],2.1,89721,DB00640,Adenosine
,7582553,Hill factor,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),,2.3,89722,DB00640,Adenosine
,7582553,EC50,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),[ng] / [ml],3.7,89723,DB00640,Adenosine
,7582553,Hill factor,"For CPA the values were (mean +/- s.e.): Emax = 198 +/- 11 b.p.m., EC50 = 2.1 +/- 0.7 ng ml-1, Hill factor = 2.3 +/- 0.6 and for CPT: EC50 = 3.7 +/- 0.3 ng ml-1 and Hill factor = 3.1 +/- 0.1.",Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582553/),,3.1,89724,DB00640,Adenosine
,8593479,Km,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [ml],1.69,90734,DB00640,Adenosine
,8593479,Vmax,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [min·ml],4.32,90735,DB00640,Adenosine
,8593479,biological half-life,"After intravenous bolus injection, Ap4A in plasma declined rapidly and the rate of elimination was dose-dependent: the biological half-life was about 3s at the dose of 1 mg/kg and was longer at 3 mg/kg.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),s,3,90736,DB00640,Adenosine
,25614114,inhibitory activities (IC50),The observed ATPase inhibitory activities (IC50) of these compounds range between 0.36 and 5.45μM.,"Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,0.36 and 5.45,91578,DB00640,Adenosine
>,25614114,CC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[μg] / [ml],300,91579,DB00640,Adenosine
,25614114,IC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,0.51,91580,DB00640,Adenosine
>,25614114,IC50,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),μM,100,91581,DB00640,Adenosine
>,25614114,selectivity,"The lead compound 9d [N-(7-chloro-2-methylquinolin-4-yl)-N-(3-((diethylamino)methyl)-4-hydroxyphenyl)-2,3-dichlorobenzenesulfonamide] with null cytotoxicity (CC50>300μg/mL) and excellent anti-mycobacterial activity and selectivity (mycobacterium ATPase IC50=0.51μM, mammalian ATPase IC50>100μM, and selectivity >200) exhibited a complete growth inhibition of replicating Mycobacterium tuberculosis H37Rv at 3.12μg/mL.","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),,200,91582,DB00640,Adenosine
,25614114,volume of distribution (Vss,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[l] / [kg],0.41,91583,DB00640,Adenosine
,25614114,clearance,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),[l] / [h·kg],0.06,91584,DB00640,Adenosine
,25614114,half-life,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),h,4.2,91585,DB00640,Adenosine
,25614114,absolute bioavailability,"It exhibited a high volume of distribution (Vss, 0.41L/kg), moderate clearance (0.06L/h/kg), long half-life (4.2h) and low absolute bioavailability (1.72%).","Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25614114/),%,1.72,91586,DB00640,Adenosine
,15229462,plasma levels,"The ABCG2 421C>A genotype significantly affected the pharmacokinetics of diflomotecan; in 5 patients heterozygous for this allele, plasma levels after intravenous drug administration were 299% (P =.015) of those in 15 patients with wild-type alleles, at mean values of 138 ng x h/mL x mg(-1) (95% confidence interval, 11.3-264 ng x h/mL x mg(-1)) versus 46.1 ng x h/mL x mg(-1) (95% confidence interval, 25.6-66.7 ng x h/mL x mg(-1)), respectively.",Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229462/),[h·ml·ng] / [mg],46.1,92257,DB00640,Adenosine
,31517281,tmax,"In vivo tmax of the IM administered poloxamer in situ forming gels was about 6 h and a short-term sustained drug release was observed in vivo in rats up to 24 h after dosing, similar to a solution of bedaquiline fumarate salt in polyethylene glycol (PEG400)/water.",In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31517281/),h,6,92697,DB00640,Adenosine
,22367426,time to maximum concentration (C(max)) (t(max)),"Ticagrelor was rapidly absorbed [time to maximum concentration (C(max)) (t(max)) 2.5-3.0 h], and its major active metabolite, AR-C124910XX rapidly formed (t(max) 3.0-3.5 h) in all groups.",Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367426/),h,2.5-3.0,92975,DB00640,Adenosine
,22367426,t(max),"Ticagrelor was rapidly absorbed [time to maximum concentration (C(max)) (t(max)) 2.5-3.0 h], and its major active metabolite, AR-C124910XX rapidly formed (t(max) 3.0-3.5 h) in all groups.",Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367426/),h,3.0-3.5,92976,DB00640,Adenosine
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,41,94855,DB00640,Adenosine
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,45.5,94856,DB00640,Adenosine
,32614585,Ki,"Extensive interrogation of structure-activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73.",Discovery of AB680: A Potent and Selective Inhibitor of CD73. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32614585/),pM,5,95033,DB00640,Adenosine
,21195038,m/z,"LC-MS/MS in positive ion mode was used to perform multiple reaction monitoring at m/z of 263/135 and 267/135 for DZNep and tubercidin, respectively.","Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21195038/),,263/135,95268,DB00640,Adenosine
,21195038,m/z,"LC-MS/MS in positive ion mode was used to perform multiple reaction monitoring at m/z of 263/135 and 267/135 for DZNep and tubercidin, respectively.","Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21195038/),,267/,95269,DB00640,Adenosine
,11076086,AUC,"The main pharmacokinetic parameters of 8-Cl-Ad, t1/2beta and AUC, were 69.30 min and 580 microg min/ml.",Determination of pharmacokinetics of 8-chloroadenosine and its two major metabolites in dogs by high-performance liquid chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076086/),[min·μg] / [ml],580,95879,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,46.2,96298,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,20.5,96299,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,25.6,96300,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,51.3,96301,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,17.9,96302,DB00640,Adenosine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,33.3,96303,DB00640,Adenosine
,14524733,overall response,These results were similar to the 48% overall response rate reported in a similar historical control group treated with intravenous fludarabine.,Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,48,96304,DB00640,Adenosine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.0,96562,DB00640,Adenosine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.25,96563,DB00640,Adenosine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,0.5,96564,DB00640,Adenosine
,23126367,elimination half-life,Grapefruit juice had a minor effect on ticagrelor elimination half-life prolonging it from 6.7 to 7.2 h (P = 0.036).,Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126367/),h,6.7 to 7.2,96591,DB00640,Adenosine
,15133532,terminal half-life (t(1/2)),The mean terminal half-life (t(1/2)) of RPR749 and RPR772 were similar (approximately 16.4 hours).,"Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15133532/),h,16.4,96826,DB00640,Adenosine
,20386016,t(max),"RO5068760 was absorbed with a t(max), of 2 hours.","The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386016/),h,2,97686,DB00640,Adenosine
,20386016,terminal elimination t(1/2),Disposition appeared to be biphasic with a terminal elimination t(1/2) of 5 to 9 hours.,"The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386016/),h,5 to 9,97687,DB00640,Adenosine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,"97,",97878,DB00640,Adenosine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,317,97879,DB00640,Adenosine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,3000,97880,DB00640,Adenosine
,18539312,IC50,"BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50=290 nM) in human blood.",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,290,97881,DB00640,Adenosine
,25243188,half-life,Pharmacokinetic studies demonstrated a short (5 min) half-life of ADAC in plasma after intravenous administration without detection of degradation products.,Adenosine amine congener as a cochlear rescue agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243188/),min,5,98236,DB00640,Adenosine
,33822617,clearance,"The rat pharmacokinetic profile is favorable with high oral bioavailability, modest clearance (0.79 L/(h kg)), and good CNS permeability.",Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822617/),[l] / [h·kg],0.79,99836,DB00640,Adenosine
,27991894,"SE, AUC","To test this hypothesis, we treated 218 patients (median age 50.7 years, male/female 50/50%) with fludarabine 40 mg/m2 once daily x4, each dose followed by IV Bu, randomized to 130 mg/m2 (N=107) or PK-guided to average daily SE, AUC of 6000 μM min (N=111), stratified for remission status and allo-grafting from HLA-matched donors.",Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27991894/),min·μM,6000,100001,DB00640,Adenosine
,20027108,apparent terminal half-life (t1/2),"The apparent terminal half-life (t1/2) for midazolam was similar in the presence/absence of rolofylline (4.31 and 4.27 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.31,101412,DB00640,Adenosine
,20027108,apparent terminal half-life (t1/2),"The apparent terminal half-life (t1/2) for midazolam was similar in the presence/absence of rolofylline (4.31 and 4.27 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.27,101413,DB00640,Adenosine
,20027108,t1/2,"The t1/2 for 1'-hydroxymidazolam was slightly higher in the presence relative to absence of rolofylline (4.24 and 3.17 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.24,101414,DB00640,Adenosine
,20027108,t1/2,"The t1/2 for 1'-hydroxymidazolam was slightly higher in the presence relative to absence of rolofylline (4.24 and 3.17 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,3.17,101415,DB00640,Adenosine
,30448313,peak plasma concentration (Cmax),"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,238.09,101782,DB00640,Adenosine
,30448313,relative bioavailability,"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,219.78,101783,DB00640,Adenosine
,33293242,plasma elimination half-life,The plasma elimination half-life of caffeine in the newborn is approximately 100 h.,"Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33293242/),h,100,103059,DB00640,Adenosine
,2502563,initial phase half-life (t1/2 alpha),"The initial phase half-life (t1/2 alpha) and final phase half-life (t1/2 beta) of Y-20811, calculated from the change in plasma concentration, were 0.1-0.3 hours and 1.9-3.1 hours, respectively.","Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by intravenous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2502563/),h,0.1-0.3,103299,DB00640,Adenosine
,2502563,final phase half-life (t1/2 beta),"The initial phase half-life (t1/2 alpha) and final phase half-life (t1/2 beta) of Y-20811, calculated from the change in plasma concentration, were 0.1-0.3 hours and 1.9-3.1 hours, respectively.","Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2502563/),h,1.9-3.1,103300,DB00640,Adenosine
,24463402,flow rate,"Analytes were recovered by liquid-liquid extraction and separated on a reverse phase C18 column (150mm×4.6mm i.d., 5μm) using methanol:0.1% formic acid buffer (70:30) as mobile phase at a flow rate of 1mL/min in isocratic mode.","Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24463402/),[ml] / [min],1,103646,DB00640,Adenosine
,33835812,A2,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104512,DB00640,Adenosine
,33835812,EC50,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104513,DB00640,Adenosine
,20688583,Total analytical run time,Total analytical run time was short (2 min).,Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20688583/),min,2,104647,DB00640,Adenosine
,34075614,area under the concentration-time curve (AUC),"Patients received standard full-dose melphalan in 17 transplants, with median area under the concentration-time curve (AUC) of 5.5 mg*h/L (range, 3.0-9.5 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],5.5,105196,DB00640,Adenosine
,34075614,AUC,Patients received test-dose melphalan in 23 transplants with a test-dose PK predicted full-dose AUC range of 2.9-16.8 mg*h/L.,Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],2.9-16.8,105197,DB00640,Adenosine
,34075614,AUC,"In seven transplants where patients had baseline organ impairment, test-dose PK predicted higher exposure for standard full-dose (median AUC 13.8 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],13.8,105198,DB00640,Adenosine
,34075614,AUC,"Melphalan full-dose was adjusted in these patients, with achievement of desired target AUC (3.6-5.4 mg*h/L) and no excess toxicity.",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],3.6-5.4,105199,DB00640,Adenosine
,19862681,elimination half-life,"Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11.3+/-4.0 vs 9.7+/-2.0 h, p=0.053).","Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),h,11.3,105315,DB00640,Adenosine
,19862681,elimination half-life,"Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11.3+/-4.0 vs 9.7+/-2.0 h, p=0.053).","Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),h,9.7,105316,DB00640,Adenosine
,19862681,oral bioavailability,Estimated mean oral bioavailability of 2F-ara-A was 58%.,"Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),%,58,105317,DB00640,Adenosine
,1515641,t1/2 alpha,"Bolus intravenous injection of G4120 was followed by a biphasic disappearance of G4120 from plasma with t1/2 alpha of 3.7 minutes and t1/2 beta of 63 minutes, corresponding to a plasma clearance of 5.2 +/- 0.68 mL/min.","Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515641/),min,3.7,105332,DB00640,Adenosine
,1515641,t1/2 beta,"Bolus intravenous injection of G4120 was followed by a biphasic disappearance of G4120 from plasma with t1/2 alpha of 3.7 minutes and t1/2 beta of 63 minutes, corresponding to a plasma clearance of 5.2 +/- 0.68 mL/min.","Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515641/),min,63,105333,DB00640,Adenosine
,1515641,plasma clearance,"Bolus intravenous injection of G4120 was followed by a biphasic disappearance of G4120 from plasma with t1/2 alpha of 3.7 minutes and t1/2 beta of 63 minutes, corresponding to a plasma clearance of 5.2 +/- 0.68 mL/min.","Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515641/),[ml] / [min],5.2,105334,DB00640,Adenosine
,1515641,ID50,"Bolus intravenous injection of G4120 inhibited ex vivo platelet aggregation with 0.5 mumol/L ADP and in vivo thrombus formation in a dose-dependent manner, with ID50 of 11 and 11 micrograms/kg, respectively.","Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515641/),[μg] / [kg],11,105335,DB00640,Adenosine
<,24041906,50% inhibitory concentrations,The two compounds inhibited the ATPase activity of GyrB and ParE with 50% inhibitory concentrations of <0.1 μg/ml.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.1,105887,DB00640,Adenosine
,24041906,MIC90s,MIC90s against clinical isolates ranged from 0.015 μg/ml for Streptococcus pneumoniae to 0.25 μg/ml for Staphylococcus aureus.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.015,105888,DB00640,Adenosine
,24041906,MIC90s,MIC90s against clinical isolates ranged from 0.015 μg/ml for Streptococcus pneumoniae to 0.25 μg/ml for Staphylococcus aureus.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.25,105889,DB00640,Adenosine
<,24041906,frequencies of spontaneous resistance,The frequencies of spontaneous resistance for S. aureus were <2.3 × 10(-10) with compound A and <5.8 × 10(-11) with compound B at concentrations equivalent to 8× the MICs.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),,2.3 × 10(-10),105890,DB00640,Adenosine
<,24041906,frequencies of spontaneous resistance,The frequencies of spontaneous resistance for S. aureus were <2.3 × 10(-10) with compound A and <5.8 × 10(-11) with compound B at concentrations equivalent to 8× the MICs.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),,5.8 × 10(-11),105891,DB00640,Adenosine
,24041906,oral bioavailability,The measured oral bioavailability of compound B was 47.7%.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),%,47.7,105892,DB00640,Adenosine
,8751041,elimination half-life,"The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 micrograms.min.",Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751041/),min,12.8,106791,DB00640,Adenosine
,8751041,area-under curve (AUC),"The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 micrograms.min.",Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751041/),min·μg,3.38,106792,DB00640,Adenosine
,9205820,binding constant Kd,"The estimate of the population parameter typical value (%CV) of the binding constant Kd and the maximal specific binding capacity (Bmax) was 0.385 (3.5) ng ml-1 plasma and 158 (2.1) ng ml-1 RBC, respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng·plasma] / [ml],0.385,107061,DB00640,Adenosine
,9205820,maximal specific binding capacity (Bmax),"The estimate of the population parameter typical value (%CV) of the binding constant Kd and the maximal specific binding capacity (Bmax) was 0.385 (3.5) ng ml-1 plasma and 158 (2.1) ng ml-1 RBC, respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng] / [ml],158,107062,DB00640,Adenosine
,9205820,Emax,"In plasma, typical values (%CV) of Emax, IC50 and Hill factor were 81.4 (1.9)%, 3.76 (9.3) ng ml-1 and 1.06 (3.4), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),%,81.,107063,DB00640,Adenosine
,9205820,Hill factor,"In plasma, typical values (%CV) of Emax, IC50 and Hill factor were 81.4 (1.9)%, 3.76 (9.3) ng ml-1 and 1.06 (3.4), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),,1.06,107064,DB00640,Adenosine
,9205820,Emax,"The relationship in whole blood was much steeper with population parameter typical values (%CV) of Emax, IC50 and Hill factor of 88.2 (2.0)%, 65.7 (2.8) ng ml-1 and 4.47 (5.5), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng] / [ml],88,107065,DB00640,Adenosine
,9205820,Hill factor,"The relationship in whole blood was much steeper with population parameter typical values (%CV) of Emax, IC50 and Hill factor of 88.2 (2.0)%, 65.7 (2.8) ng ml-1 and 4.47 (5.5), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),,4.47,107066,DB00640,Adenosine
,3512745,half-life of the terminal elimination phase,The half-life of the terminal elimination phase was 2.7 minutes.,Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),min,2.7,108574,DB00640,Adenosine
,3512745,systemic clearance,"The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ml] / [kg·min],93,108575,DB00640,Adenosine
,3512745,whole body volume of distribution,"The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ml] / [kg],357,108576,DB00640,Adenosine
greater,3512745,steady-state plasma concentrations,"At steady-state plasma concentrations of PGI2 greater than 0.1 ng/ml, the mean arterial blood pressure decreased in a concentration-dependent manner, reaching a decrease of 45 mm Hg when the plasma concentration was 7.6 ng/ml.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ng] / [ml],0,108577,DB00640,Adenosine
,31911147,intracellular half-life,The islatravir-triphosphate intracellular half-life was 78·5-128·0 h.,"Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911147/),h,78·5-128·0,108900,DB00640,Adenosine
<,20925957,AUC,We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu).,Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925957/),[μM] / [d·l·min],6000,109003,DB00640,Adenosine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB00640,Adenosine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB00640,Adenosine
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],45.97,111701,DB00640,Adenosine
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],39.23,111702,DB00640,Adenosine
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],17.97,111703,DB00640,Adenosine
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,9,112236,DB00640,Adenosine
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,4,112237,DB00640,Adenosine
,8788153,Recoveries,"Recoveries of sinefungin from plasma were 75 +/- 3.2% and 81 +/- 4.8% following dosage at concentrations of 10 micrograms/ml and 30 micrograms/ml, respectively.",Determination of sinefungin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8788153/),%,75,112332,DB00640,Adenosine
,8788153,Recoveries,"Recoveries of sinefungin from plasma were 75 +/- 3.2% and 81 +/- 4.8% following dosage at concentrations of 10 micrograms/ml and 30 micrograms/ml, respectively.",Determination of sinefungin in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8788153/),%,81,112333,DB00640,Adenosine
,17125264,ED50,Bicyclo[2.2.2]octylxanthine 16 exhibited good pharmaceutical properties and in vivo activity in a rat diuresis model (ED50=0.3 mg/kg po).,Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125264/),[mg] / [kg],0.3,114286,DB00640,Adenosine
,17125264,Ki,"Optimization of the bridgehead substituent led to propionic acid 29 (BG9928), which retained high potency (hA1, Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-fold versus adenosine A2B receptor) with improved oral efficacy in the rat diuresis model (ED50=0.01 mg/kg) as well as high oral bioavailability in rat, dog, and cynomolgus monkey.",Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125264/),nM,7,114287,DB00640,Adenosine
,17125264,ED50,"Optimization of the bridgehead substituent led to propionic acid 29 (BG9928), which retained high potency (hA1, Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-fold versus adenosine A2B receptor) with improved oral efficacy in the rat diuresis model (ED50=0.01 mg/kg) as well as high oral bioavailability in rat, dog, and cynomolgus monkey.",Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125264/),[mg] / [kg],0.01,114288,DB00640,Adenosine
,19432900,overall response rate,"The overall response rate was 50% (9/18; 80% confidence interval, 35-65%), with 11% (2/18) complete response.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),%,50,115476,DB00640,Adenosine
,19432900,time to progression,"With a median follow-up of 296 days, the estimated median time to progression for 18 eligible patients was 382 days.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),d,382,115477,DB00640,Adenosine
,28417436,area under the plasma concentration-time curve up to the last quantifiable time,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],174-175,115492,DB00640,Adenosine
,28417436,area under the plasma concentration-time curve up to the last quantifiable time,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],25-26,115493,DB00640,Adenosine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[ng] / [ml],134-153,115494,DB00640,Adenosine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],25-26,115495,DB00640,Adenosine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[ng] / [ml],25,115496,DB00640,Adenosine
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,2.3,116519,DB00640,Adenosine
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,6.4,116520,DB00640,Adenosine
,30745177,time to sputum culture conversion,The time to sputum culture conversion was 14-15 days.,"Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),d,14-15,116715,DB00640,Adenosine
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],50,116716,DB00640,Adenosine
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],"58,513",116717,DB00640,Adenosine
,30745177,AUC24h,"Plasma bedaquiline Cmax was achieved within 4-6 h of bedaquiline administration and AUC24h ranged from 50,637 to 107,300 ng*h/mL (5 patients) at week 2 and were 58,513 and 77,148 ng *h/mL (2 patients) at week 24.","Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745177/),[h·ng] / [ml],"77,148",116718,DB00640,Adenosine
,7974633,Recoveries,"Recoveries of CdA and CAde at 100 nmol/L were 90.6 +/- 4.9 and 98.7 +/- 7.8%, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,90.6,117141,DB00640,Adenosine
,7974633,Recoveries,"Recoveries of CdA and CAde at 100 nmol/L were 90.6 +/- 4.9 and 98.7 +/- 7.8%, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,98.7,117142,DB00640,Adenosine
,7974633,Recovery,Recovery of IS was 96.1 +/- 6.1% at 250 nmol/l.,Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,96.1,117143,DB00640,Adenosine
,7974633,limits of detection,"In plasma, limits of detection of CdA and CAde were 1 and 2 nmol/L, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],1,117144,DB00640,Adenosine
,7974633,limits of detection,"In plasma, limits of detection of CdA and CAde were 1 and 2 nmol/L, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],2,117145,DB00640,Adenosine
,7974633,limit of detection,"In urine, the limit of detection was 100 nmol/L for both compounds.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],100,117146,DB00640,Adenosine
,11451028,IC50,"In a cell line presenting an overexpressed amount of the human transporter, the enzyme exhibited a 40 microM IC50 for inhibition by bergamottin.",Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451028/),μM,40,117814,DB00640,Adenosine
,11451028,Km,"Additionally, using the ATP-hydrolysis assay, we showed that bergamottin increases P-gp-mediated ATP hydrolysis by approximately 2.3 fold with a Km of 8 microM.",Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451028/),μM,8,117815,DB00640,Adenosine
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,56.75,117862,DB00640,Adenosine
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,69.07,117863,DB00640,Adenosine
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,14.22,117864,DB00640,Adenosine
,28355069,EC50,"12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells.","Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28355069/),nM,57.9,117971,DB00640,Adenosine
,7906999,clearance,The mean (SD) clearance was 39.4 (12.4) liters/h/m2 and ranged from 14.4-55.4 liters/h/m2.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[l] / [h·m2],39.4,119294,DB00640,Adenosine
,7906999,steady-state plasma concentration,The mean (SD) steady-state plasma concentration (predicted 120-h concentration) was 37.7 (17.3) nM and ranged from 23.2-84.5 nM.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),nM,37.7,119295,DB00640,Adenosine
,7906999,steady-state plasma concentration,The mean (SD) steady-state plasma concentration (predicted 120-h concentration) was 37.7 (17.3) nM and ranged from 23.2-84.5 nM.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),nM,23.2-84.5,119296,DB00640,Adenosine
,7906999,terminal phase half-life,"The terminal phase half-life in 22 patients ranged from 14.3-25.8 h, with a mean (SD) of 19.7 (3.4) h.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),h,14.3-25.8,119297,DB00640,Adenosine
,7906999,terminal phase half-life,"The terminal phase half-life in 22 patients ranged from 14.3-25.8 h, with a mean (SD) of 19.7 (3.4) h.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),h,19.7,119298,DB00640,Adenosine
,7906999,volume of distribution at steady state,"The volume of distribution at steady state was highly variable, with a mean (SD) of 356.6 (225.2) liters/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[l] / [m2],356.6,119299,DB00640,Adenosine
,7906999,Renal clearance,"Renal clearance was determined in 7 patients and ranged from 34.6-643.6 ml/min/m2, with a mean (SD) of 317.9 (208.7) ml/min/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[ml] / [m2·min],34.6-643.6,119300,DB00640,Adenosine
,7906999,Renal clearance,"Renal clearance was determined in 7 patients and ranged from 34.6-643.6 ml/min/m2, with a mean (SD) of 317.9 (208.7) ml/min/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[ml] / [m2·min],317.9,119301,DB00640,Adenosine
,7906999,cerebrospinal fluid concentration,"In 11 patients, the mean (SD) cerebrospinal fluid concentration was 6.1 (3.97) nM, a mean of 18.2% of the steady-state plasma concentration.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),n,6,119302,DB00640,Adenosine
,8740794,Steady state plasma levels (Css),Steady state plasma levels (Css) of 8-Cl-cAMP in patients ranged from 0.15-0.72 microM but 8-Cl-adenosine was not detected in plasma.,"Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,0.15-0.72,120488,DB00640,Adenosine
,8740794,Css,"In mice, Css of 8-Cl-cAMP ranged from 3.2-4.6 microM and 8-Cl adenosine was present in plasma only at the higher dose (100 mg/kg/day, peak concentration of 2.3 microM).","Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,3.2-4.6,120489,DB00640,Adenosine
,8740794,peak concentration,"In mice, Css of 8-Cl-cAMP ranged from 3.2-4.6 microM and 8-Cl adenosine was present in plasma only at the higher dose (100 mg/kg/day, peak concentration of 2.3 microM).","Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,2.3,120490,DB00640,Adenosine
,30972696,oral clearances,Estimated oral clearances (35 kg patient; median bodyweight) were 22.8 L/h (ticagrelor) and 9.97 L/h (AR-C124910XX).,Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[l] / [h],22.8,120578,DB00640,Adenosine
,30972696,oral clearances,Estimated oral clearances (35 kg patient; median bodyweight) were 22.8 L/h (ticagrelor) and 9.97 L/h (AR-C124910XX).,Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[l] / [h],9.97,120579,DB00640,Adenosine
,30972696,maximum PRU effect,"Estimated baseline PRU was 283, maximum PRU effect was fixed at 1, and the ticagrelor concentration for half-maximum PRU effect was 233 nmol/L.",Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),,1,120580,DB00640,Adenosine
,30972696,half-maximum PRU effect,"Estimated baseline PRU was 283, maximum PRU effect was fixed at 1, and the ticagrelor concentration for half-maximum PRU effect was 233 nmol/L.",Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[nM] / [l],233,120581,DB00640,Adenosine
≥,34044184,trough levels,"We observed lower day +100 NRM in those with both high F-ara-ADay-4 trough levels (≥40 ng/mL; >25th percentile) and low PM AUC0-8 hr (<34,235 hr ng/mL; <75th percentile), compared with high exposures to both agents (hazard ratio, 0.06; 95% CI, 0.01 to 0.48).",Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34044184/),[ng] / [ml],40,121238,DB00640,Adenosine
<,34044184,AUC0-8 hr,"We observed lower day +100 NRM in those with both high F-ara-ADay-4 trough levels (≥40 ng/mL; >25th percentile) and low PM AUC0-8 hr (<34,235 hr ng/mL; <75th percentile), compared with high exposures to both agents (hazard ratio, 0.06; 95% CI, 0.01 to 0.48).",Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34044184/),[h·ng] / [ml],"34,235",121239,DB00640,Adenosine
,15812370,terminal half-life,The mean terminal half-life of binodenoson across all doses was 10 +/- 4 minutes.,Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15812370/),min,10,121818,DB00640,Adenosine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.9,122908,DB00640,Adenosine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.1,122909,DB00640,Adenosine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.2,122910,DB00640,Adenosine
,30532055,area under the concentration-vs-time curve (AUC),"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,4000,123452,DB00640,Adenosine
,30532055,area under the concentration-vs-time curve (AUC),"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,5000-6000,123453,DB00640,Adenosine
,30532055,total course AUC,"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,"16,000",123454,DB00640,Adenosine
,30532055,total course AUC,"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,"20,000-24,000",123455,DB00640,Adenosine
,20091161,time to peak plasma concentration (t(max)),"Absorption of ticagrelor was rapid [median time to peak plasma concentration (t(max)) 1.3-2 h], as was the formation of its main (active) metabolite, AR-C124910XX (t(max) 1.5-3 h).","Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,1.3-2,124637,DB00640,Adenosine
,20091161,t(max),"Absorption of ticagrelor was rapid [median time to peak plasma concentration (t(max)) 1.3-2 h], as was the formation of its main (active) metabolite, AR-C124910XX (t(max) 1.5-3 h).","Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,1.5-3,124638,DB00640,Adenosine
,20091161,terminal-phase half-life (t(1/2)),The mean terminal-phase half-life (t(1/2)) was approximately 7-8.5 h for ticagrelor and 8.5-10 h for AR-C124910XX; AR-C124910XX exposure was approximately one third that of ticagrelor.,"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,7-8.5,124639,DB00640,Adenosine
,20091161,terminal-phase half-life (t(1/2)),The mean terminal-phase half-life (t(1/2)) was approximately 7-8.5 h for ticagrelor and 8.5-10 h for AR-C124910XX; AR-C124910XX exposure was approximately one third that of ticagrelor.,"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,8.5-10,124640,DB00640,Adenosine
greater,28684371,cumulative area under the curve (cAUC),"In the setting of malignancy, disease-free survival was highest at 1 year after HCT in subjects achieving a systemic f-ara-a cumulative area under the curve (cAUC) greater than 15 mg*hour/L compared to patients with a cAUC less than 15 mg*hour/L (82.6% versus 52.8% P = .04).",Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684371/),[h·mg] / [l],15,124645,DB00640,Adenosine
less,28684371,cAUC,"In the setting of malignancy, disease-free survival was highest at 1 year after HCT in subjects achieving a systemic f-ara-a cumulative area under the curve (cAUC) greater than 15 mg*hour/L compared to patients with a cAUC less than 15 mg*hour/L (82.6% versus 52.8% P = .04).",Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684371/),[h·mg] / [l],15,124646,DB00640,Adenosine
,29915216,area under the concentration-time curve (AUC) from dosing to infinity,"After the first dose of fludarabine at 40 mg/m2, the median (min-max) values for the area under the concentration-time curve (AUC) from dosing to infinity and the elimination half-life were 4696 (3056-10,477) ng·h/mL and 7.95 (4.78-10.88) h, respectively.",Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915216/),[h·ng] / [ml],4696,125041,DB00640,Adenosine
,29915216,elimination half-life,"After the first dose of fludarabine at 40 mg/m2, the median (min-max) values for the area under the concentration-time curve (AUC) from dosing to infinity and the elimination half-life were 4696 (3056-10,477) ng·h/mL and 7.95 (4.78-10.88) h, respectively.",Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915216/),h,7.95,125042,DB00640,Adenosine
,1908444,total body clearance,ddIno elimination was dose-dependent with total body clearance ranging from 4 to 55 ml/min/kg in individual animals.,"Pharmacokinetics of 2',3'-dideoxyadenosine in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908444/),[ml] / [kg·min],4 to 55,126604,DB00640,Adenosine
,1908444,plasma half-life,"The plasma half-life was approximately 30 min after most routes of administration, but increased to approximately 60 min in two animals receiving a large intravenous dose of 500 mg/kg.","Pharmacokinetics of 2',3'-dideoxyadenosine in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908444/),min,30,126605,DB00640,Adenosine
,1908444,plasma half-life,"The plasma half-life was approximately 30 min after most routes of administration, but increased to approximately 60 min in two animals receiving a large intravenous dose of 500 mg/kg.","Pharmacokinetics of 2',3'-dideoxyadenosine in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908444/),min,60,126606,DB00640,Adenosine
,1908444,minimal viral inhibitory concentration,Concentrations exceeding the in vitro minimal viral inhibitory concentration (2.4 micrograms/mL) could be safely maintained in plasma for a 10-day period.,"Pharmacokinetics of 2',3'-dideoxyadenosine in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908444/),[μg] / [ml],2.4,126607,DB00640,Adenosine
,1908444,bioavailabilities,"Orally administered ddAdo was absorbed as ddIno, with bioavailabilities ranging from 28 to 93% in experiments where no emesis occurred.","Pharmacokinetics of 2',3'-dideoxyadenosine in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908444/),%,28 to 93,126608,DB00640,Adenosine
,30215770,C1,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],8.3,128963,DB00640,Adenosine
,30215770,C2,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],7.2,128964,DB00640,Adenosine
,30215770,C12,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.0,128965,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.3,128966,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],4.3,128967,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.9,128968,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.4,128969,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.8,128970,DB00640,Adenosine
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.7,128971,DB00640,Adenosine
,29475007,net efflux ratio,The net efflux ratio of afatinib was 2.3 across vector-/MDR1-MDCKII cell monolayers and was decreased by P-gp inhibitor.,P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),,2.3,129722,DB00640,Adenosine
,29475007,Km,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),μM,1.05,129723,DB00640,Adenosine
,29475007,Vmax,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),[atp·nM] / [h·mg],59.88,129724,DB00640,Adenosine
,2015726,maximal increase,"Twelve milligrams of yohimbine moderately but significantly accelerated supine heart rate (mean maximal increase, 7 +/- 3 beats/min).",The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015726/),[beats] / [min],7,131264,DB00640,Adenosine
,9459344,clearance,"Following I.V. administration to rhesus monkeys, the (mean +/- SD.) clearance, volume of distribution and terminal half-life of Ro 44-3888 were 4.4 +/- 1.8 ml/min/kg, 0.8 +/- 0.4 l/kg and 2.5 +/- 0.8 h respectively.","Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),[ml] / [kg·min],4.4,131424,DB00640,Adenosine
,9459344,volume of distribution,"Following I.V. administration to rhesus monkeys, the (mean +/- SD.) clearance, volume of distribution and terminal half-life of Ro 44-3888 were 4.4 +/- 1.8 ml/min/kg, 0.8 +/- 0.4 l/kg and 2.5 +/- 0.8 h respectively.","Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),[l] / [kg],0.8,131425,DB00640,Adenosine
,9459344,terminal half-life,"Following I.V. administration to rhesus monkeys, the (mean +/- SD.) clearance, volume of distribution and terminal half-life of Ro 44-3888 were 4.4 +/- 1.8 ml/min/kg, 0.8 +/- 0.4 l/kg and 2.5 +/- 0.8 h respectively.","Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),h,2.5,131426,DB00640,Adenosine
,9459344,peak concentrations,"Oral administration of Ro 48-3657 (1 mg/kg), a doubly protected prodrug form, produced peak concentrations of Ro 44-3888 (152 +/- 51 ng/ml), 4.2 +/- 2.2 h after dosing.","Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),[ng] / [ml],152,131427,DB00640,Adenosine
,9459344,Terminal half-life,Terminal half-life and estimated bioavailability were 5.1 +/- 1.6 h and 33 +/- 6% respectively.,"Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),h,5.1,131428,DB00640,Adenosine
,9459344,bioavailability,Terminal half-life and estimated bioavailability were 5.1 +/- 1.6 h and 33 +/- 6% respectively.,"Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),%,33,131429,DB00640,Adenosine
,9459344,IC50,The ex vivo IC50 (82 nM) for ADP-mediated PA correlated with a value (58 nM) determined in vitro.,"Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),nM,82,131430,DB00640,Adenosine
,9459344,IC50,The ex vivo IC50 (82 nM) for ADP-mediated PA correlated with a value (58 nM) determined in vitro.,"Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),nM,58,131431,DB00640,Adenosine
> or =,9459344,CBT,CBT was prolonged to > or = 25 min when levels of Ro 44-3888 exceeded 190 nM and PA was > 90% inhibited.,"Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459344/),min,25,131432,DB00640,Adenosine
,28756559,flow rate,"Chromatographic separation was carried out using a Kinetex C18 column (100 × 4.6 mm; 100 Å; 2.6 μ) with acetonitrile/water with 0.2% (v/v) formic acid (65:35, v/v) in the isocratic mode at a flow rate of 0.4 mL/min.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),[ml] / [min],0.4,131436,DB00640,Adenosine
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,412.3,131437,DB00640,Adenosine
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,294.1,131438,DB00640,Adenosine
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,423.1,131439,DB00640,Adenosine
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,207.2,131440,DB00640,Adenosine
,28756559,m/,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,412.3,131441,DB00640,Adenosine
,7574512,clearance,"The mean clearance of didanosine was 0.50 liters/h/kg, the terminal half-life was 1.8 h, and the CSF-to-plasma ratio was 4.8%.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),[l] / [h·kg],0.50,131663,DB00640,Adenosine
,7574512,terminal half-life,"The mean clearance of didanosine was 0.50 liters/h/kg, the terminal half-life was 1.8 h, and the CSF-to-plasma ratio was 4.8%.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),h,1.8,131664,DB00640,Adenosine
,7574512,CSF-to-plasma ratio,"The mean clearance of didanosine was 0.50 liters/h/kg, the terminal half-life was 1.8 h, and the CSF-to-plasma ratio was 4.8%.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,4.8,131665,DB00640,Adenosine
,7574512,clearance,"The disposition of ddG was similar, with a clearance of 0.70 liters/h/kg and a half-life of 1.7 h.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),[l] / [h·kg],0.70,131666,DB00640,Adenosine
,7574512,half-life,"The disposition of ddG was similar, with a clearance of 0.70 liters/h/kg and a half-life of 1.7 h.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),h,1.7,131667,DB00640,Adenosine
,7574512,CSF,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,8.5,131668,DB00640,Adenosine
,7574512,CSF,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,24,131669,DB00640,Adenosine
,7574512,CSF,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,17,131670,DB00640,Adenosine
,7574512,-to-plasma ratios,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,8.5,131671,DB00640,Adenosine
,7574512,-to-plasma ratios,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,24,131672,DB00640,Adenosine
,7574512,-to-plasma ratios,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),%,17,131673,DB00640,Adenosine
,7574512,area under the CSF concentration-time curve,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),h·μM,12.1,131674,DB00640,Adenosine
,7574512,area under the CSF concentration-time curve,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),h·μM,18.8,131675,DB00640,Adenosine
,7574512,area under the CSF concentration-time curve,"The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 microM.h) and the 6-halogenated-ddG prodrugs (18.8 microM.h for 6-chloro-ddG, 9.3 microM.h for 6-iodo-ddG).",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),h·μM,9.3,131676,DB00640,Adenosine
,7574512,CSF-to-plasma ratio,"6-Chloro-ddG was not detectable in plasma or CSF, and the CSF-to-plasma ratio of 6-iodo-ddG was 9.4%, so the higher CSF-to-plasma ratios of ddG with the administration of the 6-halogenated-ddG prodrugs does not appear to be the result of enhanced penetration of the prodrug and subsequent dehalogenation to ddG.",Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574512/),,9.4,131677,DB00640,Adenosine
,11304766,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P =.001) in responders (890 micromol/L, n = 6) and nonresponders (30 micromol/L, n = 6).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),[μM] / [l],890,131689,DB00640,Adenosine
,11304766,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P =.001) in responders (890 micromol/L, n = 6) and nonresponders (30 micromol/L, n = 6).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),[μM] / [l],30,131690,DB00640,Adenosine
,11304766,cellular elimination,"The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),h,35,131691,DB00640,Adenosine
,17632584,area under the curve of blood CsA versus time (AUCiv),The area under the curve of blood CsA versus time (AUCiv) increased from 27.7 +/- 5.3 to 60.6 +/- 13.8 mug.h.,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h·μg,27.7,132099,DB00640,Adenosine
,17632584,area under the curve of blood CsA versus time (AUCiv),The area under the curve of blood CsA versus time (AUCiv) increased from 27.7 +/- 5.3 to 60.6 +/- 13.8 mug.h.,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h·μg,60.6,132100,DB00640,Adenosine
,17632584,total body clearance,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [body·h·kg·mass],0.38,132101,DB00640,Adenosine
,17632584,total body clearance,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [body·h·kg·mass],0.17,132102,DB00640,Adenosine
,17632584,volume of distribution at steady state,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [kg],3.70,132103,DB00640,Adenosine
,17632584,volume of distribution at steady state,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [kg],2.85,132104,DB00640,Adenosine
,17632584,terminal half-life,These pharmacokinetic changes lead to a longer terminal half-life of CsA in P-NS rats (11.8 +/- 1.6 vs. 6.9 +/- 0.91 h).,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h,11.8,132105,DB00640,Adenosine
,17632584,terminal half-life,These pharmacokinetic changes lead to a longer terminal half-life of CsA in P-NS rats (11.8 +/- 1.6 vs. 6.9 +/- 0.91 h).,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h,6.9,132106,DB00640,Adenosine
,8472722,half-life,A peak concentration is reached 1.5 h after drug intake; elimination from the plasma compartment has a half-life of 1.5 h.,"Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472722/),h,1.5,132125,DB00640,Adenosine
,20197013,Renal clearance,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),[ml] / [min],111,132189,DB00640,Adenosine
,20197013,half-life,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),h,37.,132190,DB00640,Adenosine
,20197013,half-life,Renal clearance decreased by a factor 0.88 from 111 to 97.3 ml/min while digoxin half-life increased from 37.0 to 45.3 h.,Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197013/),h,45,132191,DB00640,Adenosine
less,1551186,half-life,Thus a single dose of ATP-MgCl2 has a half-life of less than 40 sec as ATP.,Clearance and maintenance of blood nucleotide levels with adenosine triphosphate-magnesium chloride injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551186/),s,40,132296,DB00640,Adenosine
,24070396,clearance index,"The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 ± 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 ± 0.07, P < .01).",Transplacental transfer and distribution of pravastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24070396/),,0.,132994,DB00640,Adenosine
,21692601,t(max),"Ethinyl oestradiol absorption was rapid (median t(max) approximately 1 hour), and was not affected by ticagrelor.",Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692601/),h,1,133521,DB00640,Adenosine
,34221871,t 1/2,"In our in vitro assessments, RDV exhibited prohibitively low stability in human liver microsomes (HLMs, t 1/2 = ∼1 min), with the primary CYP-mediated metabolism being the mono-oxidation likely on the phosphoramidate moiety.",Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34221871/),min,∼1,134202,DB00640,Adenosine
,34221871,oral bioavailability,"In further in vivo studies in CD-1 mice, GS-441524 displayed a favorable oral bioavailability of 57%.",Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34221871/),%,57,134203,DB00640,Adenosine
,10409529,duration of bolus activity,"Peak bolus activity was delayed (by about three seconds) and the duration of bolus activity in the left ventricle was increased with distal injection compared with proximal injection, at 17.2 (4.2) v 9.2 (3.1) seconds, p < 0.01.",Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10409529/),seconds,17.2,135137,DB00640,Adenosine
,10409529,duration of bolus activity,"Peak bolus activity was delayed (by about three seconds) and the duration of bolus activity in the left ventricle was increased with distal injection compared with proximal injection, at 17.2 (4.2) v 9.2 (3.1) seconds, p < 0.01.",Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10409529/),seconds,9.2,135138,DB00640,Adenosine
,10497138,mean residence time,F-ddA exhibited a mean residence time of 0.17 h in plasma and its plasma concentration time profile appeared to be biexponential.,"2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497138/),h,0.17,136183,DB00640,Adenosine
,10497138,area under the curve (AUC) to metabolite AUC ratio,"The majority of plasma exposure was from F-ddI, with a mean parent drug area under the curve (AUC) to metabolite AUC ratio of 0.16.","2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497138/),,0.16,136184,DB00640,Adenosine
,10497138,AUC to plasma AUC ratio,"CSF levels were low, with a mean CSF AUC to plasma AUC ratio of 0.068, with approximately one-quarter of this exposure in CSF due to unchanged drug.","2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497138/),,0.068,136185,DB00640,Adenosine
,15910799,EC50,The values of the EC50 for the anti-hyperalgesic effect were (mean+/-S.D.): 3170+/-1460 and 2660+/-1200 ng/ml for MCPA and 2'dCPA versus 178+/-51 ng/ml for the reference full agonist 5'deoxyribose-N6-cyclopentyl-adenosine (5'dCPA).,Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910799/),[ng] / [ml],3170,138894,DB00640,Adenosine
,15910799,EC50,The values of the EC50 for the anti-hyperalgesic effect were (mean+/-S.D.): 3170+/-1460 and 2660+/-1200 ng/ml for MCPA and 2'dCPA versus 178+/-51 ng/ml for the reference full agonist 5'deoxyribose-N6-cyclopentyl-adenosine (5'dCPA).,Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910799/),[ng] / [ml],2660,138895,DB00640,Adenosine
,15910799,EC50,The values of the EC50 for the anti-hyperalgesic effect were (mean+/-S.D.): 3170+/-1460 and 2660+/-1200 ng/ml for MCPA and 2'dCPA versus 178+/-51 ng/ml for the reference full agonist 5'deoxyribose-N6-cyclopentyl-adenosine (5'dCPA).,Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910799/),[ng] / [ml],178,138896,DB00640,Adenosine
,25498136,apparent elimination half-life (t½),"In plasma, peak concentrations of cis-DCCA, trans-DCCA and 3-PBA were reached about ≈7 h post-dosing, and elimination appeared monophasic with a mean apparent elimination half-life (t½) of 6.2, 7.1 and 6.5 h, respectively.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,6.2,139232,DB00640,Adenosine
,25498136,apparent elimination half-life (t½),"In plasma, peak concentrations of cis-DCCA, trans-DCCA and 3-PBA were reached about ≈7 h post-dosing, and elimination appeared monophasic with a mean apparent elimination half-life (t½) of 6.2, 7.1 and 6.5 h, respectively.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,7.1,139233,DB00640,Adenosine
,25498136,apparent elimination half-life (t½),"In plasma, peak concentrations of cis-DCCA, trans-DCCA and 3-PBA were reached about ≈7 h post-dosing, and elimination appeared monophasic with a mean apparent elimination half-life (t½) of 6.2, 7.1 and 6.5 h, respectively.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,6.5,139234,DB00640,Adenosine
,25498136,apparent elimination t½,"In urine, elimination rate time courses of cis-DCCA, trans-DCCA and 3-PBA evolved in parallel with plasma, with respective mean apparent elimination t½ of 4.5, 5.4 and 5.7 h.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,4.5,139235,DB00640,Adenosine
,25498136,apparent elimination t½,"In urine, elimination rate time courses of cis-DCCA, trans-DCCA and 3-PBA evolved in parallel with plasma, with respective mean apparent elimination t½ of 4.5, 5.4 and 5.7 h.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,5.4,139236,DB00640,Adenosine
,25498136,apparent elimination t½,"In urine, elimination rate time courses of cis-DCCA, trans-DCCA and 3-PBA evolved in parallel with plasma, with respective mean apparent elimination t½ of 4.5, 5.4 and 5.7 h.",Toxicokinetics of permethrin biomarkers of exposure in orally exposed volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498136/),h,5.7,139237,DB00640,Adenosine
,8230115,oral bioavailability,"Although 2 exhibited 25% oral bioavailability in rats, pharmacokinetic studies conducted in monkeys revealed that the parent compound was less than 5% bioavailable, the result of extensive first-pass biotransformation in the liver.","Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,25,139522,DB00640,Adenosine
,8230115,bioavailability,Tetrazole 23e exhibited 72% bioavailability following ip administration to rats compared with 35% bioavailability for 2 and 19e under the same conditions.,"Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,72,139523,DB00640,Adenosine
,8230115,bioavailability,Tetrazole 23e exhibited 72% bioavailability following ip administration to rats compared with 35% bioavailability for 2 and 19e under the same conditions.,"Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,35,139524,DB00640,Adenosine
,8230115,oral bioavailability,"However, the oral bioavailability of 19e and 23e in the rat was estimated to be only 3%, suggesting that 19e and 23e are less readily absorbed from the gastrointestinal tract than 2.","Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,3,139525,DB00640,Adenosine
>,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,200,139631,DB00640,Adenosine
,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,28,139632,DB00640,Adenosine
>,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,"20,000",139633,DB00640,Adenosine
,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,40,139634,DB00640,Adenosine
,26672197,flow rate,"The separation was performed on an Agilent ZORBAX SB-C18 column(150 mm x 3 mm, 1.8 μm) with a gradient elution of 0.2% (v/v) formic acid aqueous solution and acetonitrile as the mobile phases at a flow rate of 0.35 mL/min.",[Determination of N6-(4-hydroxybenzyl) adenine riboside in rat plasma by ultra performance liquid chromatography-quadrupole time of flight mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672197/),[ml] / [min],0.35,140224,DB00640,Adenosine
,26672197,recoveries,The recoveries were 88.41%-108.26%.,[Determination of N6-(4-hydroxybenzyl) adenine riboside in rat plasma by ultra performance liquid chromatography-quadrupole time of flight mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672197/),%,88.41,140225,DB00640,Adenosine
,26672197,recoveries,The recoveries were 88.41%-108.26%.,[Determination of N6-(4-hydroxybenzyl) adenine riboside in rat plasma by ultra performance liquid chromatography-quadrupole time of flight mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672197/),%,108.26,140226,DB00640,Adenosine
,26672197,limit of detection,The limit of detection was 0.1 ng/mL.,[Determination of N6-(4-hydroxybenzyl) adenine riboside in rat plasma by ultra performance liquid chromatography-quadrupole time of flight mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672197/),[ng] / [ml],0.1,140227,DB00640,Adenosine
,1400789,half-lives,"After an intravenous dose of 0.3 mg/kg, biphasic elimination kinetics were observed for parent I, characterized by half-lives of 1.8 min (distribution) and 15 min (elimination).","Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),min,1.8,140973,DB00640,Adenosine
,1400789,half-lives,"After an intravenous dose of 0.3 mg/kg, biphasic elimination kinetics were observed for parent I, characterized by half-lives of 1.8 min (distribution) and 15 min (elimination).","Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),min,15,140974,DB00640,Adenosine
,1400789,volume of distribution in the terminal phase (V beta),The volume of distribution in the terminal phase (V beta) was low (0.27 l/kg) and plasma clearance was moderate (0.83 l/kg/h).,"Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),[l] / [kg],0.27,140975,DB00640,Adenosine
,1400789,plasma clearance,The volume of distribution in the terminal phase (V beta) was low (0.27 l/kg) and plasma clearance was moderate (0.83 l/kg/h).,"Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),[l] / [h·kg],0.83,140976,DB00640,Adenosine
,1400789,Tmax,"Although the compound was rapidly absorbed (mean Tmax = 13 min), low concentrations (mean Cmax = 94 ng/ml) were observed after an oral dose of 3.0 mg/kg, and bioavailability was only approximately 1.4%.","Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),min,13,140977,DB00640,Adenosine
,1400789,Cmax,"Although the compound was rapidly absorbed (mean Tmax = 13 min), low concentrations (mean Cmax = 94 ng/ml) were observed after an oral dose of 3.0 mg/kg, and bioavailability was only approximately 1.4%.","Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),[ng] / [ml],94,140978,DB00640,Adenosine
,1400789,bioavailability,"Although the compound was rapidly absorbed (mean Tmax = 13 min), low concentrations (mean Cmax = 94 ng/ml) were observed after an oral dose of 3.0 mg/kg, and bioavailability was only approximately 1.4%.","Automated-extraction, high-performance liquid chromatographic method and pharmacokinetics in rats of a highly A2-selective adenosine agonist, CGS 21680. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400789/),%,1.4,140979,DB00640,Adenosine
,18981292,PFS,"Six responders received repeat therapy at relapse, and 5 responded again with a second median PFS of 10 months.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),month,10,142297,DB00640,Adenosine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],31.4,142298,DB00640,Adenosine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,65.8,142299,DB00640,Adenosine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],8.49,142300,DB00640,Adenosine
,18981292,V1,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],8.49,142301,DB00640,Adenosine
,18981292,V1,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142302,DB00640,Adenosine
,18981292,Q,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142303,DB00640,Adenosine
,18981292,V2,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142304,DB00640,Adenosine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,37 to 51,143470,DB00640,Adenosine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,100,143471,DB00640,Adenosine
,9068927,terminal half-life,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,5.7 to 19.7,143472,DB00640,Adenosine
,9068927,apparent volume of distribution,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),[l] / [m2],54 to 357,143473,DB00640,Adenosine
,9068927,half-lives,The intracellular concentration of these metabolites is several hundred-fold higher than that of cladribine in plasma and they are retained in leukaemia cells with half-lives between 9 and > 30 hours depending on diagnosis and sampling schedule.,The clinical pharmacokinetics of cladribine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,9 and > 30,143474,DB00640,Adenosine
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],398,143694,DB00640,Adenosine
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],301,143695,DB00640,Adenosine
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],332,143696,DB00640,Adenosine
,28139972,apparent clearance (CL/F),Ticagrelor apparent clearance (CL/F) was 17 L/h for the 60-mg and 15.4 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],17,144100,DB00640,Adenosine
,28139972,apparent clearance (CL/F),Ticagrelor apparent clearance (CL/F) was 17 L/h for the 60-mg and 15.4 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],15.4,144101,DB00640,Adenosine
,28139972,CL/F,The CL/F of AR-C124910XX was 11.1 L/h for the 60-mg and 9.95 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],11.1,144102,DB00640,Adenosine
,28139972,CL/F,The CL/F of AR-C124910XX was 11.1 L/h for the 60-mg and 9.95 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],9.95,144103,DB00640,Adenosine
,1600600,LD10,"In another mouse strain (NMRI), we obtained a markedly higher LD10 value (675 mg/kg x 5 days).",Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600600/),mg,675,144787,DB00640,Adenosine
,1600600,half-life,"Pharmacokinetics studies showed that after the i.p. injection of 3'-dANO, the maximal plasma concentration was reached after 10 min, after which it declined showing a half-life of about 40 min.",Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600600/),min,40,144788,DB00640,Adenosine
,2423028,Peak Ara-H concentrations,Peak Ara-H concentrations in plasma occurred within 1 to 2 h after doses and were 21 micrograms/ml in patient 1 and 2.,"High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423028/),[μg] / [ml],21,144795,DB00640,Adenosine
,32770531,Tmax,Tmax of metabolite AR-C124910XX was 4 h after LD for both groups.,Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32770531/),h,4,145309,DB00640,Adenosine
,1346800,total response rate,"Eight (47%) of the 17 patients with AML had complete hematologic remissions (four after the initial course of 2-CDA), and two (12%) had partial remissions, for a total response rate of 59%.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),%,59,145745,DB00640,Adenosine
,1346800,times to recovery,"In responding patients, the median times to recovery of neutrophil counts greater than 0.5 x 10(9)/L and platelet counts greater than 50 x 10(9)/L were 18 and 21 days, respectively.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),d,18,145746,DB00640,Adenosine
,1346800,times to recovery,"In responding patients, the median times to recovery of neutrophil counts greater than 0.5 x 10(9)/L and platelet counts greater than 50 x 10(9)/L were 18 and 21 days, respectively.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),d,21,145747,DB00640,Adenosine
,1346800,steady-state plasma concentration,"The mean steady-state plasma concentration of 2-CDA was 34.6 nmol/L (range, 20 to 54 nmol/L).",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),[nM] / [l],34.6,145748,DB00640,Adenosine
,1929259,elimination half-lives,"The elimination half-lives of intravenously administered ara-M in rats and monkeys were 29 and 45 min, respectively.",Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929259/),min,29,146388,DB00640,Adenosine
,1929259,elimination half-lives,"The elimination half-lives of intravenously administered ara-M in rats and monkeys were 29 and 45 min, respectively.",Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929259/),min,45,146389,DB00640,Adenosine
,1929259,half-lives,"The corresponding half-lives of the primary metabolite, ara-H, were 44 min and 2.3 h.",Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929259/),min,44,146390,DB00640,Adenosine
,1929259,half-lives,"The corresponding half-lives of the primary metabolite, ara-H, were 44 min and 2.3 h.",Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929259/),h,2.3,146391,DB00640,Adenosine
,32763840,lowest detectable concentrations,"Lowest concentrations that could be quantitated using the native and first derivative synchronous methods were 189 and 151 ng/mL while lowest detectable concentrations were 63 and 50 ng/mL, respectively.",Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763840/),[ng] / [ml],63,146478,DB00640,Adenosine
,32763840,lowest detectable concentrations,"Lowest concentrations that could be quantitated using the native and first derivative synchronous methods were 189 and 151 ng/mL while lowest detectable concentrations were 63 and 50 ng/mL, respectively.",Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763840/),[ng] / [ml],50,146479,DB00640,Adenosine
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[ng] / [ml],586,146646,DB00640,Adenosine
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[ng] / [ml],70.1,146647,DB00640,Adenosine
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[h·ng] / [ml],234,146648,DB00640,Adenosine
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[h·ng] / [ml],24.4,146649,DB00640,Adenosine
,26315810,Time to maximum plasma concentration,"Time to maximum plasma concentration was shorter in the crushed versus integral tablets group (median 2 vs. 4 h), with a ratio of adjusted geometric means (95% CI) of 0.69 (0.49-0.97) [p = 0.035].",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),h,2,146650,DB00640,Adenosine
,26315810,Time to maximum plasma concentration,"Time to maximum plasma concentration was shorter in the crushed versus integral tablets group (median 2 vs. 4 h), with a ratio of adjusted geometric means (95% CI) of 0.69 (0.49-0.97) [p = 0.035].",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),h,4,146651,DB00640,Adenosine
,8132850,time to reach Cmax,"The time to reach Cmax was prolonged from .42 to 2.08 hours and the Cmax was decreased by about 66%, whereas the AUC and urinary recovery showed no significant changes.","Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132850/),h,.42 to 2.08,146659,DB00640,Adenosine
,32893368,IC50,Compound 15 showed the highest activity with an IC50 value of 3.48 µM.,"Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32893368/),μM,3.48,147096,DB00640,Adenosine
,32893368,IC50,"Also, compound 20 revealed an equipotent activity with the reference cytotoxic drug, with an IC50 value of 5.95 µM.","Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32893368/),μM,5.95,147097,DB00640,Adenosine
,31838339,Ki,"Measured Ki values of non-labeled CBX, MCBX and CPFPX were 10.0 ± 0.52 nM, 3.3 ± 0.30 nM and 1.4 ± 0.15 nM, respectively (n = 3-4).",Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838339/),nM,10.0,147128,DB00640,Adenosine
,31838339,Ki,"Measured Ki values of non-labeled CBX, MCBX and CPFPX were 10.0 ± 0.52 nM, 3.3 ± 0.30 nM and 1.4 ± 0.15 nM, respectively (n = 3-4).",Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838339/),nM,3.3,147129,DB00640,Adenosine
,31838339,Ki,"Measured Ki values of non-labeled CBX, MCBX and CPFPX were 10.0 ± 0.52 nM, 3.3 ± 0.30 nM and 1.4 ± 0.15 nM, respectively (n = 3-4).",Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838339/),nM,1.4,147130,DB00640,Adenosine
,28987606,bioavailability,"In addition, compounds 4bq and 4bv were found to possess improved pharmacokinetic profiles (bioavailability 45 and 106%, respectively) compared to berberine.","Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),%,45,148110,DB00640,Adenosine
,28987606,bioavailability,"In addition, compounds 4bq and 4bv were found to possess improved pharmacokinetic profiles (bioavailability 45 and 106%, respectively) compared to berberine.","Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),%,106,148111,DB00640,Adenosine
>,28987606,IC50,Compounds 4bq and 4bv exhibited no obvious hERG inhibition (IC50 > 10 μM).,"Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),μM,10,148112,DB00640,Adenosine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],1228,148719,DB00640,Adenosine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],2753,148720,DB00640,Adenosine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],201,148721,DB00640,Adenosine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],447,148722,DB00640,Adenosine
,30327943,area under the curve,Variability was extensive where area under the curve ranged from 10 to 66 mg h/L.,Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[h·mg] / [l],10 to 66,149371,DB00640,Adenosine
,30327943,volumes of distribution,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,39,149372,DB00640,Adenosine
,30327943,V2,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,39,149373,DB00640,Adenosine
,30327943,V2,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,20,149374,DB00640,Adenosine
,30327943,V3,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·kg],50,149375,DB00640,Adenosine
,30327943,Intercompartmental clearances,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,8.6,149376,DB00640,Adenosine
,30327943,Intercompartmental clearances,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·h·kg],3.8,149377,DB00640,Adenosine
,30327943,V1,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,8.6,149378,DB00640,Adenosine
,30327943,V1,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·h·kg],3.8,149379,DB00640,Adenosine
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],6.1,149997,DB00640,Adenosine
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],3.3,149998,DB00640,Adenosine
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],1.0,149999,DB00640,Adenosine
,9657435,half-maximal in,"The mean plasma concentration required for half-maximal inhibition of thrombin-receptor agonist peptide (TRAP) induced platelet aggregation (EC50) ex vivo was 21, 28 and 11 ng/ml in Groups 1, 2 and 3.","Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657435/),ng,21,150396,DB00640,Adenosine
,9657435,half-maximal in,"The mean plasma concentration required for half-maximal inhibition of thrombin-receptor agonist peptide (TRAP) induced platelet aggregation (EC50) ex vivo was 21, 28 and 11 ng/ml in Groups 1, 2 and 3.","Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657435/),ng,28,150397,DB00640,Adenosine
,9657435,half-maximal in,"The mean plasma concentration required for half-maximal inhibition of thrombin-receptor agonist peptide (TRAP) induced platelet aggregation (EC50) ex vivo was 21, 28 and 11 ng/ml in Groups 1, 2 and 3.","Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657435/),ng,11,150398,DB00640,Adenosine
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,2.3,151330,DB00640,Adenosine
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,6.2,151331,DB00640,Adenosine
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],1.9,151332,DB00640,Adenosine
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],2.7,151333,DB00640,Adenosine
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],18.2,151334,DB00640,Adenosine
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,644,151335,DB00640,Adenosine
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,576,151336,DB00640,Adenosine
,12242461,AUC,"ml(-1) x min, respectively) compared with native GIP (AUC, 257+/-29 ng.ml(-1) x min).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[min·ng] / [ml],257,151337,DB00640,Adenosine
,15855513,t(1/2) of elimination,"In the case of TFV-DP, this t(1/2) of elimination was roughly estimated to be 180 h (7.5 days).",Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855513/),h,180,152630,DB00640,Adenosine
,15855513,t(1/2) of elimination,"In the case of TFV-DP, this t(1/2) of elimination was roughly estimated to be 180 h (7.5 days).",Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855513/),d,7.5,152631,DB00640,Adenosine
,9055136,minimum concentrations,"By day 36 the minimum concentrations in plasma were identical (0.35 +/- 0.22 mg/L and 0.36 +/- 0.21 mg/L, respectively).",Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055136/),[mg] / [l],0.35,153217,DB00640,Adenosine
,9055136,minimum concentrations,"By day 36 the minimum concentrations in plasma were identical (0.35 +/- 0.22 mg/L and 0.36 +/- 0.21 mg/L, respectively).",Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055136/),[mg] / [l],0.36,153218,DB00640,Adenosine
,19302903,C(max),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [l],2.37,153659,DB00640,Adenosine
,19302903,C(max),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [l],2.50,153660,DB00640,Adenosine
,19302903,T(max),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,5.40,153661,DB00640,Adenosine
,19302903,T(max),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,5.20,153662,DB00640,Adenosine
,19302903,AUC(0-24),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [h·l],8.56,153663,DB00640,Adenosine
,19302903,AUC(0-24),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [h·l],10.3,153664,DB00640,Adenosine
,19302903,t(1/2beta),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,6.06,153665,DB00640,Adenosine
,19302903,t(1/2beta),"The (mean [SD]) pharmacokinetic properties of singledose oral SAMe in men and women, respectively, were as follows: C(max), 2.37 (1.58) and 2.50 (1.83) micromol/L; T(max), 5.40 (1.14) and 5.20 (1.48) hours; AUC(0-24), 8.56 (5.16) and 10.3 (8.0) micromol/L/h; and t(1/2beta), 6.06 (1.80) and 6.28 (2.60) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,6.28,153666,DB00640,Adenosine
,19302903,C(max),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [l],127,153667,DB00640,Adenosine
,19302903,C(max),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [l],211,153668,DB00640,Adenosine
,19302903,T(max),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,1.90,153669,DB00640,Adenosine
,19302903,T(max),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,1.60,153670,DB00640,Adenosine
,19302903,AUC(0-24),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [h·l],329,153671,DB00640,Adenosine
,19302903,AUC(0-24),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),[μM] / [h·l],480,153672,DB00640,Adenosine
,19302903,t(1/2beta),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,4.34,153673,DB00640,Adenosine
,19302903,t(1/2beta),"Corresponding values with the single-dose IV formulation were: C(max), 127 (49) and 211 (94) micromol/L; T(max), 1.90 (0.22) and 1.60 (0.22) hours; AUC(0-24), 329 (84) and 480 (176) micromol/L/h; and t(1/2beta), 4.34 (0.57) and 3.83 (0.78) hours.","Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302903/),h,3.83,153674,DB00640,Adenosine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,292.2,154091,DB00640,Adenosine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,163.2,154092,DB00640,Adenosine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,237.1,154093,DB00640,Adenosine
,27191766,firstorder absorption rate constant,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),1/[h],0.67,154909,DB00640,Adenosine
,27191766,apparent systemic clearance,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),[l] / [h],14,154910,DB00640,Adenosine
,27191766,apparent volume of distribution,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),l,221,154911,DB00640,Adenosine
,27191766,bioavailability,"Ticagrelor bioavailability was 21% (95% CI, 19 - 22%) lower at treatment initiation (visit 1) versus subsequent visits.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,21,154912,DB00640,Adenosine
,27191766,bioavailability,"Compared with Caucasian patients, ticagrelor bioavailability was 39% (95% CI, 33 - 46%) higher in Asian patients and 18% (95% CI, 6 - 28%) lower in Black patients.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,39,154913,DB00640,Adenosine
,27191766,bioavailability,"Compared with Caucasian patients, ticagrelor bioavailability was 39% (95% CI, 33 - 46%) higher in Asian patients and 18% (95% CI, 6 - 28%) lower in Black patients.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,18,154914,DB00640,Adenosine
,8640332,pot,"For the bradycardiac effect, the potencies based on free drug concentrations (EC50,u) of 5'dCPA, 3'dCPA, 2'dCPAin blood were 5.9 +/- 1.7, 18 +/- 4 and 260 +/- 70 ng ml (-1) (19 +/- 6, 56 +/- 11 and 830 +/- 210 nM), respectively, and correlated well with the adenosine A1 receptor affinity in vitro.",Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640332/),-1·ml·ng,5.9,155443,DB00640,Adenosine
,8640332,pot,"For the bradycardiac effect, the potencies based on free drug concentrations (EC50,u) of 5'dCPA, 3'dCPA, 2'dCPAin blood were 5.9 +/- 1.7, 18 +/- 4 and 260 +/- 70 ng ml (-1) (19 +/- 6, 56 +/- 11 and 830 +/- 210 nM), respectively, and correlated well with the adenosine A1 receptor affinity in vitro.",Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640332/),-1·ml·ng,18,155444,DB00640,Adenosine
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37.2,156078,DB00640,Adenosine
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,36.7,156079,DB00640,Adenosine
,8622049,F,The F value of 2-CdA after oral administration was approximately 37% and there were no cumulative differences in bioavailability observed on multiple dosing of the drug.,Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37,156080,DB00640,Adenosine
,10430069,maximum tolerated dose,"The maximum tolerated dose for this regimen was 0.15 mg/kg/h, and the dose-limiting toxicities were reversible hypercalcemia and hepatotoxicity.","Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430069/),mg,0,156313,DB00640,Adenosine
,20670985,half-life,"Finally, oral MTA half-life was 20 min, with a C(max) of 80 mg/L and without signs of obvious toxicity (animal death, behavioural changes, liver enzymes).",Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20670985/),min,20,157086,DB00640,Adenosine
,20670985,C(max),"Finally, oral MTA half-life was 20 min, with a C(max) of 80 mg/L and without signs of obvious toxicity (animal death, behavioural changes, liver enzymes).",Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20670985/),[mg] / [l],80,157087,DB00640,Adenosine
,27517813,bioavailability,Its bioavailability at an oral dose of 2 mg/kg was 15%.,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27517813/),%,15,157381,DB00640,Adenosine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],12.1,157653,DB00640,Adenosine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],8,157654,DB00640,Adenosine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],18,157655,DB00640,Adenosine
,10208286,ED50,"Melatonin at the subconvulsive dose of 25 mg/kg potentiated the anticonvulsive activity of carbamazepine and phenobarbital (ED50 values were significantly decreased from 12.1 to 8.3 and from 18.9 to 11.8 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],11,157656,DB00640,Adenosine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],253,157657,DB00640,Adenosine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],249,157658,DB00640,Adenosine
,10208286,ED50s,"No potentiation was observed in the case of valproate and diphenylhydantoin (their ED50s were changed from 253 to 249 and from 10.3 to 9.7 mg/kg, respectively).",Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10208286/),[mg] / [kg],10,157659,DB00640,Adenosine
,29257872,AUCbrain,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],2537,157792,DB00640,Adenosine
,29257872,AUCplasma,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],520 351,157793,DB00640,Adenosine
,29257872,AUCbrain,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],3442,157794,DB00640,Adenosine
,29257872,AUCplasma,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],354,157795,DB00640,Adenosine
,11144995,Cl,ARA is a highly cleared compound (Cl: 0.79 L/h/kg) with a modest volume of distribution (Vss: 0.91 L/kg) and short half-life (t1/2: approximately 1 hour).,Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),[l] / [h·kg],0.79,157796,DB00640,Adenosine
,11144995,volume of distribution (Vss,ARA is a highly cleared compound (Cl: 0.79 L/h/kg) with a modest volume of distribution (Vss: 0.91 L/kg) and short half-life (t1/2: approximately 1 hour).,Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),[l] / [kg],0.91,157797,DB00640,Adenosine
,11144995,half-life (t1/2,ARA is a highly cleared compound (Cl: 0.79 L/h/kg) with a modest volume of distribution (Vss: 0.91 L/kg) and short half-life (t1/2: approximately 1 hour).,Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),h,1,157798,DB00640,Adenosine
,11144995,EC50,"The EC50 values (%RSE of estimate) for ARA and the hypothetical antagonist were 17.0 (5.4) and 15.6 (12.8) ng/mL, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),[ng] / [ml],17.0,157799,DB00640,Adenosine
,11144995,EC50,"The EC50 values (%RSE of estimate) for ARA and the hypothetical antagonist were 17.0 (5.4) and 15.6 (12.8) ng/mL, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),[ng] / [ml],15.6,157800,DB00640,Adenosine
,11144995,Kant0,"In the case of ARA, the value of 0.33 h-1 for Kant0 indicates that a period of approximately 11 hours should suffice.",Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144995/),1/[h],0.33,157801,DB00640,Adenosine
,22888522,AUC(0-4),"The Ara-C dose for Group A was 3g/m2 x 2, and the AUC(0-4) was 5.131 +/- 0.936.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,5.131,157904,DB00640,Adenosine
,22888522,AUC(0-4),"The Ara-C dose for Group B was 2g/m2 x 2, and the AUC(0-4) was 12.245 +/- 3.863.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,12.245,157905,DB00640,Adenosine
,24861133,AUC(,Co-administration of cyclosporine with ticagrelor significantly increased AR-C124910XX AUC(∞) (1.33 [1.23-1.42]) and decreased C(max) (0.85 [0.76-0.94]).,Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861133/),,1,157947,DB00640,Adenosine
,26433392,flow rate,"The analysis was carried out using a reversed phase C18 column with a mobile phase consisting of methanol-water (65:35, v/v) at a flow rate of 1 mL/min.",Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433392/),[ml] / [min],1,158208,DB00640,Adenosine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.0375,159981,DB00640,Adenosine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.375,159982,DB00640,Adenosine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],3.75,159983,DB00640,Adenosine
,27138785,concentration (C 0),Dose simulations show that a daily tacrolimus dose of 0.2 mg/kg generates a pre-dose concentration (C 0) ranging from 5 to 10 µg/L depending on the weight and CYP3A5 polymorphism.,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],5 to 10,160046,DB00640,Adenosine
,27138785,area under the plasma concentration-time curve (AUC),The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160047,DB00640,Adenosine
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],4-8,160048,DB00640,Adenosine
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160049,DB00640,Adenosine
,27586020,Papp(BL-AP),"Compared with the control group, 5μg/ml Cremophor EL decreased the Papp(BL-AP) of scutellarin in MDCK II-MRP2 cell monolayers by >4 fold (from 13.57±0.76×10(-7) to 2.90±0.14×10(-7)cm/s), and the Papp(BL-AP) in MDCK II-BCRP cell monolayers decreased from 9.12±0.15×10(-7) to 6.34±0.08×10(-7)cm/s.",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],13.57,160233,DB00640,Adenosine
,27586020,Papp(BL-AP),"Compared with the control group, 5μg/ml Cremophor EL decreased the Papp(BL-AP) of scutellarin in MDCK II-MRP2 cell monolayers by >4 fold (from 13.57±0.76×10(-7) to 2.90±0.14×10(-7)cm/s), and the Papp(BL-AP) in MDCK II-BCRP cell monolayers decreased from 9.12±0.15×10(-7) to 6.34±0.08×10(-7)cm/s.",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],2.90,160234,DB00640,Adenosine
,27586020,Papp(BL-AP),"Compared with the control group, 5μg/ml Cremophor EL decreased the Papp(BL-AP) of scutellarin in MDCK II-MRP2 cell monolayers by >4 fold (from 13.57±0.76×10(-7) to 2.90±0.14×10(-7)cm/s), and the Papp(BL-AP) in MDCK II-BCRP cell monolayers decreased from 9.12±0.15×10(-7) to 6.34±0.08×10(-7)cm/s.",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],9.12,160235,DB00640,Adenosine
,27586020,Papp(BL-AP),"Compared with the control group, 5μg/ml Cremophor EL decreased the Papp(BL-AP) of scutellarin in MDCK II-MRP2 cell monolayers by >4 fold (from 13.57±0.76×10(-7) to 2.90±0.14×10(-7)cm/s), and the Papp(BL-AP) in MDCK II-BCRP cell monolayers decreased from 9.12±0.15×10(-7) to 6.34±0.08×10(-7)cm/s.",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],6.34,160236,DB00640,Adenosine
,27586020,Papp,"On MDCK II-MRP3 cell monolayers, 5μg/ml Cremophor EL increased the Papp(AP-BL) of scutellarin by 3.5 fold (from 7.88±0.43×10(-7) to 2.79±1.61×10(-6)cm/s), and caused an over 5-fold increase in Papp(AP-BL)/Papp(BL-AP).",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],7.88,160237,DB00640,Adenosine
,27586020,Papp,"On MDCK II-MRP3 cell monolayers, 5μg/ml Cremophor EL increased the Papp(AP-BL) of scutellarin by 3.5 fold (from 7.88±0.43×10(-7) to 2.79±1.61×10(-6)cm/s), and caused an over 5-fold increase in Papp(AP-BL)/Papp(BL-AP).",A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27586020/),[cm] / [s],2.79,160238,DB00640,Adenosine
,9667246,MTD,The MTD of HU given as a 24-hour infusion was 27 g/m2.,Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9667246/),[g] / [m2],27,160656,DB00640,Adenosine
,10912576,"rate of elimination, k(elim)","The calculated rate of elimination, k(elim), averaged 0.336 h(-1) with s.c. and 0.397 h(-1) with i.v. administration.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),1/[h],0.336,161302,DB00640,Adenosine
,10912576,"rate of elimination, k(elim)","The calculated rate of elimination, k(elim), averaged 0.336 h(-1) with s.c. and 0.397 h(-1) with i.v. administration.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),1/[h],0.397,161303,DB00640,Adenosine
,10912576,volumes of distribution,The estimated volumes of distribution were 1.67 and 1.58 l/kg.,Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[l] / [kg],1.67,161304,DB00640,Adenosine
,10912576,volumes of distribution,The estimated volumes of distribution were 1.67 and 1.58 l/kg.,Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[l] / [kg],1.58,161305,DB00640,Adenosine
,10912576,areas under the concentration time curves,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[h·pM] / [ml],608,161306,DB00640,Adenosine
,10912576,areas under the concentration time curves,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[h·pM] / [ml],571,161307,DB00640,Adenosine
,10912576,urinary excretion,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[μM] / [24·h],4.75,161308,DB00640,Adenosine
,10912576,urinary excretion,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[μM] / [24·h],3.55,161309,DB00640,Adenosine
,20926751,bioavailability,"The bioavailability of tonapofylline was 81.2% (90% confidence interval, 70.6%-93.5%).","Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926751/),%,81.2,162036,DB00640,Adenosine
,20926751,steady-state volume of distribution,"Following intravenous administration, the steady-state volume of distribution of tonapofylline was estimated to be 756 mL/kg.","Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926751/),[ml] / [kg],756,162037,DB00640,Adenosine
,20926751,total clearance,"The total clearance of tonapofylline was low (64.8 mL/h/kg), approximately 5% of hepatic blood flow.","Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926751/),[ml] / [h·kg],64.8,162038,DB00640,Adenosine
,20926751,terminal half-life,The terminal half-life was variable within groups and ranged from 11.2 to 24.2 hours across the dose range.,"Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926751/),h,11.2 to 24.2,162039,DB00640,Adenosine
,23351306,inhibition constant,"Extracted compounds were find efficiently inhibit ADA, and the most potent (2) shows an inhibition constant equal to 20 μM.",A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23351306/),μM,20,162088,DB00640,Adenosine
,28921624,time to reach maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),h,8,162329,DB00640,Adenosine
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],355,162330,DB00640,Adenosine
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],63.20,162331,DB00640,Adenosine
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.67,162332,DB00640,Adenosine
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.53,162333,DB00640,Adenosine
>,11248509,recovery rates,The highest extraction efficiencies (recovery rates>83.3%) for the two N6-alkyl substituted adenosines were achieved by the Oasis HLB cartridges.,Determination of the adenosine A(1) agonist N(6)-cyclopentyladenosine in rat blood by solid-phase extraction and HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11248509/),%,83.3,162461,DB00640,Adenosine
,15626578,brain uptake clearance,"For 8-methylamino-N(6)cyclopentyladenosine (MCPA), N(6)-cyclopentyladenosine (CPA), 2'deoxy-N(6)-cyclopentyladenosine (2'dCPA) and 5'deoxy-N(6)-cyclopentyl adenosine (5'dCPA) the brain uptake clearance was low with values of 0.0045+/-0.0012, 0.018+/-0.0020, 0.022+/-0.0028 and 0.12+/-0.054 ml min(-1)g(-1), respectively.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.0045,162890,DB00640,Adenosine
,15626578,brain uptake clearance,"For 8-methylamino-N(6)cyclopentyladenosine (MCPA), N(6)-cyclopentyladenosine (CPA), 2'deoxy-N(6)-cyclopentyladenosine (2'dCPA) and 5'deoxy-N(6)-cyclopentyl adenosine (5'dCPA) the brain uptake clearance was low with values of 0.0045+/-0.0012, 0.018+/-0.0020, 0.022+/-0.0028 and 0.12+/-0.054 ml min(-1)g(-1), respectively.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.018,162891,DB00640,Adenosine
,15626578,brain uptake clearance,"For 8-methylamino-N(6)cyclopentyladenosine (MCPA), N(6)-cyclopentyladenosine (CPA), 2'deoxy-N(6)-cyclopentyladenosine (2'dCPA) and 5'deoxy-N(6)-cyclopentyl adenosine (5'dCPA) the brain uptake clearance was low with values of 0.0045+/-0.0012, 0.018+/-0.0020, 0.022+/-0.0028 and 0.12+/-0.054 ml min(-1)g(-1), respectively.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.022,162892,DB00640,Adenosine
,15626578,brain uptake clearance,"For 8-methylamino-N(6)cyclopentyladenosine (MCPA), N(6)-cyclopentyladenosine (CPA), 2'deoxy-N(6)-cyclopentyladenosine (2'dCPA) and 5'deoxy-N(6)-cyclopentyl adenosine (5'dCPA) the brain uptake clearance was low with values of 0.0045+/-0.0012, 0.018+/-0.0020, 0.022+/-0.0028 and 0.12+/-0.054 ml min(-1)g(-1), respectively.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.12,162893,DB00640,Adenosine
,15626578,brain uptake clearance,"In the presence of an average NBTI plasma concentration of 2.6+/-0.3 microg ml(-1) (NBTI dose: 3 mg kg(-1) i.v.) the values of the brain uptake clearance were 0.0062+/-0.0012, 0.013+/-0.0017, 0.014+/-0.0030 and 0.13+/-0.066 ml min(-1)g(-1), respectively and not significantly different from the values in the absence of NBTI.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.0062,162894,DB00640,Adenosine
,15626578,brain uptake clearance,"In the presence of an average NBTI plasma concentration of 2.6+/-0.3 microg ml(-1) (NBTI dose: 3 mg kg(-1) i.v.) the values of the brain uptake clearance were 0.0062+/-0.0012, 0.013+/-0.0017, 0.014+/-0.0030 and 0.13+/-0.066 ml min(-1)g(-1), respectively and not significantly different from the values in the absence of NBTI.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.013,162895,DB00640,Adenosine
,15626578,brain uptake clearance,"In the presence of an average NBTI plasma concentration of 2.6+/-0.3 microg ml(-1) (NBTI dose: 3 mg kg(-1) i.v.) the values of the brain uptake clearance were 0.0062+/-0.0012, 0.013+/-0.0017, 0.014+/-0.0030 and 0.13+/-0.066 ml min(-1)g(-1), respectively and not significantly different from the values in the absence of NBTI.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.014,162896,DB00640,Adenosine
,15626578,brain uptake clearance,"In the presence of an average NBTI plasma concentration of 2.6+/-0.3 microg ml(-1) (NBTI dose: 3 mg kg(-1) i.v.) the values of the brain uptake clearance were 0.0062+/-0.0012, 0.013+/-0.0017, 0.014+/-0.0030 and 0.13+/-0.066 ml min(-1)g(-1), respectively and not significantly different from the values in the absence of NBTI.",Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.13,162897,DB00640,Adenosine
,15626578,brain uptake clearance,The brain uptake clearance from whole blood (0.0012+/-0.001 ml min(-1)g(-1)) was significantly lower than from PBS (0.0045+/-0.0012 ml min(-1)g(-1)).,Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.0012,162898,DB00640,Adenosine
,15626578,brain uptake clearance,The brain uptake clearance from whole blood (0.0012+/-0.001 ml min(-1)g(-1)) was significantly lower than from PBS (0.0045+/-0.0012 ml min(-1)g(-1)).,Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626578/),[ml] / [min],0.0045,162899,DB00640,Adenosine
,2570841,t1/2,"After intravenous administration to male rats with normal renal function, 8-PT was rapidly cleared from plasma with a t1/2 of about 14 min.",Pharmacokinetics of 8-phenyltheophylline in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),min,14,163141,DB00640,Adenosine
,2570841,apparent volume of distribution,Its apparent volume of distribution was some 76 mL/100 g and plasma clearance was 3.5 mL min-1/100 g.,Pharmacokinetics of 8-phenyltheophylline in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),[ml] / [100·g],76,163142,DB00640,Adenosine
,2570841,plasma clearance,Its apparent volume of distribution was some 76 mL/100 g and plasma clearance was 3.5 mL min-1/100 g.,Pharmacokinetics of 8-phenyltheophylline in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570841/),[ml] / [100·g·min],3.5,163143,DB00640,Adenosine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,35,163691,DB00640,Adenosine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,79.4,163692,DB00640,Adenosine
,21486191,rate constants,"Hydrolytic rate constants differ between species, being 4.24, 5.96 × 10(-3) and 6.85 × 10(-2) min(-1) in rat, dog and human plasma at 37°C, respectively.","In vitro stability and metabolism of O2', O3', O5'-tri-acetyl-N6-(3-hydroxylaniline) adenosine in rat, dog and human plasma: chemical hydrolysis and role of plasma esterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21486191/),1/[min],4.24,164093,DB00640,Adenosine
,21486191,rate constants,"Hydrolytic rate constants differ between species, being 4.24, 5.96 × 10(-3) and 6.85 × 10(-2) min(-1) in rat, dog and human plasma at 37°C, respectively.","In vitro stability and metabolism of O2', O3', O5'-tri-acetyl-N6-(3-hydroxylaniline) adenosine in rat, dog and human plasma: chemical hydrolysis and role of plasma esterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21486191/),1/[min],5.96 × 10(-3),164094,DB00640,Adenosine
,21486191,rate constants,"Hydrolytic rate constants differ between species, being 4.24, 5.96 × 10(-3) and 6.85 × 10(-2) min(-1) in rat, dog and human plasma at 37°C, respectively.","In vitro stability and metabolism of O2', O3', O5'-tri-acetyl-N6-(3-hydroxylaniline) adenosine in rat, dog and human plasma: chemical hydrolysis and role of plasma esterases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21486191/),1/[min],6.85 × 10(-2),164095,DB00640,Adenosine
,16769598,bleeding time,"With prasugrel 75 mg at 4 h postdose, there was a significant increase in the mean bleeding time compared to placebo (682 vs. 161 s; P < 0.05).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769598/),s,682,164135,DB00640,Adenosine
,16769598,bleeding time,"With prasugrel 75 mg at 4 h postdose, there was a significant increase in the mean bleeding time compared to placebo (682 vs. 161 s; P < 0.05).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769598/),s,161,164136,DB00640,Adenosine
,15195855,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml [co-efficient of variance (CV) < 10%].,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),[ng] / [ml],10,164232,DB00640,Adenosine
,15195855,relative bioavailability,By comparing AUC(o-t) the relative bioavailability of test preparation has been found to be 100.88% of that of reference preparation.,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),%,100.88,164233,DB00640,Adenosine
,20699410,EC(50),"This study shows that seliciclib is a high-affinity substrate of ATP-binding cassette B1 (ABCB1) because it activates the ATPase activity of the transporter with an EC(50) of 4.2 μM and shows vectorial transport in MDCKII-MDR1 cells, yielding an efflux ratio of 8.","ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20699410/),μM,4.2,165406,DB00640,Adenosine
,20699410,efflux ratio,"This study shows that seliciclib is a high-affinity substrate of ATP-binding cassette B1 (ABCB1) because it activates the ATPase activity of the transporter with an EC(50) of 4.2 μM and shows vectorial transport in MDCKII-MDR1 cells, yielding an efflux ratio of 8.","ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20699410/),,8,165407,DB00640,Adenosine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB00640,Adenosine
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB00640,Adenosine
,17442688,t(max),The t(max) for parent drug was observed between 0.5 and 1.5 hours postdose.,Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442688/),h,0.5 and 1.5,168109,DB00640,Adenosine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,936.9,168270,DB00640,Adenosine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,368.0,168271,DB00640,Adenosine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,103.4,168272,DB00640,Adenosine
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,31.3,168273,DB00640,Adenosine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,6.7,170083,DB00640,Adenosine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,5.8,170084,DB00640,Adenosine
,14554106,volume of distribution,"A covariate analysis revealed that the volume of distribution of 2'dCPA in blood was different in sarin-poisoned rats, 177 +/- 7 versus 148 +/- 8 ml in control rats.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),ml,177,170685,DB00640,Adenosine
,14554106,volume of distribution,"A covariate analysis revealed that the volume of distribution of 2'dCPA in blood was different in sarin-poisoned rats, 177 +/- 7 versus 148 +/- 8 ml in control rats.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),ml,148,170686,DB00640,Adenosine
,14554106,intercompartmental transport clearances,"However, the transport of 2'dCPA from blood to the brain was unaffected as reflected by the values of the intercompartmental transport clearances, 0.21 +/- 0.02 and 0.21 +/- 0.04 microl/min in control and sarin-poisoned rats, respectively.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),[μl] / [min],0.21,170687,DB00640,Adenosine
,14554106,intercompartmental transport clearances,"However, the transport of 2'dCPA from blood to the brain was unaffected as reflected by the values of the intercompartmental transport clearances, 0.21 +/- 0.02 and 0.21 +/- 0.04 microl/min in control and sarin-poisoned rats, respectively.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),[μl] / [min],0.21,170688,DB00640,Adenosine
,14554106,area-under-curve (AUC) ratios,"Also the area-under-curve (AUC) ratios of brain microdialysate and blood were identical with values of 0.02 +/- 0.001 and 0.02 +/- 0.002, respectively, demonstrating the restricted transport of 2'dCPA into the brain in both treatment groups.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),,0.02,170689,DB00640,Adenosine
,14554106,area-under-curve (AUC) ratios,"Also the area-under-curve (AUC) ratios of brain microdialysate and blood were identical with values of 0.02 +/- 0.001 and 0.02 +/- 0.002, respectively, demonstrating the restricted transport of 2'dCPA into the brain in both treatment groups.","Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14554106/),,0.02,170690,DB00640,Adenosine
,28174232,fraction unbound,Flavopiridol fraction unbound was 10.9% and not different between schedules.,Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),%,10.9,171040,DB00640,Adenosine
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],780,171041,DB00640,Adenosine
≥,28174232,AUC,"Clinical response was associated with AUC ≥ 780 h*ng/mL for newly diagnosed patients and AUC ≥ 1,690 h*ng/mL for relapsed/refractory patients.",Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28174232/),[h·ng] / [ml],"1,690",171042,DB00640,Adenosine
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],97·5,171354,DB00640,Adenosine
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],61·5,171355,DB00640,Adenosine
,11683239,in,Mathematical models were utilized to show that in full-length intestinal perfusions an optimal log mean lumenal EHNA perfusate concentration of 0.5 microg/ml could achieve an intestinal bioavailability of 80% with <20% systemic inhibition.,"Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683239/),%,80,171430,DB00640,Adenosine
,11683239,bioavailability,Mathematical models were utilized to show that in full-length intestinal perfusions an optimal log mean lumenal EHNA perfusate concentration of 0.5 microg/ml could achieve an intestinal bioavailability of 80% with <20% systemic inhibition.,"Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683239/),%,80,171431,DB00640,Adenosine
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,67,172014,DB00640,Adenosine
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,51,172015,DB00640,Adenosine
>,34022093,AUC,Trends toward improved survival were seen in patients transplanted for myeloid disease using bone marrow as stem cell source who achieved a busulfan AUC > 4000 μmol*min/day with two-year relapse-free survival approaching 80% CONCLUSIONS:,"Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),[min·μM] / [d],4000,172016,DB00640,Adenosine
,4357610,plasma clearance rates,The plasma clearance rates (PCR) were 271+/-27 ml/min (mean+/-SE) for cGMP and 261+/-17 for cAMP.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],271,172727,DB00640,Adenosine
,4357610,plasma clearance rates,The plasma clearance rates (PCR) were 271+/-27 ml/min (mean+/-SE) for cGMP and 261+/-17 for cAMP.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),,261,172728,DB00640,Adenosine
,4357610,urinary clearances,The urinary clearances of (3)H-labeled cGMP (40.9+/-4.2 ml/min) and endogenous cGMP (45.0+/-2.3 ml/min) were not significantly different from each other.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],40.9,172729,DB00640,Adenosine
,4357610,urinary clearances,The urinary clearances of (3)H-labeled cGMP (40.9+/-4.2 ml/min) and endogenous cGMP (45.0+/-2.3 ml/min) were not significantly different from each other.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],45.0,172730,DB00640,Adenosine
,4357610,urinary clearances,"In contrast, the urinary clearances of (3)H-labeled cAMP (23.7+/-1.9 ml/min) and endogenous cAMP (27.2+/-2.6 ml/min) were nearly equal both to each other and to the glomerular filtration rate, which was 24.6+/-1.7 ml/min.",Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],23.7,172731,DB00640,Adenosine
,4357610,urinary clearances,"In contrast, the urinary clearances of (3)H-labeled cAMP (23.7+/-1.9 ml/min) and endogenous cAMP (27.2+/-2.6 ml/min) were nearly equal both to each other and to the glomerular filtration rate, which was 24.6+/-1.7 ml/min.",Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],27.2,172732,DB00640,Adenosine
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],221.34,172770,DB00640,Adenosine
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],691.18,172771,DB00640,Adenosine
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],1060.97,172772,DB00640,Adenosine
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],3483.03,172773,DB00640,Adenosine
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,4.41,172774,DB00640,Adenosine
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,5.97,172775,DB00640,Adenosine
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],9.93,172776,DB00640,Adenosine
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],2.89,172777,DB00640,Adenosine
,32633174,IC50,Enzyme kinetic study indicated that ticagrelor decreased rivaroxaban metabolic clearance with the IC50 value of 14.04 μmol/L.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[μM] / [l],14.04,172778,DB00640,Adenosine
,6313815,Peak serum concentrations,"Peak serum concentrations of arabinosyl hypoxanthine, the major metabolite of vidarabine, ranged from 2.3 to 11.4 micrograms/ml.",Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313815/),[μg] / [ml],2.3 to 11.4,172887,DB00640,Adenosine
,6313815,elimination half-life,"The mean elimination half-life estimated from cumulative urinary excretion was 2.4 hr in a preterm infant, 3.1 hr in full-term infants, and 2.8 hr in older children.",Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313815/),h,2.4,172888,DB00640,Adenosine
,6313815,elimination half-life,"The mean elimination half-life estimated from cumulative urinary excretion was 2.4 hr in a preterm infant, 3.1 hr in full-term infants, and 2.8 hr in older children.",Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313815/),h,3.1,172889,DB00640,Adenosine
,6313815,elimination half-life,"The mean elimination half-life estimated from cumulative urinary excretion was 2.4 hr in a preterm infant, 3.1 hr in full-term infants, and 2.8 hr in older children.",Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313815/),h,2.8,172890,DB00640,Adenosine
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,7·50,173644,DB00640,Adenosine
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,10·50,173645,DB00640,Adenosine
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,4667,173646,DB00640,Adenosine
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,2750,173647,DB00640,Adenosine
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,3.0,173797,DB00640,Adenosine
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,1.5,173798,DB00640,Adenosine
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,4.0,173799,DB00640,Adenosine
,31513867,absolute bioavailability,Absorption of inhaled nitrite was rapid with the absolute bioavailability of 18%.,Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),%,18,175882,DB00640,Adenosine
,31513867,clearance (CL),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),[l] / [h·kg],1.5,175883,DB00640,Adenosine
,31513867,volume of distribution (Vd),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),[l] / [kg],1.3,175884,DB00640,Adenosine
,31513867,half-life (t1/2),"In whole blood, nitrite exhibited the dose-independent pharmacokinetics with clearance (CL) of 1.5 l/h/kg, volume of distribution (Vd) of 1.3 l/kg and half-life (t1/2) of 0.6 h.",Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31513867/),h,0.6,175885,DB00640,Adenosine
,10516939,systemic clearance,"Based on a noncompartmental method of analysis, the pharmacokinetics of AMP 579 were characterized by rapid systemic clearance (0.77 to 0.85 L/h/kg), a moderate steady-state volume of distribution (0.80 to 0.94 L/kg), and a short terminal elimination half-life (0.84 to 1.13 h).","Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516939/),[l] / [h·kg],0.77 to 0.85,176868,DB00640,Adenosine
,10516939,steady-state volume of distribution,"Based on a noncompartmental method of analysis, the pharmacokinetics of AMP 579 were characterized by rapid systemic clearance (0.77 to 0.85 L/h/kg), a moderate steady-state volume of distribution (0.80 to 0.94 L/kg), and a short terminal elimination half-life (0.84 to 1.13 h).","Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516939/),[l] / [kg],0.80 to 0.94,176869,DB00640,Adenosine
,10516939,terminal elimination half-life,"Based on a noncompartmental method of analysis, the pharmacokinetics of AMP 579 were characterized by rapid systemic clearance (0.77 to 0.85 L/h/kg), a moderate steady-state volume of distribution (0.80 to 0.94 L/kg), and a short terminal elimination half-life (0.84 to 1.13 h).","Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516939/),h,0.84 to 1.13,176870,DB00640,Adenosine
,2754025,maximum plasma concentration time (tmax),The maximum plasma concentration time (tmax) of Y-20811 was 0.5-1.1 hours.,"Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754025/),h,0.5-1.1,176930,DB00640,Adenosine
,2754025,initial-phase half-life (t1/2 alpha),The initial-phase half-life (t1/2 alpha) was 0.8-1.1 hours and the final-phase half-life (t1/2 beta) was 4.7-9.2 hours.,"Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754025/),h,0.8-1.1,176931,DB00640,Adenosine
,2754025,final-phase half-life (t1/2 beta),The initial-phase half-life (t1/2 alpha) was 0.8-1.1 hours and the final-phase half-life (t1/2 beta) was 4.7-9.2 hours.,"Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754025/),h,4.7-9.2,176932,DB00640,Adenosine
,20601034,clearance,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [h·kg],0.173,177221,DB00640,Adenosine
,20601034,volume of distribution,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [kg],0.71,177222,DB00640,Adenosine
,20601034,half-life time,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),h,3.0,177223,DB00640,Adenosine
,19446152,C(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.2,177642,DB00640,Adenosine
,19446152,T(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177643,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.1,177644,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.4,177645,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177646,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.3,177647,DB00640,Adenosine
,19446152,Cmax,"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],10.9,177648,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],38.8,177649,DB00640,Adenosine
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177650,DB00640,Adenosine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.0,177651,DB00640,Adenosine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],11.9,177652,DB00640,Adenosine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177653,DB00640,Adenosine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.8,177654,DB00640,Adenosine
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,58.8,177655,DB00640,Adenosine
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177656,DB00640,Adenosine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4299.1,177657,DB00640,Adenosine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177658,DB00640,Adenosine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4406.9,177659,DB00640,Adenosine
,15876260,clearance,The average dialysis clearance was 33.85 ml/min which is about 25% of the clearance in patients without renal failure.,Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876260/),[ml] / [min],33.85,178607,DB00640,Adenosine
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],2491,178677,DB00640,Adenosine
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],3991,178678,DB00640,Adenosine
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],473,178679,DB00640,Adenosine
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],712,178680,DB00640,Adenosine
,29023473,tmax,STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012).,"Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),h,4.0,178681,DB00640,Adenosine
,29023473,tmax,STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012).,"Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),h,2.5,178682,DB00640,Adenosine
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,4558,178766,DB00640,Adenosine
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,"136,572",178767,DB00640,Adenosine
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,2896,178768,DB00640,Adenosine
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,"35,819",178769,DB00640,Adenosine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1740,178770,DB00640,Adenosine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1253,178771,DB00640,Adenosine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],127,178772,DB00640,Adenosine
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,4.26,179643,DB00640,Adenosine
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,3.38,179644,DB00640,Adenosine
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,6.69,179645,DB00640,Adenosine
,26838160,half-life,"The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively.","Metabolism and Disposition of Aditoprim in Swine, Broilers, Carp and Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838160/),d,5.21,179646,DB00640,Adenosine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,102,179814,DB00640,Adenosine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,19,179815,DB00640,Adenosine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,24,179816,DB00640,Adenosine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,60,179817,DB00640,Adenosine
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,48,179818,DB00640,Adenosine
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,55,179819,DB00640,Adenosine
,23159667,t(1/2β),"However, 8CA is intensively metabolized shortly after i.v. administration, with a t(1/2β) of approximately 1h.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),h,1,180445,DB00640,Adenosine
,23159667,entrapment efficiency,"The liposomes, comprising egg phosphatidylcholine, cholesterol and poly (ethylene glycol) 2000-distearoyl phosphatidylethanolamine (PEG-DSPE), had mean diameters of approximately 100 nm and an entrapment efficiency of 69-86%.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),%,69-86,180446,DB00640,Adenosine
,23159667,IC(50),"MTT assays showed that the cytotoxicity of 8CAS and its pegylated liposomes (8CAS-PL) were retained, with IC(50) values of 1.0 μM and 1.9 μM at 72 h on MCF-7 cells, respectively, slightly higher than that of 8CA (0.6 μM).",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),μM,1.0,180447,DB00640,Adenosine
,23159667,IC(50),"MTT assays showed that the cytotoxicity of 8CAS and its pegylated liposomes (8CAS-PL) were retained, with IC(50) values of 1.0 μM and 1.9 μM at 72 h on MCF-7 cells, respectively, slightly higher than that of 8CA (0.6 μM).",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),μM,1.9,180448,DB00640,Adenosine
,23159667,IC(50),"MTT assays showed that the cytotoxicity of 8CAS and its pegylated liposomes (8CAS-PL) were retained, with IC(50) values of 1.0 μM and 1.9 μM at 72 h on MCF-7 cells, respectively, slightly higher than that of 8CA (0.6 μM).",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),μM,0.6,180449,DB00640,Adenosine
,23159667,elimination half-lives (t(1/2),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),min,128.4,180450,DB00640,Adenosine
,23159667,elimination half-lives (t(1/2),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),min,249.2,180451,DB00640,Adenosine
,23159667,elimination half-lives (t(1/2),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),min,74.7,180452,DB00640,Adenosine
,23159667,clearance rates (Cl,"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[l] / [kg·min],0.0135,180453,DB00640,Adenosine
,23159667,clearance rates (Cl,"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[l] / [kg·min],0.00875,180454,DB00640,Adenosine
,23159667,clearance rates (Cl,"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[l] / [kg·min],0.2398,180455,DB00640,Adenosine
,23159667,area under the concentration-time curve (AUC(0-∞),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[mg·min] / [l],741.4,180456,DB00640,Adenosine
,23159667,area under the concentration-time curve (AUC(0-∞),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[mg·min] / [l],1163.6,180457,DB00640,Adenosine
,23159667,area under the concentration-time curve (AUC(0-∞),"Pharmacokinetic studies in rats after i.v. injection showed that both 8CAS and 8 CAS-PL had increased elimination half-lives (t(1/2), 128.4, 249.2 vs. 74.7 min), decreased clearance rates (Cl, 0.0135, 0.00875 vs. 0.2398 L/min/kg) and increased area under the concentration-time curve (AUC(0-∞), 741.4, 1163.6 vs. 42.0 mg min/L) compared to 8CA.",A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23159667/),[mg·min] / [l],42.0,180458,DB00640,Adenosine
,23093043,maximum plasma concentration (Cmax),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[ng] / [ml],109,181360,DB00640,Adenosine
,23093043,area under the plasma concentration-time curve from time zero to infinity (AUC),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[h·ng] / [ml],62,181361,DB00640,Adenosine
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,8,181362,DB00640,Adenosine
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,2,181363,DB00640,Adenosine
,10647619,alpha phase half-life,"The blood clearance was biphasic, with an alpha phase half-life of approximately 4 min (20%) and a beta phase half-life of approximately 13 min (88%).",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),min,4,181446,DB00640,Adenosine
,10647619,beta phase half-life,"The blood clearance was biphasic, with an alpha phase half-life of approximately 4 min (20%) and a beta phase half-life of approximately 13 min (88%).",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),min,13,181447,DB00640,Adenosine
,10647619,binding,"The mean binding of 99mTc-TP 850 to human, dog, and rabbit fibrin was 46% +/- 2%, 60% +/- 3%, and 56% +/- 2.5%, respectively, and the inhibitory concentration of 50% for dog and rabbit platelet aggregation was 236 pm and 167 pm, respectively.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),%,46,181448,DB00640,Adenosine
,10647619,binding,"The mean binding of 99mTc-TP 850 to human, dog, and rabbit fibrin was 46% +/- 2%, 60% +/- 3%, and 56% +/- 2.5%, respectively, and the inhibitory concentration of 50% for dog and rabbit platelet aggregation was 236 pm and 167 pm, respectively.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),%,60,181449,DB00640,Adenosine
,10647619,binding,"The mean binding of 99mTc-TP 850 to human, dog, and rabbit fibrin was 46% +/- 2%, 60% +/- 3%, and 56% +/- 2.5%, respectively, and the inhibitory concentration of 50% for dog and rabbit platelet aggregation was 236 pm and 167 pm, respectively.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),%,56,181450,DB00640,Adenosine
,10647619,inhibitory concentration of 50%,"The mean binding of 99mTc-TP 850 to human, dog, and rabbit fibrin was 46% +/- 2%, 60% +/- 3%, and 56% +/- 2.5%, respectively, and the inhibitory concentration of 50% for dog and rabbit platelet aggregation was 236 pm and 167 pm, respectively.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),pm,236,181451,DB00640,Adenosine
,10647619,inhibitory concentration of 50%,"The mean binding of 99mTc-TP 850 to human, dog, and rabbit fibrin was 46% +/- 2%, 60% +/- 3%, and 56% +/- 2.5%, respectively, and the inhibitory concentration of 50% for dog and rabbit platelet aggregation was 236 pm and 167 pm, respectively.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),pm,167,181452,DB00640,Adenosine
,10647619,radioactivity,"The radioactivity associated with clots varied from 0.01 to 0.09 %ID/g, with clot-to-blood radioactivity ratios ranging from 1.2 to 12.0.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),[%id] / [g],0.01 to 0.09,181453,DB00640,Adenosine
,10647619,radioactivity ratios,"The radioactivity associated with clots varied from 0.01 to 0.09 %ID/g, with clot-to-blood radioactivity ratios ranging from 1.2 to 12.0.",Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10647619/),,1.2 to 12.0,181454,DB00640,Adenosine
,8350844,half-life,"Because of its half-life of 0.6 to 10 seconds, adenosine will not prevent reinitiation of SVT, therefore other medications should be considered if prophylaxis is required.",Adenosine administration for neonatal SVT. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8350844/),seconds,0.6 to 10,183553,DB00640,Adenosine
,23748750,maximum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],1.8,184643,DB00640,Adenosine
,23748750,maximum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],3.0,184644,DB00640,Adenosine
,23748750,minimum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],0.5,184645,DB00640,Adenosine
,23748750,minimum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],0.7,184646,DB00640,Adenosine
,23748750,area under the curve,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[h·ng] / [ml],16.8,184647,DB00640,Adenosine
,23748750,area under the curve,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[h·ng] / [ml],21.0,184648,DB00640,Adenosine
,15937757,terminal elimination half-life,The mean terminal elimination half-life ranged from 15 to 19 days.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),d,15 to 19,185338,DB00640,Adenosine
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,50,185339,DB00640,Adenosine
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,71,185340,DB00640,Adenosine
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,85,185341,DB00640,Adenosine
less,6628545,half-life,"The half-life for adenosine in undiluted blood was less than 10 s; therefore, to accurately evaluate the effects of dipyridamole, blood was diluted 1 : 12 in isotonic saline.",Dipyridamole inhibition of adenosine metabolism in human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628545/),s,10,185362,DB00640,Adenosine
,6628545,half-life,"At this dilution, the half-life for adenosine was 1.3 min.",Dipyridamole inhibition of adenosine metabolism in human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628545/),min,1.3,185363,DB00640,Adenosine
,25248972,K i,"In vitro binding assay revealed a K i value of 0.96 nM for PQ-69 in cloned hA1 receptor, which was 217-fold more selective compared with hA2A receptors and >1,000-fold selectivity for hA1 over hA3 receptor.","PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248972/),nM,0.96,185716,DB00640,Adenosine
,25248972,pA2,"In addition, PQ-69 displayed highly inhibitory activities on isolated guinea pig contraction (pA2 value of 8.99) induced by an A1AR agonist, 2-chloro-N6-cyclopentyl adenosine.","PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248972/),,8.99,185717,DB00640,Adenosine
,20228156,elimination half-lives,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),h,1.49 to 3.27,187646,DB00640,Adenosine
,20228156,volumes of distribution,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),[l] / [kg],5.95-14.19,187647,DB00640,Adenosine
,20228156,brain-to-plasma ratios,The brain-to-plasma ratios ranged from 2.93 to 11.81 and were higher than those previously reported for cocaine.,"Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),,2.93 to 11.81,187648,DB00640,Adenosine
,8863284,retention times,"The nominal retention times were 9, 14, and 26 min for Fddl, IS, and FddA, respectively.","High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863284/),min,9,187943,DB00640,Adenosine
,8863284,retention times,"The nominal retention times were 9, 14, and 26 min for Fddl, IS, and FddA, respectively.","High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863284/),min,14,187944,DB00640,Adenosine
,8863284,retention times,"The nominal retention times were 9, 14, and 26 min for Fddl, IS, and FddA, respectively.","High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863284/),min,26,187945,DB00640,Adenosine
greater,8863284,extraction recoveries,The extraction recoveries of the analytes were greater than 80%.,"High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863284/),%,80,187946,DB00640,Adenosine
,30675914,flow rate,Acetonitrile and 5 mΜ ammonium acetate was used as the mobile phase with a gradient elution at a flow rate of 0.5 mL/min.,Validated liquid chromatography-tandem mass spectrometry method for quantification of ticagrelor and its active metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30675914/),[ml] / [min],0.5,188670,DB00640,Adenosine
,1963813,IC50,"SDB inhibited both the K(+)-dependent adenosine triphosphatase (ATPase) activity of a hog gastric proton pump (H+, K(+)-ATPase) with a value of 20-30 microM for IC50 and proton transport into gastric vesicles.","Scopadulcic acid B, a new tetracyclic diterpenoid from Scoparia dulcis L. Its structure, H+, K(+)-adenosine triphosphatase inhibitory activity and pharmacokinetic behaviour in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963813/),μM,20-30,189631,DB00640,Adenosine
,33420642,peak plasma concentrations (Cmax),"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[ng] / [ml],2395.17,190027,DB00640,Adenosine
,33420642,area under the curve (AUC) within 72 h (AUC0 - 72 h),"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],26669.09,190028,DB00640,Adenosine
,33420642,AUC0-∞,"The peak plasma concentrations (Cmax) after fluzoparib administration was 2395.17 ± 418.27 ng/mL, the area under the curve (AUC) within 72 h (AUC0 - 72 h) was 26669.09 ± 7320.12 h·ng/mL, and AUC0-∞ was 26897.44 ± 7573.61 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],26897.44,190029,DB00640,Adenosine
,33420642,Cmax,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),ml·ng,2489.43,190030,DB00640,Adenosine
,33420642,AUC0 - 72 h,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],30300.49,190031,DB00640,Adenosine
,33420642,AUC0-∞,"The Cmax after co-administration of fluzoparib and omeprazole was 2489.43 ± 423.72 ng·mL, AUC0 - 72 h was 30300.49 ± 8350.08 h·ng/mL, and AUC0-∞ was 30678.74 ± 8595.55 h·ng/mL.","Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33420642/),[h·ng] / [ml],30678.74,190032,DB00640,Adenosine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],45.39,190502,DB00640,Adenosine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],29.15,190503,DB00640,Adenosine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],19.55,190504,DB00640,Adenosine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],61.05,190505,DB00640,Adenosine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],37.67,190506,DB00640,Adenosine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],27.08,190507,DB00640,Adenosine
,7955799,plasma clearance,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),[ml] / [min],329,190673,DB00640,Adenosine
,7955799,steady-state volume of distribution,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),l,76,190674,DB00640,Adenosine
,7955799,half-life,"The pharmacokinetics of MK-383 include a mean plasma clearance of 329 ml/min, steady-state volume of distribution of 76 L, and half-life of 1.6 hours.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),h,1.6,190675,DB00640,Adenosine
,7955799,percentage of,The percentage of dose excreted in the urine was 37%.,"Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),%,37,190676,DB00640,Adenosine
,7955799,plasma concentration yielding 50% inhibition (C50),"The plasma concentration yielding 50% inhibition (C50) for MK-383 in healthy volunteers is approximately 13 ng/ml, with a Hill coefficient > 5.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),[ng] / [ml],13,190677,DB00640,Adenosine
>,7955799,Hill coefficient,"The plasma concentration yielding 50% inhibition (C50) for MK-383 in healthy volunteers is approximately 13 ng/ml, with a Hill coefficient > 5.","Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955799/),,5,190678,DB00640,Adenosine
,7494823,apparent oral bioavailability,"6-Cl-ddP has poor apparent oral bioavailability (7% +/- 3%, n = 3) but high bioavailability after portal administration (97% +/- 11%), suggesting either poor absorption or extensive gut wall metabolism.","Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494823/),%,7,190695,DB00640,Adenosine
,7494823,bioavailability,"6-Cl-ddP has poor apparent oral bioavailability (7% +/- 3%, n = 3) but high bioavailability after portal administration (97% +/- 11%), suggesting either poor absorption or extensive gut wall metabolism.","Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494823/),%,97,190696,DB00640,Adenosine
,7494823,oral bioavailability,"Gastric administration of 6-Cl-ddP resulted in a > 10-fold increase in the oral bioavailability of ddI, from 3-7% to > 50%, and a significant decrease in the variability in apparent bioavailability.","Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494823/),%,3-7,190697,DB00640,Adenosine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32-35,191092,DB00640,Adenosine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32,191093,DB00640,Adenosine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4315-5027,191094,DB00640,Adenosine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4398,191095,DB00640,Adenosine
,10806603,elimination half-life,"The pharmacokinetics of MK-852 include an elimination half-life of approximately 2 hours, total clearance of about 150 ml/min, and volume of distribution of about 18 liters.","Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806603/),h,2,193188,DB00640,Adenosine
,10806603,total clearance,"The pharmacokinetics of MK-852 include an elimination half-life of approximately 2 hours, total clearance of about 150 ml/min, and volume of distribution of about 18 liters.","Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806603/),[ml] / [min],150,193189,DB00640,Adenosine
,10806603,volume of distribution,"The pharmacokinetics of MK-852 include an elimination half-life of approximately 2 hours, total clearance of about 150 ml/min, and volume of distribution of about 18 liters.","Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806603/),l,18,193190,DB00640,Adenosine
,10806603,EC50,Examination of the relationship between MK-852 whole-blood concentration in vitro and inhibition of platelet aggregation showed an EC50 of about 55 ng/ml and a Hill coefficient of 1.55.,"Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806603/),[ng] / [ml],55,193191,DB00640,Adenosine
,10806603,Hill coefficient,Examination of the relationship between MK-852 whole-blood concentration in vitro and inhibition of platelet aggregation showed an EC50 of about 55 ng/ml and a Hill coefficient of 1.55.,"Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806603/),,1.55,193192,DB00640,Adenosine
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],40-48,195152,DB00640,Adenosine
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195153,DB00640,Adenosine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],7-9,195154,DB00640,Adenosine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195155,DB00640,Adenosine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],3,195156,DB00640,Adenosine
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,2,195157,DB00640,Adenosine
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,4,195158,DB00640,Adenosine
,17220241,renal clearance of unbound drug,"The renal clearance of unbound drug in rats, 32 to 39 ml/min/kg, far exceeded the glomerular filtration rate, indicative of active renal elimination of parent drug.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],32 to 39,195159,DB00640,Adenosine
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,31,195243,DB00640,Adenosine
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,25,195244,DB00640,Adenosine
,7503639,bioavailability,"Recently, however, pharmacokinetic studies have shown that the bioavailability of oral CdA is 50% and of s.c. injection 100%.","2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503639/),%,50,195364,DB00640,Adenosine
,7503639,bioavailability,"Recently, however, pharmacokinetic studies have shown that the bioavailability of oral CdA is 50% and of s.c. injection 100%.","2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503639/),%,100,195365,DB00640,Adenosine
,18766965,MTD,The duration of MTD for gemcitabine was 12 h.,"Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18766965/),h,12,195846,DB00640,Adenosine
,11515591,Ki,"In particular, compound 7 was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A(2A)/A1=5400).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),nM,0.026,197678,DB00640,Adenosine
,11515591,A(2A)/A1,"In particular, compound 7 was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A(2A)/A1=5400).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),,5400,197679,DB00640,Adenosine
,11515591,brain/plasma ratio,"In particular, 32 displayed good plasma and brain concentrations (dose: 32 mg/kg (n=3); after 30 min, plasma conc.=3390+/-651nM, brain conc.=3670+/-496nM; after 60min, plasma conc.=1580+/-348nM, brain conc.=2143+/-434nM), and a good brain/plasma ratio (1.11+/-0.060 (30min), 1.39+/-0.172 (60min)).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),,1.11,197680,DB00640,Adenosine
,11515591,brain/plasma ratio,"In particular, 32 displayed good plasma and brain concentrations (dose: 32 mg/kg (n=3); after 30 min, plasma conc.=3390+/-651nM, brain conc.=3670+/-496nM; after 60min, plasma conc.=1580+/-348nM, brain conc.=2143+/-434nM), and a good brain/plasma ratio (1.11+/-0.060 (30min), 1.39+/-0.172 (60min)).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),,1.39,197681,DB00640,Adenosine
,11515591,bioavailability (Ki,"As a result, we could show that 32 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6nM, A(2A)/A1=820, BA=60.6+/-4.9% (32 mg/kg)).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),nM,6.6,197682,DB00640,Adenosine
,11515591,A(2A)/A1,"As a result, we could show that 32 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6nM, A(2A)/A1=820, BA=60.6+/-4.9% (32 mg/kg)).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),,820,197683,DB00640,Adenosine
,11515591,BA,"As a result, we could show that 32 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6nM, A(2A)/A1=820, BA=60.6+/-4.9% (32 mg/kg)).","Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11515591/),%,60.6,197684,DB00640,Adenosine
,23512128,half-life,"After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h.","Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23512128/),h,50,198226,DB00640,Adenosine
,27165805,matrix effects,The matrix effects of plasma and urine were in the range of 98.3-110.7% for ticagrelor and 102.1-112.3% for M8.,Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165805/),,98.3-110.7,198289,DB00640,Adenosine
,27165805,matrix effects,The matrix effects of plasma and urine were in the range of 98.3-110.7% for ticagrelor and 102.1-112.3% for M8.,Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165805/),,102.1-112.3,198290,DB00640,Adenosine
,11568514,area under the curve,The median area under the curve of omeprazole was 0.78 microg.,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),μg,0.78,199857,DB00640,Adenosine
,11568514,Systemic clearance,Systemic clearance was not different between the two groups: median values were 0.68 and 0.42 L. kg-1. h-1 (P = 0.22).,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),[l] / [h·kg],0.68,199858,DB00640,Adenosine
,11568514,Systemic clearance,Systemic clearance was not different between the two groups: median values were 0.68 and 0.42 L. kg-1. h-1 (P = 0.22).,Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568514/),[l] / [h·kg],0.42,199859,DB00640,Adenosine
,25271258,brain-to-plasma ratio,"In this study, we characterized JNJ-42253432 [2-methyl-N-([1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide] as a centrally permeable (brain-to-plasma ratio of 1), high-affinity P2X7 antagonist with desirable pharmacokinetic and pharmacodynamic properties for in vivo testing in rodents.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,1,200086,DB00640,Adenosine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,9.1,200087,DB00640,Adenosine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,7.9,200088,DB00640,Adenosine
,25271258,ED50,"When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],0.3,200089,DB00640,Adenosine
,25271258,ED50,"At higher doses/exposure, JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],10,200090,DB00640,Adenosine
,27632986,blood/dialysate flow rates,Regadenoson transmembrane clearance (CLD) was assessed for both a standard permeability and a high permeability polysulfone hemodialyzer with blood/dialysate flow rates of 300/600 and 400/800 mL/min.,Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632986/),[ml] / [min],300/600,200320,DB00640,Adenosine
,27632986,blood/dialysate flow rates,Regadenoson transmembrane clearance (CLD) was assessed for both a standard permeability and a high permeability polysulfone hemodialyzer with blood/dialysate flow rates of 300/600 and 400/800 mL/min.,Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632986/),[ml] / [min],400/800,200321,DB00640,Adenosine
,27632986,CLD,The mean ± SD regadenoson CLD values ranged between 62.5 ± 11.8 and 89.1 ± 24.0 mL/min for all dialytic conditions.,Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632986/),[ml] / [min],62.5,200322,DB00640,Adenosine
,27632986,CLD,The mean ± SD regadenoson CLD values ranged between 62.5 ± 11.8 and 89.1 ± 24.0 mL/min for all dialytic conditions.,Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632986/),[ml] / [min],89.1,200323,DB00640,Adenosine
,7882513,detection limit,"The assay's linear range extended to 10 mumol/L; the detection limit was 0.1 mumol/L, analytical recovery 97.7%, and run-to-run imprecision (CV) < 4.7%.","HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7882513/),[μM] / [l],0.1,202309,DB00640,Adenosine
,15978101,terminal half-life,"Pharmacokinetics of S18886 was linear, with peak plasma levels being reached between 30 min and 2 h and a terminal half-life of 5.8-10 h.",The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15978101/),h,5.8-10,202544,DB00640,Adenosine
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00640,Adenosine
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00640,Adenosine
,9172100,overall absolute,"The overall absolute and relative recovery of I using the tandem SPE procedure was 85.5 +/- 5.1% and 96.5 +/- 5.0%, respectively.","A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172100/),%,85.5,205979,DB00640,Adenosine
,9172100,relative recovery,"The overall absolute and relative recovery of I using the tandem SPE procedure was 85.5 +/- 5.1% and 96.5 +/- 5.0%, respectively.","A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172100/),%,96.5,205980,DB00640,Adenosine
,22743338,limits of detection,"The applied HPLC-MS/MS method allowed low limits of detection, as calculated from calibration curves, of 6.6 and 24.4 ng/mL for water matrix and rat blood extracts, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[ng] / [ml],6.6,206371,DB00640,Adenosine
,22743338,limits of detection,"The applied HPLC-MS/MS method allowed low limits of detection, as calculated from calibration curves, of 6.6 and 24.4 ng/mL for water matrix and rat blood extracts, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[ng] / [ml],24.4,206372,DB00640,Adenosine
,22743338,terminal half-life,"The intravenous infusion of 20 μg zolmitriptan to male Sprague-Dawley rats produced blood concentrations ranging from 9.4±0.7 to 1.24±0.07 μg/mL within 10 h, with a terminal half-life of 3.4±0.2h.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),h,3.4,206373,DB00640,Adenosine
,22743338,CSF,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0539,206374,DB00640,Adenosine
,22743338,CSF,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0453,206375,DB00640,Adenosine
,22743338,concentrations,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0539,206376,DB00640,Adenosine
,22743338,concentrations,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0453,206377,DB00640,Adenosine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],6307,206850,DB00640,Adenosine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],9791,206851,DB00640,Adenosine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],1503,206852,DB00640,Adenosine
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],2388,206853,DB00640,Adenosine
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,4,206854,DB00640,Adenosine
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,2,206855,DB00640,Adenosine
,20383215,area-under-the-curve (AUC((0-∞))),"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[h·μg] / [ml],5.0,207060,DB00640,Adenosine
,20383215,clearance,"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[l] / [h],15.3,207061,DB00640,Adenosine
,20383215,C(min),"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[ng] / [ml],55,207062,DB00640,Adenosine
,20383215,concentration,"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[ng] / [ml],16.0,207063,DB00640,Adenosine
greater,20383215,AUC((0-∞)),Patients with an AUC((0-∞)) greater than 6.5 μg h/mL had 4.56 greater risk of TRM and significantly lower OS.,High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[h·μg] / [ml],6.5,207064,DB00640,Adenosine
,9855320,total clearance,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),[l] / [h],13.68,207466,DB00640,Adenosine
,9855320,volume of distribution at steady state,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),l,170.08,207467,DB00640,Adenosine
,9855320,beta-half-life,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),h,10.9,207468,DB00640,Adenosine
,9855320,terminal half-life,"Fludarabine pharmacokinetics in patients with RA are characterized by an intermediate-length distribution phase (approximately 40 min), terminal half-life of 10.9 hours, and significant amount of tissue distribution.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),h,10.9,207469,DB00640,Adenosine
,22883407,inhibitory concentration 50%,The inhibitory concentration 50% values of different pairs of L-OHP-sensitive and -resistant cells were 7.2 and 89.00.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,7.2,207520,DB00640,Adenosine
,22883407,inhibitory concentration 50%,The inhibitory concentration 50% values of different pairs of L-OHP-sensitive and -resistant cells were 7.2 and 89.00.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,89.00,207521,DB00640,Adenosine
,22883407,resistance index,The resistance index of HCT116/L-OHP cells was 12.36.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,12.36,207522,DB00640,Adenosine
,16371327,Peak plasma concentrations,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),μM,50,207769,DB00640,Adenosine
,16371327,half-lives for elimination,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),h,2.5-10,207770,DB00640,Adenosine
,20237073,K(i),PF-3644022 is a potent freely reversible ATP-competitive compound that inhibits MK2 activity (K(i) = 3 nM) with good selectivity when profiled against 200 human kinases.,A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),nM,3,207882,DB00640,Adenosine
,20237073,IC(50),"In the human U937 monocytic cell line or peripheral blood mononuclear cells, PF-3644022 potently inhibits TNFalpha production with similar activity (IC(50) = 160 nM).",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),nM,160,207883,DB00640,Adenosine
,20237073,IC(50),"PF-3644022 blocks TNFalpha and IL-6 production in LPS-stimulated human whole blood with IC(50) values of 1.6 and 10.3 microM, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),μM,1.6,207884,DB00640,Adenosine
,20237073,IC(50),"PF-3644022 blocks TNFalpha and IL-6 production in LPS-stimulated human whole blood with IC(50) values of 1.6 and 10.3 microM, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),μM,10.3,207885,DB00640,Adenosine
,20237073,ED(50),"Dose-dependent inhibition of TNFalpha production in the acute model and inhibition of paw swelling in the chronic model is observed with ED(50) values of 6.9 and 20 mg/kg, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),[mg] / [kg],6.9,207886,DB00640,Adenosine
,20237073,ED(50),"Dose-dependent inhibition of TNFalpha production in the acute model and inhibition of paw swelling in the chronic model is observed with ED(50) values of 6.9 and 20 mg/kg, respectively.",A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237073/),[mg] / [kg],20,207887,DB00640,Adenosine
,8894519,clearance,"The clearance of F-ddI was substantially reduced, in comparison with that of ddI (27.3 ml/min/kg vs. 90.9 ml/min/kg), resulting in higher systemic concentrations at steady state and prolonged retention of F-ddI after termination of infusions, consistent with a significant metabolic component in the clearance of ddI.","Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894519/),[ml] / [kg·min],27.3,208798,DB00640,Adenosine
,8894519,clearance,"The clearance of F-ddI was substantially reduced, in comparison with that of ddI (27.3 ml/min/kg vs. 90.9 ml/min/kg), resulting in higher systemic concentrations at steady state and prolonged retention of F-ddI after termination of infusions, consistent with a significant metabolic component in the clearance of ddI.","Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894519/),[ml] / [kg·min],90.9,208799,DB00640,Adenosine
,8894519,total clearance,"In untreated rats, F-ddA was rapidly eliminated from plasma, with a total clearance of 68.5 ml/kg/min.","Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894519/),[ml] / [kg·min],68.5,208800,DB00640,Adenosine
,8894519,bioconversion t1/2,Metabolic clearance of F-ddA to F-ddI accounted for 58% of this value (bioconversion t1/2 = 9.8 +/- 1.9 min).,"Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894519/),min,9.8,208801,DB00640,Adenosine
,8894519,clearance,"Pretreatment with 2'-deoxycoformycin, an ADA inhibitor, reduced the clearance of F-ddA to 23.8 ml/min/kg, leading to 2.9 +/- 0.4-fold higher steady-state plasma concentrations of F-ddA, in agreement with a 2.5-fold enhancement predicted by a compartmental model assuming complete ADA inhibition.","Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894519/),[ml] / [kg·min],23.8,208802,DB00640,Adenosine
,7773536,potency,"The potency based on free drug concentrations (EC50,u) was 5.8 ng ml-1 (11 nM) (mean +/- s.e.; n = 19) and correlated well with the reported adenosine A2a receptor affinity (Ki 19 nM).",Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773536/),[ng] / [ml],5.8,210053,DB00640,Adenosine
,7773536,"EC50,u)","The potency based on free drug concentrations (EC50,u) was 5.8 ng ml-1 (11 nM) (mean +/- s.e.; n = 19) and correlated well with the reported adenosine A2a receptor affinity (Ki 19 nM).",Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773536/),[ng] / [ml],5.8,210054,DB00640,Adenosine
,7773536,Ki,"The potency based on free drug concentrations (EC50,u) was 5.8 ng ml-1 (11 nM) (mean +/- s.e.; n = 19) and correlated well with the reported adenosine A2a receptor affinity (Ki 19 nM).",Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7773536/),nM,19,210055,DB00640,Adenosine
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],148.6,211238,DB00640,Adenosine
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],264.6,211239,DB00640,Adenosine
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],28.6,211240,DB00640,Adenosine
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],33.3,211241,DB00640,Adenosine
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],5.2,211242,DB00640,Adenosine
,25500486,tmax,"Ticagrelor tmax was shorter following crushed vs. whole-tablet administration (1 vs. 2 hours, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),h,1,211243,DB00640,Adenosine
,25500486,tmax,"Ticagrelor tmax was shorter following crushed vs. whole-tablet administration (1 vs. 2 hours, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),h,2,211244,DB00640,Adenosine
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],12.8,212063,DB00640,Adenosine
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],17.9,212064,DB00640,Adenosine
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,7.8,212192,DB00640,Adenosine
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),%,28,212193,DB00640,Adenosine
,23299770,overall survival,"Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months.","CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23299770/),month,8.1,212194,DB00640,Adenosine
,18558486,solubility,"In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 microM at physiological pH.","Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18558486/),μM,100,212953,DB00640,Adenosine
,27082762,flow rate,"The chromatographic separation was performed on a ReproSil-Pur 120C18 column (3μm, 2mm×100mm) with a gradient mobile phase of methanol/water containing 0.1% formic acid (v/v) in a flow rate of 0.2mL/min.","Simultaneous quantification of 2',3',5'-tri-O-acetyl-N6-(3-hydroxylaniline)adenosine and its principal metabolites in hamster blood by LC-MS/MS and its application in pharmacokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27082762/),[ml] / [min],0.2,213055,DB00640,Adenosine
more,27082762,recoveries,The average recoveries of the analytes were more than 80.0%.,"Simultaneous quantification of 2',3',5'-tri-O-acetyl-N6-(3-hydroxylaniline)adenosine and its principal metabolites in hamster blood by LC-MS/MS and its application in pharmacokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27082762/),%,80.0,213056,DB00640,Adenosine
,2037706,t1/2 beta,"The post-infusion plasma concentrations of AICA-riboside declined rapidly in a biphasic fashion, and the terminal elimination phase had a harmonic mean t1/2 beta of 1.4 hours.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),h,1.4,213336,DB00640,Adenosine
,2037706,Total plasma clearance (CL),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [h·kg],2.5,213337,DB00640,Adenosine
,2037706,mean residence time (MRTIV),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),h,0.7,213338,DB00640,Adenosine
,2037706,volume of distribution at steady-state (VSS),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [kg],1.6,213339,DB00640,Adenosine
,2037706,Renal clearance (CLR),Renal clearance (CLR) was 0.2 L/hr/kg with only 8% of the IV dose excreted in the urine as intact AICA-riboside.,"AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [h·kg],0.2,213340,DB00640,Adenosine
less,2037706,bioavailable,The drug was poorly bioavailable (less than 5%) when administered orally in solution.,"AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),%,5,213341,DB00640,Adenosine
,15073038,CR rate,The CR rate for 54 patients with active disease was 85%.,"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),%,85,213392,DB00640,Adenosine
,15073038,clearance,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),[ml] / [m2·min],109,213393,DB00640,Adenosine
,15073038,area-under-the-plasma-concentration-versus-time-curve,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),μmol-min,4871,213394,DB00640,Adenosine
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.54,213428,DB00640,Adenosine
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.71,213429,DB00640,Adenosine
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,1.81,213430,DB00640,Adenosine
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.97,213431,DB00640,Adenosine
,23284689,Tmax,Mean Tmax was 2-4 hours with elimination half-life of 15-20 hours.,"A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284689/),h,2-4,213643,DB00640,Adenosine
,23284689,elimination half-life,Mean Tmax was 2-4 hours with elimination half-life of 15-20 hours.,"A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284689/),h,15-20,213644,DB00640,Adenosine
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],7.7,213912,DB00640,Adenosine
,10561275,area under the concentration-time curve [AUC],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [h·l],8.8,213913,DB00640,Adenosine
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],3.2,213914,DB00640,Adenosine
,10561275,maximum plasma concentration [C(max)],"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],4.0,213915,DB00640,Adenosine
,10561275,C(max),"Gemcitabine did not influence paclitaxel pharmacokinetics at 150 and 200 mg/m(2) (area under the concentration-time curve [AUC], 7.7 and 8.8 micromol/ L. h, respectively; maximum plasma concentration [C(max)], 3.2 and 4.0 micromol/L, respectively), and paclitaxel did not influence that of gemcitabine (C(max), 30 +/- 3 micromol/L) and 2',2'-difluorodeoxyuridine.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[μM] / [l],30,213916,DB00640,Adenosine
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],55,213917,DB00640,Adenosine
,10561275,C(max),"Paclitaxel, however, dose-dependently increased the C(max) of gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine, from 55 +/- 10 to 106 +/- 16 pmol/10(6) cells.( )No significant difference in the AUC of dFdCTP was observed.",Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561275/),[pM] / [10(6)·cells],106,213918,DB00640,Adenosine
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],7.78,214333,DB00640,Adenosine
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],10.6,214334,DB00640,Adenosine
,19289530,50% inhibitory concentration,"One of the analogs synthesized (Genz-644131) was shown to be highly active against Trypanosoma brucei rhodesiense in vitro (50% inhibitory concentration, 400 pg/ml).",Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19289530/),[pg] / [ml],400,215098,DB00640,Adenosine
,19289530,half-life,Pharmacokinetic studies of mice following intraperitoneal dosing showed that the half-life of Genz-644131 was threefold greater than that of MDL 73811 (7.4 h versus 2.5 h).,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19289530/),h,7.4,215099,DB00640,Adenosine
,19289530,half-life,Pharmacokinetic studies of mice following intraperitoneal dosing showed that the half-life of Genz-644131 was threefold greater than that of MDL 73811 (7.4 h versus 2.5 h).,Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19289530/),h,2.5,215100,DB00640,Adenosine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,104,215212,DB00640,Adenosine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,114,215213,DB00640,Adenosine
,3300758,time after ingestion to peak concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),min,105,215214,DB00640,Adenosine
,3300758,concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),[ng] / [ml],7.8,215215,DB00640,Adenosine
,12374619,half-lives,The in vivo half-lives of TEMPOL of the kidney from 7 to 14 d after PAN administration were significantly longer than those of the controls.,Identification by an EPR technique of decreased mitochondrial reducing activity in puromycin aminonucleoside-induced nephrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374619/),d,7 to 14,217400,DB00640,Adenosine
,12374619,mitochondrial half-lives,"The mitochondrial half-lives of TEMPOL on the 9th day after the PAN administration prolonged remarkably compared to the controls (378 +/- 69 vs. 676 +/- 183 s, p <.01).",Identification by an EPR technique of decreased mitochondrial reducing activity in puromycin aminonucleoside-induced nephrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374619/),s,378,217401,DB00640,Adenosine
,12374619,mitochondrial half-lives,"The mitochondrial half-lives of TEMPOL on the 9th day after the PAN administration prolonged remarkably compared to the controls (378 +/- 69 vs. 676 +/- 183 s, p <.01).",Identification by an EPR technique of decreased mitochondrial reducing activity in puromycin aminonucleoside-induced nephrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374619/),s,676,217402,DB00640,Adenosine
,7018678,alpha-phase half-life,"The alpha-phase half-life of LV was about 15 mins, but LV was readily detectable by the assay for 3-4 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),min,15,218709,DB00640,Adenosine
,7018678,apparent half-life,"The level of mTHFA increased for at least 60 mins, being equimolar with LV by 30 mins, and then decreased slowly with an apparent half-life of 2-3 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),h,2-3,218710,DB00640,Adenosine
,15516022,t(max),"RESULTS PHARMACOKINETICS: For oral CF101, the t(max) was always 1 - 2 h post-dose and t 1/2 about 9 h, in both the single- and multiple-dose studies.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),h,1 - 2,219059,DB00640,Adenosine
,15516022,t 1/2,"RESULTS PHARMACOKINETICS: For oral CF101, the t(max) was always 1 - 2 h post-dose and t 1/2 about 9 h, in both the single- and multiple-dose studies.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),h,9,219060,DB00640,Adenosine
,15516022,C(max),"For a single 5 mg dose (mean +/- SD) C(max) = 81.6 +/- 23.6 ng/ml in the single dose study, and 63.6 +/- 22.0 ng/ml after the first of the multiple doses; AUC if was 904.0 +/- 221.9 ng.h/ml and 596.1 +/- 196.6 ng.h/ml for the 2 studies, respectively.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),[ng] / [ml],81.6,219061,DB00640,Adenosine
,15516022,C(max),"For a single 5 mg dose (mean +/- SD) C(max) = 81.6 +/- 23.6 ng/ml in the single dose study, and 63.6 +/- 22.0 ng/ml after the first of the multiple doses; AUC if was 904.0 +/- 221.9 ng.h/ml and 596.1 +/- 196.6 ng.h/ml for the 2 studies, respectively.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),[ng] / [ml],63.6,219062,DB00640,Adenosine
,15516022,AUC if,"For a single 5 mg dose (mean +/- SD) C(max) = 81.6 +/- 23.6 ng/ml in the single dose study, and 63.6 +/- 22.0 ng/ml after the first of the multiple doses; AUC if was 904.0 +/- 221.9 ng.h/ml and 596.1 +/- 196.6 ng.h/ml for the 2 studies, respectively.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),[h·ng] / [ml],904.0,219063,DB00640,Adenosine
,15516022,AUC if,"For a single 5 mg dose (mean +/- SD) C(max) = 81.6 +/- 23.6 ng/ml in the single dose study, and 63.6 +/- 22.0 ng/ml after the first of the multiple doses; AUC if was 904.0 +/- 221.9 ng.h/ml and 596.1 +/- 196.6 ng.h/ml for the 2 studies, respectively.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),[h·ng] / [ml],596.1,219064,DB00640,Adenosine
,15516022,AUC(0-24h),"After 7 days of multiple dosing there was little change, and AUC(0-24h) = 601.0 +/- 163.6 ng.h/ml.","Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516022/),[h·ng] / [ml],601.0,219065,DB00640,Adenosine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB00640,Adenosine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB00640,Adenosine
exceed,23716541,trough level,"Although rituximab trough levels increased progressively with each cycle, only by cycle 4 did the median trough level exceed 10 ug/mL.",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),[ug] / [ml],10,220088,DB00640,Adenosine
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,27,220089,DB00640,Adenosine
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,199,220090,DB00640,Adenosine
,23291288,recovery,Sample pretreatment by liquid-liquid extraction in diethyl ether yielded a recovery of 50% from human and mouse plasma.,Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291288/),%,50,220599,DB00640,Adenosine
,23291288,flow rate,"The mobile phase consisted of methanol:10mM ammonium acetate pH 5.0 (62:38, v/v), delivered at a flow rate of 0.2mL/min.",Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291288/),[ml] / [min],0.2,220600,DB00640,Adenosine
,20594086,maximum concentration,"Clopidogrel was not detected in any samples; in dogs given 1.13 +/- 0.17 mg/kg, maximum concentration of SR 26334 (mean +/- SD, 0.206 +/- 0.2 microg/mL) was detected 1 hour after administration.",Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594086/),[μg] / [ml],0.206,221241,DB00640,Adenosine
,11583325,terminal catabolic half-life,"The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)].",A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583325/),d,3.4,222209,DB00640,Adenosine
,11583325,terminal catabolic half-life,"The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)].",A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583325/),d,4.0,222210,DB00640,Adenosine
,11583325,terminal catabolic half-life,"The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)].",A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583325/),d,0.15,222211,DB00640,Adenosine
,22168538,time [t(max)] to reach maximum plasma concentration [C(max)],"Following single and multiple doses at both dose levels, ticagrelor was rapidly absorbed (median time [t(max)] to reach maximum plasma concentration [C(max)] 2 hours) with a mean elimination half-life (t(1/2;)) of 10.9-14.9 hours.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,2,222637,DB00640,Adenosine
,22168538,elimination half-life (t(1/2;)),"Following single and multiple doses at both dose levels, ticagrelor was rapidly absorbed (median time [t(max)] to reach maximum plasma concentration [C(max)] 2 hours) with a mean elimination half-life (t(1/2;)) of 10.9-14.9 hours.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,10.9-14.9,222638,DB00640,Adenosine
,22168538,t(max),AR-C124910XX was rapidly formed (median t(max) 2.0-3.0 hours; mean t(1/2;) 9.1-11.9 hours).,"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,2.0-3.0,222639,DB00640,Adenosine
,22168538,t(1/2;),AR-C124910XX was rapidly formed (median t(max) 2.0-3.0 hours; mean t(1/2;) 9.1-11.9 hours).,"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,9.1-11.9,222640,DB00640,Adenosine
,22168538,C(max),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,1973,222641,DB00640,Adenosine
,22168538,AUC(∞),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,18 035,222642,DB00640,Adenosine
,22168538,C(max),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,915,222643,DB00640,Adenosine
,22168538,AUC(∞),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,7168,222644,DB00640,Adenosine
,7721399,time to peak,"After acute administration in conscious rats, the A1 agonist 2-chloro-N6-cyclopentyladenosine induced dose-related hypotension (eg, 0.03 mg/kg; peak, -70 mm Hg; time to peak, 0.34 hour) and bradycardia (eg, 0.03 mg/kg; peak, -186 beats per minute [bpm]; time to peak, 0.38 hour).",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,0.34,223374,DB00640,Adenosine
,7721399,time to peak,"After acute administration in conscious rats, the A1 agonist 2-chloro-N6-cyclopentyladenosine induced dose-related hypotension (eg, 0.03 mg/kg; peak, -70 mm Hg; time to peak, 0.34 hour) and bradycardia (eg, 0.03 mg/kg; peak, -186 beats per minute [bpm]; time to peak, 0.38 hour).",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,0.38,223375,DB00640,Adenosine
,7721399,time to peak,"The A2a agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine induced dose-related hypotension (eg, 0.003 mg/kg; peak, -36 mm Hg; time to peak, 0.32 hour) with reflex tachycardia (eg, 0.003 mg/kg; peak, 152 bpm; time to peak, 0.35 hour).",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,0.32,223376,DB00640,Adenosine
,7721399,peak,"The A2a agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine induced dose-related hypotension (eg, 0.003 mg/kg; peak, -36 mm Hg; time to peak, 0.32 hour) with reflex tachycardia (eg, 0.003 mg/kg; peak, 152 bpm; time to peak, 0.35 hour).",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),bpm,152,223377,DB00640,Adenosine
,7721399,time to peak,"The A2a agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine induced dose-related hypotension (eg, 0.003 mg/kg; peak, -36 mm Hg; time to peak, 0.32 hour) with reflex tachycardia (eg, 0.003 mg/kg; peak, 152 bpm; time to peak, 0.35 hour).",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,0.35,223378,DB00640,Adenosine
,7721399,time to peak,"The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (0.1 mg/kg) induced hypotension (peak, -75 mm Hg; time to peak, 2.2 hours) and bradycardia followed by tachycardia (first peak, -131 bpm; time to peak, 1.26 hours; second peak, 123 bpm; time to peak, 13.9 hours.",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,2.2,223379,DB00640,Adenosine
,7721399,time to peak,"The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (0.1 mg/kg) induced hypotension (peak, -75 mm Hg; time to peak, 2.2 hours) and bradycardia followed by tachycardia (first peak, -131 bpm; time to peak, 1.26 hours; second peak, 123 bpm; time to peak, 13.9 hours.",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,1.26,223380,DB00640,Adenosine
,7721399,second peak,"The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (0.1 mg/kg) induced hypotension (peak, -75 mm Hg; time to peak, 2.2 hours) and bradycardia followed by tachycardia (first peak, -131 bpm; time to peak, 1.26 hours; second peak, 123 bpm; time to peak, 13.9 hours.",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),bpm,123,223381,DB00640,Adenosine
,7721399,time to peak,"The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (0.1 mg/kg) induced hypotension (peak, -75 mm Hg; time to peak, 2.2 hours) and bradycardia followed by tachycardia (first peak, -131 bpm; time to peak, 1.26 hours; second peak, 123 bpm; time to peak, 13.9 hours.",Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721399/),h,13.9,223382,DB00640,Adenosine
,25456831,DLC,"Doxorubicin (DOX) could be effectively loaded into PEG5K-Fmoc-VE2 micelles at a DLC of 39.9%, which compares favorably to most reported DOX nanoformulations.",An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456831/),%,39.9,223643,DB00640,Adenosine
,1318679,Ki,ara-MAP was shown to be a competitive alternative substrate inhibitor of adenosine deaminase (Ki = 16 microM).,Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318679/),μM,16,223792,DB00640,Adenosine
,18309944,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P = .0003) between responders (440 micromol/L; range, 35 to 1,438 micromol/L; n = 10) and nonresponders (50 micromol/L; range, 22 to 178 micromol/L; n = 15).",Phase I trial of nelarabine in indolent leukemias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18309944/),[μM] / [l],440,224357,DB00640,Adenosine
,18309944,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P = .0003) between responders (440 micromol/L; range, 35 to 1,438 micromol/L; n = 10) and nonresponders (50 micromol/L; range, 22 to 178 micromol/L; n = 15).",Phase I trial of nelarabine in indolent leukemias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18309944/),[μM] / [l],50,224358,DB00640,Adenosine
,20551239,half-life,"In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively).","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),h,6.3,225044,DB00640,Adenosine
,20551239,half-life,"In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively).","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),h,4.6,225045,DB00640,Adenosine
,20551239,ratio of radioactivity,"The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space.","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),,1.69,225046,DB00640,Adenosine
,20551239,radioactivity recovery,Mean radioactivity recovery was 26.5% in urine and 57.8% in feces.,"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),%,26.5,225047,DB00640,Adenosine
,20551239,radioactivity recovery,Mean radioactivity recovery was 26.5% in urine and 57.8% in feces.,"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),%,57.8,225048,DB00640,Adenosine
,7564508,half-life of the initial phase,"In the present study, time-courses of 2-CdA loss from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 microM nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),h,0.30,225139,DB00640,Adenosine
,7564508,half-life,"In the present study, time-courses of 2-CdA loss from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 microM nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),h,0.43,225140,DB00640,Adenosine
,7564508,AUCs,"As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol.h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol.h/10(6) cells; n = 19).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),[h·pM] / [10(6)·cells],4.56,225141,DB00640,Adenosine
,7564508,AUCs,"As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol.h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol.h/10(6) cells; n = 19).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),[h·pM] / [10(6)·cells],3.83,225142,DB00640,Adenosine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,13.6,225363,DB00640,Adenosine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,19.9,225364,DB00640,Adenosine
,976195,Plasma half-life,"Plasma half-life was determined to be 13.6 and 19.9 min in euthyroid and chronically hypothyroid rats, respectively; it was not significantly altered from the latter during rebound (18.7 min).",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),min,18.7,225365,DB00640,Adenosine
,976195,secretory rates,"Calculations of theoretical TSH secretory rates prior to (50.5 +/- 4.4 mU/h) and after rebound with 20 mug T4 (25.4 +/- 4.2 mU/H) revealed that the reaccumulation of TSH in the pituitary induced with T4 cannot be attributed solely to inhibition of release, but may also involve enhancement of synthesis.",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),[mu] / [h],50.5,225366,DB00640,Adenosine
,976195,secretory rates,"Calculations of theoretical TSH secretory rates prior to (50.5 +/- 4.4 mU/h) and after rebound with 20 mug T4 (25.4 +/- 4.2 mU/H) revealed that the reaccumulation of TSH in the pituitary induced with T4 cannot be attributed solely to inhibition of release, but may also involve enhancement of synthesis.",Pituitary thyrotropin (TSH) rebound phenomenon and kinetics of secretion in the goitrous rat: differential effects of thyroxine on synthesis and release of TSH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976195/),[mu] / [h],25.4,225367,DB00640,Adenosine
,28481355,clearance,Patients carrying a 5'-UTR polymorphism in NT5E gene (rs2295890 G>C) exhibited significantly lower plasma F-araA clearance compared to those with wild-type genotype (7.12 vs 5.03 L/h/m2 (29%) P<0.05).,Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),[l] / [h·m2],7.12,225399,DB00640,Adenosine
,28481355,clearance,Patients carrying a 5'-UTR polymorphism in NT5E gene (rs2295890 G>C) exhibited significantly lower plasma F-araA clearance compared to those with wild-type genotype (7.12 vs 5.03 L/h/m2 (29%) P<0.05).,Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),[l] / [h·m2],5.03,225400,DB00640,Adenosine
>,28481355,AUC,"Of all the outcome parameters evaluated (engraftment, rejection/graft failure, GvHD, TRM, OS), high F-araA AUC (>29.4 μm*h) was the only significant factor associated with the development of aGvHD by both univariate and multivariate analysis (P=0.02).",Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),h·μm,29.4,225401,DB00640,Adenosine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,8.4,226337,DB00640,Adenosine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,2.2,226338,DB00640,Adenosine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,12.2,226339,DB00640,Adenosine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,1.9,226340,DB00640,Adenosine
,30575938,Bioavailability,"Bioavailability in male and female golden hamsters after oral administration of IMM-H007 was calculated using the sum of Ml and MP, resulting in 6.97% and 8.95%, respectively.","Preclinical pharmacokinetic study of a novel lipid-lowering agent, IMM-H007. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30575938/),%,6.97,226369,DB00640,Adenosine
,30575938,Bioavailability,"Bioavailability in male and female golden hamsters after oral administration of IMM-H007 was calculated using the sum of Ml and MP, resulting in 6.97% and 8.95%, respectively.","Preclinical pharmacokinetic study of a novel lipid-lowering agent, IMM-H007. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30575938/),%,8.95,226370,DB00640,Adenosine
,23355301,clearance,"The simultaneous PK model comprised, in part, a two-compartment linear PK model for rolofylline, with estimates of clearance and volume of distribution at steady-state of 24.4 L/h and 239 L, respectively.",Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355301/),[l] / [h],24.4,227267,DB00640,Adenosine
,23355301,volume of distribution at steady-state,"The simultaneous PK model comprised, in part, a two-compartment linear PK model for rolofylline, with estimates of clearance and volume of distribution at steady-state of 24.4 L/h and 239 L, respectively.",Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355301/),l,239,227268,DB00640,Adenosine
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],0.5,228162,DB00640,Adenosine
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],5.7,228163,DB00640,Adenosine
,3499581,t1/2 phases,The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t1/2 phases of about 1-5 hr and 50 hr.,"Pharmacokinetics of 2'-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499581/),h,1-5,228575,DB00640,Adenosine
,3499581,t1/2 phases,The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t1/2 phases of about 1-5 hr and 50 hr.,"Pharmacokinetics of 2'-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499581/),h,50,228576,DB00640,Adenosine
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,1947.4,228949,DB00640,Adenosine
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,739.2,228950,DB00640,Adenosine
,20027105,Cmax,"Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.",A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027105/),nM,54.8,228951,DB00640,Adenosine
,17192496,area under the curve (AUC),"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],28.3,229900,DB00640,Adenosine
,17192496,oral AUC,"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],16.7,229901,DB00640,Adenosine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],12.18,229902,DB00640,Adenosine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],5.29,229903,DB00640,Adenosine
,17192496,oral bioavailability,"The median oral bioavailability was 72.3% (20.5%-172%), with 8-fold variability.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,72.3,229904,DB00640,Adenosine
< or =,17192496,oral bioavailability,Five patients (28%) had an oral bioavailability < or = 50%.,Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,50,229905,DB00640,Adenosine
<,17192496,AUC(0-12),"At time of oral pharmacokinetics, 15 patients (83%) had an AUC(0-12) < 30 microg x h/mL.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],30,229906,DB00640,Adenosine
,9375754,response rate,Clinical trials with intravenous cladribine infusions in pretreated patients with Waldenström's macroglobulinaemia have shown a response rate of 40%.,Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),%,40,230529,DB00640,Adenosine
,9375754,Overall response rate,Overall response rate including disease stabilization which had been progressive under previous therapy was 68%.,Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),%,68,230530,DB00640,Adenosine
,9375754,time to treatment failure,"Median time to treatment failure and remission duration were 4.4 (range 0.5-33) and 8 months (5-29), respectively.",Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),,4.4,230531,DB00640,Adenosine
,9375754,remission duration,"Median time to treatment failure and remission duration were 4.4 (range 0.5-33) and 8 months (5-29), respectively.",Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),month,8,230532,DB00640,Adenosine
,29787262,oral bioavailability,"What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.",Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29787262/),%,72,231871,DB00640,Adenosine
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],5.81,232760,DB00640,Adenosine
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],11.30,232761,DB00640,Adenosine
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,15.2,232762,DB00640,Adenosine
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,43.4,232763,DB00640,Adenosine
,34341510,IC50,"Among 6 known K2P channel modulators tested (DCPIB, quinine, fluoxetine, ML365, ML335, and TKDC), ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07 ± 1.5 μM.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),μM,4.07,233069,DB00640,Adenosine
,34341510,F,"In a preliminary pharmacokinetic study conducted in rats, ML365 showed good absolute oral bioavailability with F value of 22.49%.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),%,22.49,233070,DB00640,Adenosine
,10853877,ATP concentration,"Baseline ATP concentration in erythrocytes was 1,554 +/- 51 micromol l(-1).",Pharmacokinetics of intravenous ATP in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853877/),[μM] / [l],"1,554",233610,DB00640,Adenosine
,10853877,half-time for disappearance,"The mean half-time for disappearance of ATP from erythrocytes, measured in five patients, was 5.9 +/- 0.5 h.",Pharmacokinetics of intravenous ATP in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853877/),h,5.9,233611,DB00640,Adenosine
,31701524,area under the curve from zero to infinity (AUC(0-∞) ),"For each increase in treosulfan area under the curve from zero to infinity (AUC(0-∞) ) of 1,000 mg hour/L the hazard ratio (95% confidence interval) for mortality increase was 1.46 (1.23-1.74), and the hazard ratio for low engraftment was 0.61 (0.36-1.04).",Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31701524/),[h·mg] / [l],"1,000",234028,DB00640,Adenosine
,31701524,AUC(0-∞),"A cumulative AUC(0-∞) of 4,800 mg hour/L maximized the probability of success (> 20% engraftment and no mortality) at 82%.",Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31701524/),[h·mg] / [l],"4,800",234029,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,10,234189,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,24--96,234190,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,0.8,234191,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,33,234192,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,1.0,234193,DB00640,Adenosine
,573901,half-lives,"Two exponential components were determined for peptide disappearance rates in plasma and brain; peptide half-lives in plasma up to 10 hr and from 24--96 hr after injection were, respectively, 0.8 and 33 hr; in brain, 1.0 and 42 hr.","Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/573901/),h,42,234194,DB00640,Adenosine
,8924915,biological half-life,"After intravenous bolus injection, APS in plasma declined rapidly and the rate of elimination was dose-dependent: the biological half-life was about 2s at the dose of 0.3 mg/kg and was longer at 3 mg/kg.",Disposition of intravenously administered adenosine 5'-phosphosulfate (APS) in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924915/),s,2,235773,DB00640,Adenosine
>,9572908,bioavailability,Transport experiments conducted in isolated ileal segments from mesenteric cannulated rats using perfusate containing prodrug and various concentrations of EHNA demonstrated that a 0.1 microg/mL logarithmic mean lumenal concentration of EHNA was effective in increasing the intestinal bioavailability of Cl-ddP to > 90%.,Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572908/),%,90,235975,DB00640,Adenosine
>,9572908,bioavailability,"Thus, in continuous perfusions it is possible to increase the intestinal bioavailability of 6-Cl-ddP to >90% with minimal (<10%) inhibition of systemic ADA.",Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572908/),%,90,235976,DB00640,Adenosine
,24023367,Km,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),μM,21,236646,DB00640,Adenosine
,24023367,Vmax,"Membrane vesicle experiments revealed that RSV is a substrate of MRP4 (Km = 21 ± 7 µM, Vmax = 1140 ± 210 pmol/min per milligram of protein).",Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24023367/),[pM] / [milligram·min],1140,236647,DB00640,Adenosine
,1680554,alpha-,"The plasma concentration data from individual patients were fitted to a two-compartment model with alpha- and beta-half-lives of 35 +/- 12 (mean +/- SD) min and 6.7 +/- 2.5 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,35,239878,DB00640,Adenosine
,1680554,beta-half-lives,"The plasma concentration data from individual patients were fitted to a two-compartment model with alpha- and beta-half-lives of 35 +/- 12 (mean +/- SD) min and 6.7 +/- 2.5 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,6.7,239879,DB00640,Adenosine
,1680554,volume of distribution,The volume of distribution was 9.2 +/- 5.4 liters/kg.,On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),[l] / [kg],9.2,239880,DB00640,Adenosine
,1680554,steady-state concentration,The steady-state concentration of CdA during the 24-h infusion was 22.5 +/- 11.1 nM.,On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),nM,22.5,239881,DB00640,Adenosine
,1680554,areas under the time versus concentration curves,"The areas under the time versus concentration curves were 552 +/- 258 and 588 +/- 185 nM x h, respectively, for the 24- and 2-h infusions.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h·nM,552,239882,DB00640,Adenosine
,1680554,areas under the time versus concentration curves,"The areas under the time versus concentration curves were 552 +/- 258 and 588 +/- 185 nM x h, respectively, for the 24- and 2-h infusions.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h·nM,588,239883,DB00640,Adenosine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,8,239884,DB00640,Adenosine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,1,239885,DB00640,Adenosine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,6,239886,DB00640,Adenosine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,6.3,239887,DB00640,Adenosine
exceeding,33962189,recoveries,"Using a simple protein precipitation method, quantitation of these analytes was accomplished with recoveries exceeding 85% and with a run time of 4 min.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),%,85,240234,DB00640,Adenosine
,33962189,run time,"Using a simple protein precipitation method, quantitation of these analytes was accomplished with recoveries exceeding 85% and with a run time of 4 min.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),min,4,240235,DB00640,Adenosine
,33962189,half-life,"TCNP accumulates in RBC, has low clearance and a half-life of 18 to 23 h.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),h,18 to 23,240236,DB00640,Adenosine
,10883416,C6 h),"Noncompartmental analysis yielded mean values for the plasma AMP 579 concentration at the end of the 6-hour infusion (C6 h) of 9.6 and 10.5 ng/mL and for systemic clearances (Cl) of 0.91 and 0.72 L/h/kg in renally impaired patients and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[ng] / [ml],9.6,241415,DB00640,Adenosine
,10883416,C6 h),"Noncompartmental analysis yielded mean values for the plasma AMP 579 concentration at the end of the 6-hour infusion (C6 h) of 9.6 and 10.5 ng/mL and for systemic clearances (Cl) of 0.91 and 0.72 L/h/kg in renally impaired patients and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[ng] / [ml],10.5,241416,DB00640,Adenosine
,10883416,systemic clearances (Cl),"Noncompartmental analysis yielded mean values for the plasma AMP 579 concentration at the end of the 6-hour infusion (C6 h) of 9.6 and 10.5 ng/mL and for systemic clearances (Cl) of 0.91 and 0.72 L/h/kg in renally impaired patients and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[l] / [h·kg],0.91,241417,DB00640,Adenosine
,10883416,systemic clearances (Cl),"Noncompartmental analysis yielded mean values for the plasma AMP 579 concentration at the end of the 6-hour infusion (C6 h) of 9.6 and 10.5 ng/mL and for systemic clearances (Cl) of 0.91 and 0.72 L/h/kg in renally impaired patients and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[l] / [h·kg],0.72,241418,DB00640,Adenosine
,10883416,volumes of distribution (Vss),"Mean volumes of distribution (Vss) in the renally impaired and healthy volunteers were 0.92 and 0.84 L/kg, and terminal elimination half-life values (t1/2) were 1.61 and 1.33 hours, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[l] / [kg],0.92,241419,DB00640,Adenosine
,10883416,volumes of distribution (Vss),"Mean volumes of distribution (Vss) in the renally impaired and healthy volunteers were 0.92 and 0.84 L/kg, and terminal elimination half-life values (t1/2) were 1.61 and 1.33 hours, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),[l] / [kg],0.84,241420,DB00640,Adenosine
,10883416,terminal elimination half-life values (t1/2),"Mean volumes of distribution (Vss) in the renally impaired and healthy volunteers were 0.92 and 0.84 L/kg, and terminal elimination half-life values (t1/2) were 1.61 and 1.33 hours, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),h,1.61,241421,DB00640,Adenosine
,10883416,terminal elimination half-life values (t1/2),"Mean volumes of distribution (Vss) in the renally impaired and healthy volunteers were 0.92 and 0.84 L/kg, and terminal elimination half-life values (t1/2) were 1.61 and 1.33 hours, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),h,1.33,241422,DB00640,Adenosine
,10883416,free fractions,"The extent to which AMP 579 is bound to plasma protein was not altered in renally impaired patients since the free fractions were 4.0% and 3.4% for renally impaired and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),%,4.0,241423,DB00640,Adenosine
,10883416,free fractions,"The extent to which AMP 579 is bound to plasma protein was not altered in renally impaired patients since the free fractions were 4.0% and 3.4% for renally impaired and healthy volunteers, respectively.","Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10883416/),%,3.4,241424,DB00640,Adenosine
,16033948,K(i),"K(i) values for the inhibition of CYP2C9 and CYP2C19 activities by methysticin, dihydromethysticin, and desmethoxyyangonin ranged from 5 to 10 microM.",Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033948/),μM,5 to 10,241565,DB00640,Adenosine
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00640,Adenosine
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00640,Adenosine
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00640,Adenosine
,30863054,area under the inhibitory curve,"And, a 10 mg/kg dose of raw TCG suspension and a 5 mg/kg dose of TCG-SM had a similar area under the inhibitory curve (907.0%±408.8% and 907.8%±200.5%⋅hours, respectively) for antiplatelet activity.",Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30863054/),%,907.0,242418,DB00640,Adenosine
,30863054,area under the inhibitory curve,"And, a 10 mg/kg dose of raw TCG suspension and a 5 mg/kg dose of TCG-SM had a similar area under the inhibitory curve (907.0%±408.8% and 907.8%±200.5%⋅hours, respectively) for antiplatelet activity.",Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30863054/),%,907.8,242419,DB00640,Adenosine
,23361621,MTD,The MTD is 40 mg BID continuously.,"A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),mg,40,242438,DB00640,Adenosine
,23361621,CA19-9,"Patients with prostate and pancreatic cancer also had significant biomarker decreases (PSA, 205 ng/mL to 39 ng/mL; CA19-9, 38,838 U/mL to 267 U/mL).","A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),[u] / [ml],"38,838",242439,DB00640,Adenosine
,23361621,CA19-9,"Patients with prostate and pancreatic cancer also had significant biomarker decreases (PSA, 205 ng/mL to 39 ng/mL; CA19-9, 38,838 U/mL to 267 U/mL).","A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23361621/),[u] / [ml],267,242440,DB00640,Adenosine
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],32.4,242480,DB00640,Adenosine
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],78.7,242481,DB00640,Adenosine
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],4.1,242482,DB00640,Adenosine
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],11.5,242483,DB00640,Adenosine
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242484,DB00640,Adenosine
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242485,DB00640,Adenosine
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,17,242486,DB00640,Adenosine
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,11,242487,DB00640,Adenosine
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242488,DB00640,Adenosine
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242489,DB00640,Adenosine
,11133092,IC50,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),μM,0.081,242724,DB00640,Adenosine
,11133092,oral bioavailability,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),%,56,242725,DB00640,Adenosine
,11133092,half-life,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),h,4.3,242726,DB00640,Adenosine
,8244516,plasma renin activity,Caffeine did not alter either baseline blood pressure or the blood pressure response to Ang II but did increase baseline plasma renin activity from 0.72 +/- 0.09 to 1.42 +/- 0.26 ng angiotensin I/mL per hour (P = .01).,Caffeine attenuates the renal vascular response to angiotensin II infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8244516/),an·ng,0.72,244579,DB00640,Adenosine
,8244516,plasma renin activity,Caffeine did not alter either baseline blood pressure or the blood pressure response to Ang II but did increase baseline plasma renin activity from 0.72 +/- 0.09 to 1.42 +/- 0.26 ng angiotensin I/mL per hour (P = .01).,Caffeine attenuates the renal vascular response to angiotensin II infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8244516/),an·ng,1.42,244580,DB00640,Adenosine
,2111751,half-life,The plasma kinetics of ddI were generally monoexponential and were characterized by a half-life of 38 minutes.,"Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111751/),min,38,245020,DB00640,Adenosine
,2111751,Oral bioavailability,Oral bioavailability was 38% for oral liquid given with antacid.,"Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111751/),%,38,245021,DB00640,Adenosine
,2111751,total body clearance,"The total body clearance averaged 1.00 L/kg/hr, with a volume of distribution of 1.01 L/kg.","Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111751/),[l] / [h·kg],1.00,245022,DB00640,Adenosine
,2111751,volume of distribution,"The total body clearance averaged 1.00 L/kg/hr, with a volume of distribution of 1.01 L/kg.","Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111751/),[l] / [kg],1.01,245023,DB00640,Adenosine
,25150000,fm,"Following iv PCr, Cr appeared in plasma as early as 1.0 min postdose with a longer t1/2 than PCr and had a fm of 72%.",Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150000/),%,72,245320,DB00640,Adenosine
,15286054,plasma clearance,"Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%).",Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286054/),[ml] / [kg·min],5.8,246026,DB00640,Adenosine
,15286054,terminal elimination half-life,"Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%).",Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286054/),h,17.5,246027,DB00640,Adenosine
,15286054,oral bioavailability,"Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%).",Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286054/),%,103,246028,DB00640,Adenosine
,30260294,plasma effective concentration (EC)50,Target plasma concentrations were based on estimated plasma effective concentration (EC)50 (105 ng/mL) and EC90 (900 ng/mL) values for central nervous system P2X7 receptor binding.,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],105,247751,DB00640,Adenosine
,30260294,EC90,Target plasma concentrations were based on estimated plasma effective concentration (EC)50 (105 ng/mL) and EC90 (900 ng/mL) values for central nervous system P2X7 receptor binding.,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],900,247752,DB00640,Adenosine
,30260294,Cmax,"The highest Cmax,plasma reached (600 mg, fed) was 1475±163 ng/mL.","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],1475,247753,DB00640,Adenosine
,30260294,unbound Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],88.3,247754,DB00640,Adenosine
,30260294,Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],88.3,247755,DB00640,Adenosine
,30260294,Cmax,"JNJ-54175446 Cmax in cerebrospinal fluid, a proxy for brain penetration, was seven times lower than in total plasma; unbound Cmax,plasma and Cmax,CSF were comparable (88.3±35.7 vs 114±39 ng/mL).","Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],114,247756,DB00640,Adenosine
,30260294,inhibitory concentration (IC)50,JNJ-54175446 inhibited lipopolysaccharide/3'-O-(4-benzoylbenzoyl)-ATP-induced interleukin-1β release from peripheral blood in a dose-dependent manner (inhibitory concentration (IC)50:82 ng/mL; 95% confidence interval: 48-94).,"Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260294/),[ng] / [ml],82,247757,DB00640,Adenosine
,22190065,excretion,Urinary uric acid excretion was significantly higher on day 1 (7%) and at 24-48 h after the morning dose on day 5 (17%) relative to placebo.,Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22190065/),,7,248109,DB00640,Adenosine
,24498990,ED50,Here we demonstrate the experimental evidence that oral administration of NAM could completely prevent the occurrence of experimental arthritis in CIA mouse model at 0.3 mg/kg with ED50 value of approximately 0.1 mg/kg twice daily.,"A novel IKKα inhibitor, noraristeromycin, blocks the chronic inflammation associated with collagen-induced arthritis in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498990/),[mg] / [kg],0.1,249907,DB00640,Adenosine
,22515556,maximum (peak) plasma concentration (C(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],733,250416,DB00640,Adenosine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.0,250417,DB00640,Adenosine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],210,250418,DB00640,Adenosine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.1,250419,DB00640,Adenosine
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],4130,250420,DB00640,Adenosine
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],1325,250421,DB00640,Adenosine
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],305,250422,DB00640,Adenosine
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],121,250423,DB00640,Adenosine
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],724,250424,DB00640,Adenosine
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],764,250425,DB00640,Adenosine
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3983,250426,DB00640,Adenosine
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3986,250427,DB00640,Adenosine
,9697077,EC50,"The PD parameter estimates for EC50, EMAX, and Hill factor were 23 +/- 2 ng/ml, 74 +/- 3% (change from baseline), and 3.3 +/- 0.5, respectively.",Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),[ng] / [ml],23,251044,DB00640,Adenosine
,9697077,EMAX,"The PD parameter estimates for EC50, EMAX, and Hill factor were 23 +/- 2 ng/ml, 74 +/- 3% (change from baseline), and 3.3 +/- 0.5, respectively.",Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),%,74,251045,DB00640,Adenosine
,9697077,Hill factor,"The PD parameter estimates for EC50, EMAX, and Hill factor were 23 +/- 2 ng/ml, 74 +/- 3% (change from baseline), and 3.3 +/- 0.5, respectively.",Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),,3.3,251046,DB00640,Adenosine
,9697077,EC50,"Furthermore, the EC50 values for the reduction in glycerol or NEFA levels were identical (23 +/- 2 and 21 +/- 3 ng/ml, respectively) indicating that both PD endpoints reflect the same physiological process.",Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),[ng] / [ml],23,251047,DB00640,Adenosine
,9697077,EC50,"Furthermore, the EC50 values for the reduction in glycerol or NEFA levels were identical (23 +/- 2 and 21 +/- 3 ng/ml, respectively) indicating that both PD endpoints reflect the same physiological process.",Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),[ng] / [ml],21,251048,DB00640,Adenosine
,9697077,kout,The value for kout in the PK/PD model (0.19 +/- 0.03 min-1) corresponded very well to the terminal elimination rate constant determined after i.v. administration of glycerol (0.25 +/- 0.03 min-1).,Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),1/[min],0.19,251049,DB00640,Adenosine
,9697077,terminal elimination rate constant,The value for kout in the PK/PD model (0.19 +/- 0.03 min-1) corresponded very well to the terminal elimination rate constant determined after i.v. administration of glycerol (0.25 +/- 0.03 min-1).,Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697077/),1/[min],0.25,251050,DB00640,Adenosine
,26801247,PFS,"Median PFS for all 50 patients was 5.5 months (95% confidence interval, 4.1-6.7).",Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26801247/),month,5.5,251225,DB00640,Adenosine
,18215782,Plasma AUC,"Plasma AUC varied 3.6-fold (2184-7794 microM.min, median 4699 microM.min).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,2184-7794,251757,DB00640,Adenosine
,18215782,Plasma AUC,"Plasma AUC varied 3.6-fold (2184-7794 microM.min, median 4699 microM.min).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,4699,251758,DB00640,Adenosine
>,18215782,AUC,"Patients with an AUC >6000 microM.min had lower overall survival (OS) than those with AUC < or =6000 microM.min at 12 months (38% versus 74%) and 36 months (23% versus 68%, P < .001).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251759,DB00640,Adenosine
<,18215782,AUC,"Patients with an AUC >6000 microM.min had lower overall survival (OS) than those with AUC < or =6000 microM.min at 12 months (38% versus 74%) and 36 months (23% versus 68%, P < .001).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251760,DB00640,Adenosine
< or =,18215782,AUC,Nonrelapse mortality (NRM) at 100 days (6% versus 19%) and progression free survival (PFS; 58% versus 16%) at 3 years were better with AUC < or =6000 microM.min.,High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251761,DB00640,Adenosine
,28881378,CL/F,"These changes were primarily because of the effect of rifampin on the elimination parameters of istradefylline; mean CL/F was increased from 4.0 to 20.6 L/h, and mean t1/2 was reduced from 94.8 to 31.5 hours.",Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28881378/),[l] / [h],4.0 to 20.6,251841,DB00640,Adenosine
,28881378,t1/2,"These changes were primarily because of the effect of rifampin on the elimination parameters of istradefylline; mean CL/F was increased from 4.0 to 20.6 L/h, and mean t1/2 was reduced from 94.8 to 31.5 hours.",Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28881378/),h,94.8 to 31.5,251842,DB00640,Adenosine
,17112296,terminal elimination half-life,"Following intravenous bolus dose administration, regadenoson was rapidly distributed throughout the body, followed by relatively slower elimination (terminal elimination half-life of approximately 2 hours).","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),h,2,251983,DB00640,Adenosine
,17112296,clearance,"The clearance was estimated to be 37.8 L/h, with renal excretion accounting for approximately 58% of the total elimination.","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),[l] / [h],37.8,251984,DB00640,Adenosine
,17112296,volume of distribution of the central compartment,"The volume of distribution of the central compartment and the volume of distribution at steady state were estimated to be 11.5L and 78.7L, respectively.","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),l,11.5,251985,DB00640,Adenosine
,17112296,volume of distribution at steady state,"The volume of distribution of the central compartment and the volume of distribution at steady state were estimated to be 11.5L and 78.7L, respectively.","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),l,78.7,251986,DB00640,Adenosine
,17112296,maximum heart rate increase (Emax),"The maximum heart rate increase (Emax) and plasma regadenoson concentration causing a 50% increase in the maximum heart rate (EC50) were estimated to be 76 beats per minute and 12.3 ng/mL, respectively.","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),[beats] / [min],76,251987,DB00640,Adenosine
,17112296,maximum heart rate (EC50),"The maximum heart rate increase (Emax) and plasma regadenoson concentration causing a 50% increase in the maximum heart rate (EC50) were estimated to be 76 beats per minute and 12.3 ng/mL, respectively.","A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112296/),[ng] / [ml],12.3,251988,DB00640,Adenosine
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],2,252285,DB00640,Adenosine
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],3,252286,DB00640,Adenosine
,1400730,quantification,The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),[ng] / [ml],5,252287,DB00640,Adenosine
,1400730,overall recovery,The mean overall recovery was between 75 and 95% for lansoprazole and its metabolites.,Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400730/),%,75 and 95,252288,DB00640,Adenosine
,18321039,K(i),"This effort has led to the discovery of compound 62, that displayed high affinity and selectivity for the hA(2B)-AdoR (K(i) = 22 nM).",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,22,252373,DB00640,Adenosine
,18321039,K(B),"In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcarboxamidoadenosine in HEK-A(2B)-AdoR and NIH3T3 cells with K(B) values of 6 and 2 nM, respectively.",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,6,252374,DB00640,Adenosine
,18321039,K(B),"In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcarboxamidoadenosine in HEK-A(2B)-AdoR and NIH3T3 cells with K(B) values of 6 and 2 nM, respectively.",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,2,252375,DB00640,Adenosine
,18030066,area under the concentration-time curve (AUC0-tlast),Active metabolite area under the concentration-time curve (AUC0-tlast) after prasugrel 60-mg (594 ng.hr/mL) was 2.2 times that after clopidogrel 600-mg.,Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030066/),[h·ng] / [ml],594,252650,DB00640,Adenosine
,15976066,concentrations at steady state (Css),The average plasma BU concentrations at steady state (Css) ranged from 745 to 2422 ng/ml.,An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],745 to 2422,254351,DB00640,Adenosine
>,15976066,Css,"Four of seven patients had BU Css >1000 ng/ml, the previously defined concentration associated with an increased risk of regimen-related toxicity (RRT).",An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],1000,254352,DB00640,Adenosine
<,15976066,Css,"On the other hand, no severe toxicity greater than grade II except stomatitis was observed in the remaining patients whose Css were <1000 ng/ml.",An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],1000,254353,DB00640,Adenosine
,32397307,hepatic clearance,"The extrapolated hepatic clearance value of SCH 58261 was 39.97 mL/min/kg, indicating that the drug is greatly affected by hepatic metabolism.",Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography-Mass Spectrometric Method. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32397307/),[ml] / [kg·min],39.97,255498,DB00640,Adenosine
,19543331,area under the curve (AUC),Targeted BU area under the curve (AUC) range was 4800-5200 microM min.,Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543331/),min·μM,4800-5200,255668,DB00640,Adenosine
below,19543331,AUC,An AUC below the therapeutic value of 4000 microM min was observed in 23% of the patients receiving a wt-based dose and in 0% of patients whose dose was calculated on the basis of the test dose (P=0.03).,Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543331/),min·μM,4000,255669,DB00640,Adenosine
,27046445,time to maximum concentration (tmax),"Trabodenoson was rapidly absorbed [median time to maximum concentration (tmax): ∼0.08 to 0.27 h] and eliminated (t½: 0.48-2.0 h), with no evidence of drug accumulation.","A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27046445/),h,∼0.08 to 0.27,257915,DB00640,Adenosine
,27046445,t½,"Trabodenoson was rapidly absorbed [median time to maximum concentration (tmax): ∼0.08 to 0.27 h] and eliminated (t½: 0.48-2.0 h), with no evidence of drug accumulation.","A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27046445/),h,0.48-2.0,257916,DB00640,Adenosine
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2·kg],826,257963,DB00640,Adenosine
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2o·kg],920,257964,DB00640,Adenosine
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-1.40,257965,DB00640,Adenosine
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-,257966,DB00640,Adenosine
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],1.63,257967,DB00640,Adenosine
,27785737,plasma half-life,Entospletinib displayed a median plasma half-life of 9-15 h; entospletinib exposures reached a plateau at ≥600 mg twice daily (likely due to solubility-limited absorption) and provided >90% CD63 inhibition at peak concentrations and >60% inhibition at trough concentrations (corresponding pSYK inhibition of >70 and >50%).,"Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27785737/),h,9-15,258854,DB00640,Adenosine
,15743978,half-lives,"Plasma radioactivity (of which clofarabine accounted for 63% to 93%) exhibited three phases of exponential elimination, with half-lives of 0.3, 1.3, and 12.8 h after administration of the 25 mg/kg/day regimen.","The distribution, metabolism, and elimination of clofarabine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743978/),h,0.3,261702,DB00640,Adenosine
,15743978,half-lives,"Plasma radioactivity (of which clofarabine accounted for 63% to 93%) exhibited three phases of exponential elimination, with half-lives of 0.3, 1.3, and 12.8 h after administration of the 25 mg/kg/day regimen.","The distribution, metabolism, and elimination of clofarabine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743978/),h,1.3,261703,DB00640,Adenosine
,15743978,half-lives,"Plasma radioactivity (of which clofarabine accounted for 63% to 93%) exhibited three phases of exponential elimination, with half-lives of 0.3, 1.3, and 12.8 h after administration of the 25 mg/kg/day regimen.","The distribution, metabolism, and elimination of clofarabine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743978/),h,12.8,261704,DB00640,Adenosine
,17280881,run time,The chromatographic separation was achieved on a Waters Atlantis C18 column with a run time of 4 min.,"Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry--evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17280881/),min,4,262144,DB00640,Adenosine
,9868540,half-life,The mean half-life of PPF was 0.74 hr.,Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868540/),h,0.74,262366,DB00640,Adenosine
,9868540,areas under the curve (AUCs),"The areas under the curve (AUCs) of PPF and PPFOH were 508 and 460 ng.hr/ml, respectively.",Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868540/),[h·ng] / [ml],508,262367,DB00640,Adenosine
,9868540,areas under the curve (AUCs),"The areas under the curve (AUCs) of PPF and PPFOH were 508 and 460 ng.hr/ml, respectively.",Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868540/),[h·ng] / [ml],460,262368,DB00640,Adenosine
,9868540,Cmax,Cmax of PPF was about 828.4 ng/ml and the peak concentration was achieved at about 2.2 hr (Tmax).,Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868540/),[ng] / [ml],828.4,262369,DB00640,Adenosine
,9868540,Tmax,Cmax of PPF was about 828.4 ng/ml and the peak concentration was achieved at about 2.2 hr (Tmax).,Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868540/),h,2.2,262370,DB00640,Adenosine
,26111639,K i,"We reported that 2-(3,4-difluorophenylethynyl)-N (6)-3-chlorobenzyl (N)-methanocarba adenosine derivative 1 (MRS5698) binds selectively to human and mouse A3 adenosine receptors (A3ARs, K i 3 nM).","Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),nM,3,262823,DB00640,Adenosine
,26111639,t 1/2,It was well tolerated in the rat at doses of ≤200 mg/kg i.p. A 1 mg/kg i.p. dose in the mouse displayed t 1/2 of 1.09 h and plasma Cmax of 204 nM at 1 h with an AUC of 213 ng × h/mL.,"Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),h,1.09,262824,DB00640,Adenosine
,26111639,plasma Cmax,It was well tolerated in the rat at doses of ≤200 mg/kg i.p. A 1 mg/kg i.p. dose in the mouse displayed t 1/2 of 1.09 h and plasma Cmax of 204 nM at 1 h with an AUC of 213 ng × h/mL.,"Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),nM,204,262825,DB00640,Adenosine
,26111639,AUC,It was well tolerated in the rat at doses of ≤200 mg/kg i.p. A 1 mg/kg i.p. dose in the mouse displayed t 1/2 of 1.09 h and plasma Cmax of 204 nM at 1 h with an AUC of 213 ng × h/mL.,"Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),[h·ng] / [ml],213,262826,DB00640,Adenosine
,26111639,efflux ratio,CACO-2 bidirectional transport studies suggested intestinal efflux of MRS5698 (efflux ratio 86).,"Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),,86,262827,DB00640,Adenosine
,26111639,oral %F,"Although the oral %F is only 5 %, the beneficial effect to reverse pain lasted for at least 2 h in the CCI model in rats, using the same vehicle for oral administration of a high dose.","Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111639/),%,5,262828,DB00640,Adenosine
,8106577,flow-rate,"The mobile phase consisted of a mixture of 10 mM acetate buffer (pH 4.0)-methanol-acetonitrile (56:40:4, v/v/v) with a flow-rate of 0.50 ml/min.",High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ml] / [min],0.50,263838,DB00640,Adenosine
,8106577,total run time,The total run time was ca. 19 min.,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),min,19,263839,DB00640,Adenosine
,8106577,limits of detection,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ng] / [ml],3.3,263840,DB00640,Adenosine
,8106577,limits of detection,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),[ng] / [ml],6.2,263841,DB00640,Adenosine
,8106577,signal-to-noise ratio,In 100 microliter blood samples the corresponding limits of detection were 3.3 and 6.2 ng/ml (signal-to-noise ratio = 3).,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),,3,263842,DB00640,Adenosine
,8106577,half-life,CPA was found to be degraded in rat blood in vitro with a half-life of 24 min at 37 degrees C.,High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8106577/),min,24,263843,DB00640,Adenosine
,33190084,flow rate,"The chromatographic separation was performed on an Eclipse Plus C18 column (2.1 × 50 mm, 3.5 μm) at a flow rate of 0.3 mL/min with a gradient mobile phase of methanol/water containing 0.5 % formic acid (v/v).",Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),[ml] / [min],0.3,265072,DB00640,Adenosine
,33190084,recoveries,There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,90.6,265073,DB00640,Adenosine
,33190084,recoveries,There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,118.2,265074,DB00640,Adenosine
,33190084,oral bioavailability,The oral bioavailability of YZG-331 in monkeys is 74.1 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,74.1,265075,DB00640,Adenosine
,3147196,V2,"Seven atopic asthmatic subjects (age 25 +/- 2 yrs) inhaled dry powder SCG from a Spinhaler on separate occasions at three flow rates, maximum (V1), 100 l.min-1 (V2), and 50 l.min-1 (V3), or placebo, according to a double-blind structured study.",Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147196/),[l] / [min],100,265156,DB00640,Adenosine
,3147196,V3,"Seven atopic asthmatic subjects (age 25 +/- 2 yrs) inhaled dry powder SCG from a Spinhaler on separate occasions at three flow rates, maximum (V1), 100 l.min-1 (V2), and 50 l.min-1 (V3), or placebo, according to a double-blind structured study.",Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147196/),[l] / [min],50,265157,DB00640,Adenosine
,11349741,maximum concentrations,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[mg] / [l],0.51,265385,DB00640,Adenosine
,11349741,maximum concentrations,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[mg] / [l],0.75,265386,DB00640,Adenosine
,11349741,area under the concentration-time curves from 0-24 hours,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[h·mg] / [l],4.65,265387,DB00640,Adenosine
,11349741,area under the concentration-time curves from 0-24 hours,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[h·mg] / [l],4.55,265388,DB00640,Adenosine
,11349741,Bioavailability,Bioavailability of F-ara-A after subcutaneous dosing was approximately 105% of the bioavailability after intravenous administration.,Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),%,105,265389,DB00640,Adenosine
,11935212,total body clearance,"The total body clearance of SPI-77 varied from 14 to 30 ml/h and was significantly lower than reported clearance values for cisplatin of 20 l/m(2) per h, due to the slow release of cisplatin from the liposomes.","Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935212/),[ml] / [h],14 to 30,265897,DB00640,Adenosine
,11935212,clearance,"The total body clearance of SPI-77 varied from 14 to 30 ml/h and was significantly lower than reported clearance values for cisplatin of 20 l/m(2) per h, due to the slow release of cisplatin from the liposomes.","Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935212/),[l] / [h·m(2)],20,265898,DB00640,Adenosine
,33621324,accumulation ratio,Mean Cmax and AUC0-24 of niraparib increased dose-proportionally after multiple doses (accumulation ratio of between 1.64 and 3.65); median tmax was 3-4 h.,"The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33621324/),,1.64 and 3.65,266031,DB00640,Adenosine
,33621324,tmax,Mean Cmax and AUC0-24 of niraparib increased dose-proportionally after multiple doses (accumulation ratio of between 1.64 and 3.65); median tmax was 3-4 h.,"The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33621324/),h,3-4,266032,DB00640,Adenosine
,15139750,K(i),"We disclose optimization efforts based on the novel non-nucleoside adenosine deaminase (ADA) inhibitor, 4 (K(i) = 680 nM).","Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139750/),nM,680,266251,DB00640,Adenosine
,15139750,K(i),"Structure-based drug design utilizing the crystal structure of the 4/ADA complex led to discovery of 5 (K(i) = 11 nM, BA = 30% in rats).","Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139750/),nM,11,266252,DB00640,Adenosine
,15139750,K(i),"Furthermore, from metabolic considerations, we discovered two inhibitors with improved oral bioavailability [6 (K(i) = 13 nM, BA = 44%) and 7 (K(i) = 9.8 nM, BA = 42%)].","Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139750/),nM,13,266253,DB00640,Adenosine
,15139750,K(i),"Furthermore, from metabolic considerations, we discovered two inhibitors with improved oral bioavailability [6 (K(i) = 13 nM, BA = 44%) and 7 (K(i) = 9.8 nM, BA = 42%)].","Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139750/),nM,9.8,266254,DB00640,Adenosine
,15139750,BA,"Furthermore, from metabolic considerations, we discovered two inhibitors with improved oral bioavailability [6 (K(i) = 13 nM, BA = 44%) and 7 (K(i) = 9.8 nM, BA = 42%)].","Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139750/),%,42,266255,DB00640,Adenosine
,8359193,CL,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),[l] / [min],10.7,267758,DB00640,Adenosine
,8359193,CL,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),[l] / [min],4.70,267759,DB00640,Adenosine
,8359193,CL,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),[l] / [min],4.14,267760,DB00640,Adenosine
,8359193,half-life,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),min,0.91,267761,DB00640,Adenosine
,8359193,half-life,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),min,1.24,267762,DB00640,Adenosine
,8359193,half-life,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),min,1.86,267763,DB00640,Adenosine
,8359193,volume of distribution,"As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l).",Pharmacokinetics of exogenous adenosine in man after infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),l,8-13,267764,DB00640,Adenosine
,8359193,clearance,"After the 20 minute infusion the plasma level of adenosine reached a peak value comparable to that observed after infusion of 5 mg in 1 min (about 0.5 micrograms.ml-1), but the mean clearance and half-life were significantly different (12.1 l.min-1 and 0.63 min respectively).",Pharmacokinetics of exogenous adenosine in man after infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),[l] / [min],12.1,267765,DB00640,Adenosine
,8359193,half-life,"After the 20 minute infusion the plasma level of adenosine reached a peak value comparable to that observed after infusion of 5 mg in 1 min (about 0.5 micrograms.ml-1), but the mean clearance and half-life were significantly different (12.1 l.min-1 and 0.63 min respectively).",Pharmacokinetics of exogenous adenosine in man after infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359193/),min,0.63,267766,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,96.0,268604,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,94.9,268605,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,98.7,268606,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268607,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268608,DB00640,Adenosine
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268609,DB00640,Adenosine
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268610,DB00640,Adenosine
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268611,DB00640,Adenosine
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268612,DB00640,Adenosine
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,36.2,268613,DB00640,Adenosine
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,20.7,268614,DB00640,Adenosine
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,40.7,268615,DB00640,Adenosine
<,11307804,plasma half-life,90% patients had a plasma half-life for AR-C69931XX of <9 min.,"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9,268616,DB00640,Adenosine
,16423907,impedance,Mean (SD) impedance of the healthy cohort was 12.2 (2.2) Omega.,Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,12.2,268825,DB00640,Adenosine
<,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268826,DB00640,Adenosine
>,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268827,DB00640,Adenosine
,17220239,fecal excretion,Mean fecal excretion was 13% of the administered dose.,Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220239/),%,13,268927,DB00640,Adenosine
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],5.29,269288,DB00640,Adenosine
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],7.13,269289,DB00640,Adenosine
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],7.37,269290,DB00640,Adenosine
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],11.30,269291,DB00640,Adenosine
,24127209,Platelet,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269292,DB00640,Adenosine
,24127209,aggregation,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269293,DB00640,Adenosine
,15239652,K(i),"We disclose herein optimization efforts around the novel, highly potent non-nucleoside adenosine deaminase (ADA) inhibitor, 1-[(R)-1-hydroxy-4-(6-(3-(1-methylbenzimidazol-2-yl)propionylamino)indol-1-yl)-2-butyl]imidazole-4-carboxamide 1 (K(i)= 7.7 nM), which we recently reported.","Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15239652/),nM,7.7,269386,DB00640,Adenosine
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,86,269684,DB00640,Adenosine
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,47,269685,DB00640,Adenosine
,22511498,area under the curve,"Rituximab pharmacokinetic analysis showed a high variability ranging over almost 1 order of magnitude at maintenance cycle 1 (area under the curve 1,540-12,025 g/L*days).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[g] / [d·l],"1,540-12,025",269686,DB00640,Adenosine
below,22511498,C(trough),"A decline in rituximab C(trough) below 25,000 ng/mL was observed 9.5 to 62 months before clinical relapse (P=0.008).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[ng] / [ml],"25,000",269687,DB00640,Adenosine
,24440085,MTD,The MTD was determined to be 75 mg BID or 100mg QD.,"A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440085/),,75,270020,DB00640,Adenosine
,8794987,elimination half-life (V0),"In the single-dose study (200, 300, 400 mg), the area under the plasma concentration-time curve (AUC) and the maximum plasma concentration (Cmax) increased non-linearly with dose, while the mean elimination half-life (V0) was essentially unchanged (3.9-7.3h).","Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794987/),h,3.9-7.3,270914,DB00640,Adenosine
,8794987,Recovery,Recovery of the unchanged drug in the urine was 12-25%.,"Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794987/),%,12-25,270915,DB00640,Adenosine
,26116990,plasma elimination half-life,"DZNep showed a short plasma elimination half-life (1.1h) in rats, a low protein binding in plasma (18.5%), a low partitioning to erythrocyte (0.78), and a low intrinsic hepatic clearance in rats and humans.","Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116990/),h,1.1,271179,DB00640,Adenosine
,26116990,protein binding,"DZNep showed a short plasma elimination half-life (1.1h) in rats, a low protein binding in plasma (18.5%), a low partitioning to erythrocyte (0.78), and a low intrinsic hepatic clearance in rats and humans.","Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116990/),%,18.5,271180,DB00640,Adenosine
,26116990,partitioning to erythrocyte,"DZNep showed a short plasma elimination half-life (1.1h) in rats, a low protein binding in plasma (18.5%), a low partitioning to erythrocyte (0.78), and a low intrinsic hepatic clearance in rats and humans.","Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116990/),,0.78,271181,DB00640,Adenosine
,15855656,half-life,Plasma tHcy concentrations reached a peak at 34 +/- 11 min after an oral load with l-homocysteine and decreased with a half-life of 257 +/- 41 min (means +/- SD).,Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855656/),min,257,271622,DB00640,Adenosine
,1296857,alpha-phase t1/2,The time-dependent decay of plasma levels of N0861 fitted a two-compartment polyexponential model with alpha-phase t1/2 = 3.80 min and beta-phase t1/2 = 80.55 min.,"Effects of N6-endonorbornan-2-yl-9-methyladenine, N0861, on negative chronotropic and vasodilatory actions of adenosine in the canine heart in vivo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296857/),min,3.80,272384,DB00640,Adenosine
,1296857,beta-phase t1/2,The time-dependent decay of plasma levels of N0861 fitted a two-compartment polyexponential model with alpha-phase t1/2 = 3.80 min and beta-phase t1/2 = 80.55 min.,"Effects of N6-endonorbornan-2-yl-9-methyladenine, N0861, on negative chronotropic and vasodilatory actions of adenosine in the canine heart in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296857/),min,80.55,272385,DB00640,Adenosine
,9084461,Serum terminal half-life,Serum terminal half-life of PTH(1-84) was approximately 2 1/2 hours.,Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084461/),h,2 1/2,273436,DB00640,Adenosine
,11707860,IC(50),"DAB(486)IL-2, in which the native receptor-binding domain of diphtheria toxin was replaced with the full-length interleukin-2 (IL-2) gene, was capable of intoxicating high-affinity IL-2 receptor-bearing cells in vitro with an IC(50) of 10(-10) M; whereas, cells lacking the full component of the high-affinity IL-2 receptor (p55, p75, p64) were relatively resistant (IC(50) of 10(-8) M).","DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707860/),M,10(-10),273894,DB00640,Adenosine
,11707860,IC(50),"DAB(486)IL-2, in which the native receptor-binding domain of diphtheria toxin was replaced with the full-length interleukin-2 (IL-2) gene, was capable of intoxicating high-affinity IL-2 receptor-bearing cells in vitro with an IC(50) of 10(-10) M; whereas, cells lacking the full component of the high-affinity IL-2 receptor (p55, p75, p64) were relatively resistant (IC(50) of 10(-8) M).","DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707860/),M,10(-8),273895,DB00640,Adenosine
